,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,11112125,3440,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,377,1,3,,10321703,3440,Inactive,42741659.0,5243.0,,,MDR-1,Other,,
2,410,1,5,,11112125,3440,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
3,411,2,1,,11112125,3440,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
4,421,1,3,,17389872,3440,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
5,426,1,2,,17389872,3440,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
6,427,1,1,,17389872,3440,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
7,433,1,1,,17389872,3440,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
8,434,1,2,,17389872,3440,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
9,435,1,2,,17389872,3440,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
10,444,1,1,,11112125,3440,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
11,445,3,1,,11112125,3440,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
12,445,3,1,,17389872,3440,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
13,446,1,1,,11112125,3440,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
14,447,1,1,,11112125,3440,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
15,448,1,2,,11112125,3440,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
16,450,1,2,,11112125,3440,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
17,451,1,2,,11112125,3440,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
18,526,1,1,,11112125,3440,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
19,530,1,1,,11112125,3440,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
20,530,1,1,,17389872,3440,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
21,540,1,1,,17389872,3440,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
22,541,1,1,,17389872,3440,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
23,542,1,1,,17389872,3440,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
24,543,1,1,,17389872,3440,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
25,544,2,1,,17389872,3440,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
26,545,1,1,,17389872,3440,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
27,546,1,1,,17389872,3440,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
28,584,1,3,,11112125,3440,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
29,584,1,3,,17389872,3440,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
30,585,1,4,,11112125,3440,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
31,585,1,4,,17389872,3440,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
32,587,1,5,,11112125,3440,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
33,588,1,4,,11112125,3440,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
34,589,1,3,,11112125,3440,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
35,590,1,3,,11112125,3440,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
36,591,1,4,,11112125,3440,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
37,592,1,6,,11112125,3440,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
38,593,1,4,,11112125,3440,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
39,594,1,4,,11112125,3440,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
40,595,1,3,,11112125,3440,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
41,595,1,3,,17389872,3440,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
42,596,1,2,,11112125,3440,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
43,596,1,2,,17389872,3440,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
44,597,1,3,,11112125,3440,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
45,603,1,2,,11112125,3440,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
46,603,1,2,,17389872,3440,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
47,605,1,2,,11112125,3440,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
48,605,1,2,,17389872,3440,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
49,607,1,3,,11112125,3440,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
50,654,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
51,655,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
52,656,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
53,657,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
54,658,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
55,659,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
56,660,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
57,661,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
58,662,1,1,,11112125,3440,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
59,662,1,1,,17389872,3440,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
60,663,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
61,664,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
62,665,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
63,666,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
64,667,1,1,,17389872,3440,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
65,875,1,2,,11112125,3440,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
66,875,1,2,,17389872,3440,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
67,880,2,1,,11112125,3440,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
68,880,2,1,,11112125,3440,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
69,880,2,1,,17389872,3440,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
70,880,2,1,,17389872,3440,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
71,880,2,1,,26747275,3440,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
72,880,2,1,,26747275,3440,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
73,880,2,1,,26752834,3440,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
74,880,2,1,,26752834,3440,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
75,881,2,2,,11112125,3440,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
76,881,2,2,,17389872,3440,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
77,881,2,2,,26752834,3440,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
78,883,1,3,,11112125,3440,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
79,884,1,2,,11112125,3440,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
80,884,1,2,,17389872,3440,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
81,885,1,2,,11112125,3440,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
82,885,1,2,,17389872,3440,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
83,886,1,2,,11112125,3440,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
84,886,1,2,,11112125,3440,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
85,886,1,2,,17389872,3440,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
86,886,1,2,,17389872,3440,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
87,887,1,2,,11112125,3440,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
88,887,1,2,,17389872,3440,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
89,889,1,3,,11112125,3440,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
90,889,1,3,,17389872,3440,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
91,891,1,2,,11112125,3440,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
92,892,1,2,,11112125,3440,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
93,892,1,2,,17389872,3440,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
94,893,1,2,,11112125,3440,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
95,893,1,2,,11112125,3440,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
96,893,1,2,,17389872,3440,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
97,893,1,2,,17389872,3440,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
98,894,2,1,,11112125,3440,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
99,894,2,1,,17389872,3440,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
100,894,2,1,,26747275,3440,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
101,894,2,1,,26752834,3440,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
102,899,1,2,,11112125,3440,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
103,900,1,3,,11112125,3440,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
104,900,1,3,,17389872,3440,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
105,901,1,2,,11112125,3440,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
106,902,1,2,,11112125,3440,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
107,902,1,2,,17389872,3440,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
108,910,1,2,,17389872,3440,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
109,912,1,2,,11112125,3440,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
110,912,1,2,,17389872,3440,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
111,914,1,3,,11112125,3440,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
112,915,1,3,,11112125,3440,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
113,921,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
114,923,1,2,,11112125,3440,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
115,923,1,2,,17389872,3440,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
116,924,1,2,,11112125,3440,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
117,924,1,2,,17389872,3440,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
118,925,1,2,,11112125,3440,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
119,925,1,2,,17389872,3440,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
120,926,1,2,,11112125,3440,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
121,926,1,2,,17389872,3440,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
122,927,1,3,,11112125,3440,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
123,927,1,3,,17389872,3440,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
124,930,1,2,,17389872,3440,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
125,938,1,2,,11112125,3440,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
126,938,1,2,,17389872,3440,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
127,940,1,2,,26611753,3440,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
128,946,1,2,,17389872,3440,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
129,947,1,2,,17389872,3440,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
130,948,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
131,955,1,2,,17389872,3440,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
132,960,1,2,,17389872,3440,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
133,961,1,2,,17389872,3440,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
134,962,1,2,,17389872,3440,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
135,963,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
136,964,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
137,965,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
138,966,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
139,967,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
140,968,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
141,969,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
142,970,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
143,971,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
144,972,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
145,973,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
146,974,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
147,975,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
148,976,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
149,977,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
150,978,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
151,979,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
152,980,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
153,981,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
154,982,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
155,983,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
156,984,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
157,985,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
158,986,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
159,987,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
160,988,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
161,989,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
162,993,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
163,994,1,2,,17389872,3440,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
164,995,1,2,,11112125,3440,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
165,995,1,2,,17389872,3440,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
166,999,1,1,,46487913,3440,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor Using a Diverse Compound Set,Screening,,
167,1004,1,1,,46487913,3440,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression Using a Diverse Compound Set,Screening,,
168,1030,2,1,,11112125,3440,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
169,1030,2,1,,17389872,3440,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
170,1030,2,1,,26747275,3440,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
171,1030,2,1,,26752834,3440,Inactive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
172,1189,1,5,,48413804,3440,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
173,1194,1,3,,48413804,3440,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
174,1195,1,2,,48416042,3440,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
175,1199,1,3,,48413804,3440,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
176,1208,1,3,,48413804,3440,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
177,1332,1,1,,49698703,3440,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
178,1376,1,2,,47193739,3440,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
179,1379,1,2,,11112125,3440,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
180,1379,1,2,,26747275,3440,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
181,1379,1,2,,26752834,3440,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
182,1385,2,2,,47193739,3440,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
183,1422,1,1,,26611753,3440,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
184,1422,1,1,,47193739,3440,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
185,1452,1,1,,11112125,3440,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
186,1452,1,1,,17389872,3440,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
187,1452,1,1,,26752834,3440,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
188,1454,1,1,,11112125,3440,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
189,1454,1,1,,26747275,3440,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
190,1457,1,1,,11112125,3440,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
191,1457,1,1,,17389872,3440,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
192,1457,1,1,,26747275,3440,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
193,1457,1,1,,26752834,3440,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
194,1458,1,1,,11112125,3440,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
195,1458,1,1,,17389872,3440,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
196,1458,1,1,,26747275,3440,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
197,1460,1,3,,26747275,3440,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
198,1460,1,3,,26752834,3440,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
199,1463,1,1,,26747275,3440,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
200,1463,1,1,,26752834,3440,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
201,1465,1,1,,47193739,3440,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
202,1467,1,3,,11112125,3440,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
203,1467,1,3,,26747275,3440,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
204,1467,1,3,,26752834,3440,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
205,1468,1,1,,26747275,3440,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
206,1468,1,1,,26752834,3440,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
207,1469,1,1,,11112125,3440,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
208,1469,1,1,,17389872,3440,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
209,1469,1,1,,26747275,3440,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
210,1469,1,1,,26752834,3440,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
211,1469,1,1,,26752835,3440,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
212,1471,2,1,,11112125,3440,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
213,1471,2,1,,17389872,3440,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
214,1471,2,1,,26747275,3440,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
215,1471,2,1,,26752834,3440,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
216,1471,2,1,,26752835,3440,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
217,1476,2,1,,11112125,3440,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
218,1476,2,1,,17389872,3440,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
219,1476,2,1,,26747275,3440,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
220,1476,2,1,,26752834,3440,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
221,1477,1,1,,11112125,3440,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
222,1477,1,1,,17389872,3440,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
223,1477,1,1,,26747275,3440,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
224,1477,1,1,,26752834,3440,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
225,1478,2,1,,11112125,3440,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
226,1478,2,1,,17389872,3440,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
227,1478,2,1,,26747275,3440,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
228,1478,2,1,,26752834,3440,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
229,1479,1,2,,11112125,3440,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
230,1479,1,2,,17389872,3440,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
231,1479,1,2,,26747275,3440,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
232,1479,1,2,,26752834,3440,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
233,1479,1,2,,26752835,3440,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
234,1487,1,1,,11112125,3440,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
235,1490,2,1,,11112125,3440,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
236,1490,2,1,,26747275,3440,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
237,1490,2,1,,26752834,3440,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
238,1490,2,1,,26752835,3440,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
239,1511,1,3,,47193739,3440,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
240,1519,1,3,,11112125,3440,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
241,1519,1,3,,26747275,3440,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
242,1529,1,1,,47193739,3440,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
243,1530,1,1,,47193739,3440,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
244,1531,1,1,,47193739,3440,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
245,1532,1,1,,47193739,3440,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
246,1554,1,1,,47193739,3440,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
247,1580,1,1,,8149353,3440,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
248,1581,1,1,,8149353,3440,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
249,1582,1,1,,8149353,3440,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
250,1583,1,1,,8149353,3440,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
251,1584,1,1,,8149353,3440,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
252,1585,1,1,,8149353,3440,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
253,1586,1,1,,8149353,3440,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
254,1587,1,1,,8149353,3440,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
255,1588,1,1,,8149353,3440,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
256,1589,1,1,,8149353,3440,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
257,1590,1,1,,8149353,3440,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
258,1593,1,1,,8149353,3440,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
259,1594,1,1,,8149353,3440,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
260,1595,1,1,,8149353,3440,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
261,1596,1,1,,8149353,3440,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
262,1597,1,1,,8149353,3440,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
263,1598,1,1,,8149353,3440,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
264,1599,1,1,,8149353,3440,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
265,1600,1,1,,8149353,3440,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
266,1601,1,1,,8149353,3440,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
267,1602,1,1,,8149353,3440,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
268,1603,1,1,,8149353,3440,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
269,1604,1,1,,8149353,3440,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
270,1605,1,1,,8149353,3440,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
271,1606,1,1,,8149353,3440,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
272,1607,1,1,,8149353,3440,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
273,1608,1,1,,8149353,3440,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
274,1609,1,1,,8149353,3440,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
275,1610,1,1,,8149353,3440,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
276,1612,1,1,,8149353,3440,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
277,1613,1,1,,8149353,3440,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
278,1614,1,1,,8149353,3440,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
279,1616,1,1,,8149353,3440,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
280,1621,1,2,,47193739,3440,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
281,1626,1,2,,47193739,3440,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
282,1662,1,2,,47193739,3440,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
283,1663,1,2,,47193739,3440,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
284,1672,1,3,,47193739,3440,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
285,1688,1,1,,26752835,3440,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
286,1766,1,1,,11112125,3440,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
287,1766,1,1,,11112125,3440,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
288,1766,1,1,,26747275,3440,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
289,1766,1,1,,26747275,3440,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
290,1766,1,1,,26752834,3440,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
291,1766,1,1,,26752834,3440,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
292,1766,1,1,,26752835,3440,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
293,1766,1,1,,26752835,3440,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
294,1768,1,1,,11112125,3440,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
295,1768,1,1,,11112125,3440,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
296,1768,1,1,,26747275,3440,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
297,1768,1,1,,26747275,3440,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
298,1768,1,1,,26752834,3440,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
299,1768,1,1,,26752834,3440,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
300,1768,1,1,,26752835,3440,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
301,1768,1,1,,26752835,3440,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
302,1813,1,2,,47193739,3440,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
303,1814,1,2,,47193739,3440,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
304,1832,2,1,,47193739,3440,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
305,1850,2,1,,47193739,3440,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
306,1851,1,2,,11112125,3440,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
307,1851,1,2,1.0,11112125,3440,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
308,1851,1,2,2.0,11112125,3440,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
309,1851,1,2,3.0,11112125,3440,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
310,1851,1,2,4.0,11112125,3440,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
311,1851,1,2,5.0,11112125,3440,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
312,1863,2,1,,47193739,3440,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
313,1865,1,1,,11112125,3440,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
314,1865,1,1,,26747275,3440,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
315,1865,1,1,,26752834,3440,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
316,1875,2,1,,47193739,3440,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
317,1885,2,1,,47193739,3440,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
318,1899,1,3,,47193739,3440,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
319,1903,2,3,,47193739,3440,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
320,1906,1,3,,47193739,3440,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
321,1910,1,2,,47193739,3440,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
322,1947,1,2,,47193739,3440,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
323,1948,1,1,,11112125,3440,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
324,1948,1,1,,17389872,3440,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
325,1948,1,1,,26747275,3440,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
326,1948,1,1,,26752834,3440,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
327,1950,1,3,,47193739,3440,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
328,1956,1,1,,47193739,3440,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
329,1962,1,2,,47193739,3440,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
330,1974,1,2,,47193739,3440,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
331,1987,1,2,,47193739,3440,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
332,1996,2,2,,47193739,3440,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
333,2016,1,3,,47193739,3440,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
334,2023,1,3,,47193739,3440,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
335,2025,1,3,,47193739,3440,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
336,2029,1,3,,47193739,3440,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
337,2052,2,1,,47193739,3440,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
338,2057,1,2,,47193739,3440,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
339,2066,1,4,,47193739,3440,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
340,2094,1,2,,47193739,3440,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
341,2094,1,2,,47193739,3440,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
342,2094,1,2,,47193739,3440,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
343,2097,1,2,,47193739,3440,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
344,2098,1,1,,47193739,3440,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
345,2099,1,1,,47193739,3440,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
346,2101,1,1,,11112125,3440,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
347,2101,1,1,,17389872,3440,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
348,2101,1,1,,26747275,3440,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
349,2101,1,1,,26752834,3440,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
350,2107,1,1,,11112125,3440,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
351,2107,1,1,,17389872,3440,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
352,2107,1,1,,26747275,3440,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
353,2107,1,1,,26752834,3440,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
354,2112,1,1,,11112125,3440,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
355,2112,1,1,,17389872,3440,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
356,2112,1,1,,26747275,3440,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
357,2112,1,1,,26752834,3440,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
358,2120,1,1,,17389872,3440,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
359,2129,1,2,,47193739,3440,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
360,2130,1,3,,47193739,3440,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
361,2147,1,1,,11112125,3440,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
362,2147,1,1,,26747275,3440,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
363,2156,2,2,,47193739,3440,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
364,2174,1,3,,47193739,3440,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
365,2177,1,3,,47193739,3440,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
366,2216,1,3,,47193739,3440,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
367,2221,1,2,,47193739,3440,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
368,2227,1,2,,47193739,3440,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
369,2234,1,2,,47193739,3440,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
370,2235,1,2,,47193739,3440,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
371,2237,1,2,,47193739,3440,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
372,2239,1,2,,47193739,3440,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
373,2240,1,1,,85788855,3440,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
374,2241,1,1,,85788855,3440,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
375,2247,1,2,,47193739,3440,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
376,2275,1,1,,85788855,3440,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
377,2280,2,3,,47193739,3440,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
378,2300,1,3,,47193739,3440,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
379,2313,1,1,,85788855,3440,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
380,2322,1,1,,85788855,3440,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
381,2330,1,1,,85788855,3440,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
382,2380,1,2,,47193739,3440,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
383,2391,1,1,,47193739,3440,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
384,2435,1,2,,47193739,3440,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
385,2445,1,2,,47193739,3440,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
386,2451,1,2,,11112125,3440,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
387,2451,1,2,,26747275,3440,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
388,2451,1,2,,26752834,3440,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
389,2462,1,1,,47193739,3440,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
390,2462,1,1,,47193739,3440,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
391,2472,1,2,,11112125,3440,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
392,2472,1,2,,26747275,3440,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
393,2472,1,2,,26752834,3440,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
394,2517,2,1,,11112125,3440,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
395,2517,2,1,,17389872,3440,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
396,2517,2,1,,26747275,3440,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
397,2517,2,1,,26752834,3440,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
398,2520,1,4,,47193739,3440,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
399,2521,1,3,,47193739,3440,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
400,2524,1,2,,47193739,3440,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
401,2528,1,2,,11112125,3440,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
402,2528,1,2,,26747275,3440,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
403,2528,1,2,,26752834,3440,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
404,2528,1,2,,26752835,3440,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
405,2540,1,2,,47193739,3440,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
406,2544,1,2,,47193739,3440,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
407,2546,1,1,,11112125,3440,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
408,2546,1,1,,17389872,3440,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
409,2546,1,1,,26747275,3440,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
410,2546,1,1,,26752834,3440,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
411,2546,1,1,,26752835,3440,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
412,2549,1,1,,11112125,3440,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
413,2549,1,1,,17389872,3440,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
414,2549,1,1,,26747275,3440,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
415,2549,1,1,,26752834,3440,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
416,2550,1,3,,47193739,3440,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
417,2551,1,1,,11112125,3440,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
418,2551,1,1,,17389872,3440,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
419,2551,1,1,,26747275,3440,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
420,2551,1,1,,26752834,3440,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
421,2551,1,1,,26752835,3440,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
422,2553,1,2,,47193739,3440,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
423,2557,1,3,,47193739,3440,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
424,2563,1,1,,47193739,3440,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
425,2599,1,2,,47193739,3440,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
426,2606,1,2,,47193739,3440,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
427,2629,1,1,,47193739,3440,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
428,2642,1,2,,47193739,3440,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
429,2648,1,2,,47193739,3440,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
430,2650,2,1,,47193739,3440,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
431,2661,1,1,,47193739,3440,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
432,2690,1,2,,47193739,3440,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
433,2716,1,1,,47193739,3440,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
434,2717,1,2,,47193739,3440,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
435,2718,1,1,,47193739,3440,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
436,2751,2,2,,47193739,3440,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
437,2796,1,4,,47193739,3440,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
438,2797,1,2,,47193739,3440,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
439,2805,2,2,,47193739,3440,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
440,2806,2,2,,47193739,3440,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
441,2825,1,2,,47193739,3440,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
442,13764,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),Other,7452697.0,
443,13770,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Other,7452697.0,
444,13782,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Other,7452697.0,
445,13788,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Other,7452697.0,
446,13797,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),Other,7452697.0,
447,13801,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),Other,7452697.0,
448,13951,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),Other,7452697.0,
449,13957,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Other,7452697.0,
450,13969,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Other,7452697.0,
451,13974,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Other,7452697.0,
452,13983,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),Other,7452697.0,
453,13987,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),Other,7452697.0,
454,14155,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),Other,7452697.0,
455,15233,4,4,,103165562,3440,Unspecified,,,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,Other,7086844.0,
456,15711,3,3,,103165562,3440,Unspecified,,,,,Calculated partition coefficient (clogP),Other,9836611.0,
457,15928,3,3,,103165562,3440,Unspecified,,,,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Other,1433206.0,
458,15929,3,3,,103165562,3440,Unspecified,,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Other,1433206.0,
459,15987,3,3,,103165562,3440,Unspecified,,,,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,Other,7452697.0,
460,16002,3,4,,103165562,3440,Unspecified,,,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",Other,7452697.0,
461,16004,3,4,,103165562,3440,Unspecified,,,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",Other,7452697.0,
462,16005,3,4,,103165562,3440,Unspecified,,,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Other,7452697.0,
463,16006,3,3,,103165562,3440,Unspecified,,,,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Other,7452697.0,
464,16060,3,3,,103165562,3440,Unspecified,,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Other,1433206.0,
465,16064,3,3,,103165562,3440,Unspecified,,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Other,1433206.0,
466,16068,3,3,,103165562,3440,Unspecified,,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Other,1433206.0,
467,16072,3,3,,103165562,3440,Unspecified,,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Other,1433206.0,
468,16076,3,3,,103165562,3440,Unspecified,,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Other,1433206.0,
469,16080,3,3,,103165562,3440,Unspecified,,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Other,1433206.0,
470,16565,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Other,7452697.0,
471,16577,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Other,7452697.0,
472,16583,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Other,7452697.0,
473,16592,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),Other,7452697.0,
474,16599,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),Other,7452697.0,
475,16689,5,1,,103165562,3440,Unspecified,,,,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Other,1433206.0,
476,16690,5,1,,103165562,3440,Unspecified,,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Other,1433206.0,
477,16694,5,1,,103165562,3440,Unspecified,,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Other,1433206.0,
478,16698,5,1,,103165562,3440,Unspecified,,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Other,1433206.0,
479,16844,5,1,,103165562,3440,Unspecified,,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Other,1433206.0,
480,16848,5,1,,103165562,3440,Unspecified,,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Other,1433206.0,
481,16852,5,1,,103165562,3440,Unspecified,,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Other,1433206.0,
482,16856,5,1,,103165562,3440,Unspecified,,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Other,1433206.0,
483,16932,3,5,,103165562,3440,Unspecified,,,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Other,2724291.0,
484,16934,3,5,,103165562,3440,Unspecified,,,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Other,2724291.0,
485,16935,3,4,,103165562,3440,Unspecified,,,,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,Other,2724291.0,
486,16936,3,4,,103165562,3440,Unspecified,,,,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,Other,2724291.0,
487,16937,3,4,,103165562,3440,Unspecified,,,,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,Other,2724291.0,
488,16938,3,4,,103165562,3440,Unspecified,,,,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,Other,2724291.0,
489,16943,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Other,7966129.0,
490,16944,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Other,7966129.0,
491,16946,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,Other,7966129.0,
492,16977,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,Other,7966129.0,
493,16978,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,Other,7966129.0,
494,17152,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,Other,7966129.0,
495,17153,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,Other,7966129.0,
496,17169,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Other,7966129.0,
497,17170,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Other,7966129.0,
498,17171,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,Other,7966129.0,
499,17293,5,1,,103165562,3440,Unspecified,,,,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Other,1433206.0,
500,17294,5,1,,103165562,3440,Unspecified,,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Other,1433206.0,
501,17298,5,1,,103165562,3440,Unspecified,,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Other,1433206.0,
502,17302,5,1,,103165562,3440,Unspecified,,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Other,1433206.0,
503,17306,5,1,,103165562,3440,Unspecified,,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Other,1433206.0,
504,17310,5,1,,103165562,3440,Unspecified,,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Other,1433206.0,
505,17314,5,1,,103165562,3440,Unspecified,,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Other,1433206.0,
506,17318,5,1,,103165562,3440,Unspecified,,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Other,1433206.0,
507,17323,8,1,,103165562,3440,Unspecified,,,,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,Other,6431103.0,
508,17324,8,1,,103165562,3440,Unspecified,,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Other,6431103.0,
509,17326,7,1,,103165562,3440,Unspecified,,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Other,6431103.0,
510,17327,8,1,,103165562,3440,Unspecified,,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,Other,6431103.0,
511,17353,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,Other,7966129.0,
512,17354,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,Other,7966129.0,
513,17381,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Other,7966129.0,
514,17382,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Other,7966129.0,
515,17549,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,Other,7966129.0,
516,17550,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Other,7966129.0,
517,17552,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,Other,7966129.0,
518,17739,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,Other,7966129.0,
519,17740,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,Other,7966129.0,
520,17764,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Other,7966129.0,
521,17765,3,4,,103165562,3440,Unspecified,,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Other,7966129.0,
522,18861,3,4,,103165562,3440,Unspecified,,,,,GOF value represents multisets of log P data,Other,9836611.0,
523,19861,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of chloride in conscious rats at a dose of 1.0 mg/kg given orally,Other,2724291.0,
524,19862,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of chloride in conscious rats at a dose of 10 mg/kg given orally,Other,2724291.0,
525,19863,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of chloride in conscious rats at a dose of 100 mg/kg given orally,Other,2724291.0,
526,19864,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of chloride in conscious rats at a dose of 30 mg/kg given orally,Other,2724291.0,
527,19865,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of chloride in conscious rats at a dose of 3.0 mg/kg given orally,Other,2724291.0,
528,19866,3,4,,103165562,3440,Unspecified,,,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Other,2724291.0,
529,19867,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of potassium in conscious rats at a dose of 0.3 mg/kg given orally,Other,2724291.0,
530,19868,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of potassium in conscious rats at a dose of 1.0 mg/kg given orally,Other,2724291.0,
531,19869,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of potassium in conscious rats at a dose of 10 mg/kg given orally,Other,2724291.0,
532,19870,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of potassium in conscious rats at a dose of 100 mg/kg given orally,Other,2724291.0,
533,19871,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of potassium in conscious rats at a dose of 3.0 mg/kg given orally,Other,2724291.0,
534,19872,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of potassium in conscious rats at a dose of 30 mg/kg given orally,Other,2724291.0,
535,19873,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of sodium in conscious rats at a dose of 0.3 mg/kg given orally,Other,2724291.0,
536,19874,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of sodium in conscious rats at a dose of 1.0 mg/kg given orally,Other,2724291.0,
537,19875,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of sodium in conscious rats at a dose of 10 mg/kg given orally,Other,2724291.0,
538,19876,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of sodium in conscious rats at a dose of 100 mg/kg given orally,Other,2724291.0,
539,19877,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of sodium in conscious rats at a dose of 3.0 mg/kg given orally,Other,2724291.0,
540,19878,3,4,,103165562,3440,Unspecified,,,,,Mean excretion of sodium in conscious rats at a dose of 30 mg/kg given orally,Other,2724291.0,
541,19932,3,4,,103165562,3440,Unspecified,,,,,Oral dose necessary to produce an excretion of 2 mequiv of Na+/kg in the rat urine in the 4-h period after peroral administration,Other,6502592.0,
542,20710,3,4,,103165562,3440,Unspecified,,,,,"Compound administered at a dose of 6.25 mg/25 mL/kg orally to rats, urine collected for 6 hr and measured for Na+ excretion.",Other,1992150.0,
543,21074,3,5,,103165562,3440,Unspecified,,,,,Partion coefficient in octanol/H2O system at pH=7,Other,6876086.0,
544,21166,3,4,,103165562,3440,Unspecified,,,,,"Compound administered at a dose of 6.25 mg/25 mL/kg orally to rats, urine collected for 6 hr and measured for urine volume.",Other,1992150.0,
545,21264,3,3,,103165562,3440,Unspecified,,,,,Effective permeability measured in human.,Other,9836611.0,
546,21573,3,4,,103165562,3440,Unspecified,,,,,Urinary sodium 1 hr after the compound was administered 84 mg/kg po in rat,Other,1433206.0,
547,21576,3,4,,103165562,3440,Unspecified,,,,,Urinary sodium 2 hr after the compound was administered 84 mg/kg po in rat,Other,1433206.0,
548,21579,3,4,,103165562,3440,Unspecified,,,,,Urinary sodium 3h after the compound was administered 84 mg/kg po in rat,Other,1433206.0,
549,21582,3,4,,103165562,3440,Unspecified,,,,,Urinary sodium 4 hr after the compound was administered 84 mg/kg po in rat,Other,1433206.0,
550,21585,3,4,,103165562,3440,Unspecified,,,,,Urinary sodium 6 hr after the compound was administered 84 mg/kg po in rat,Other,1433206.0,
551,21591,3,4,,103165562,3440,Unspecified,,,,,Volume of urine 1 hr after the compound was administered 84 mg/kg po in rat,Other,1433206.0,
552,21594,3,4,,103165562,3440,Unspecified,,,,,Volume of urine 2 hr after the compound was administered 84 mg/kg po in rat,Other,1433206.0,
553,21597,3,4,,103165562,3440,Unspecified,,,,,Volume of urine 3h after the compound was administered 84 mg/kg po in rat,Other,1433206.0,
554,21600,3,4,,103165562,3440,Unspecified,,,,,Volume of urine 4 hr after the compound was administered 84 mg/kg po in rat,Other,1433206.0,
555,21603,3,4,,103165562,3440,Unspecified,,,,,Volume of urine 6 hr after the compound was administered 84 mg/kg po in rat,Other,1433206.0,
556,21604,3,4,,103165562,3440,Unspecified,,,,,"Compound was evaluated for diuretic activity, in female mongrel dogs by measuring volume of urine, after iv administration of 5 mg/kg (control/compound treatment results) Control = 1",Other,6737427.0,
557,21772,3,5,,103165562,3440,Unspecified,,,,,volume of urine at 27 mg/kg,Other,6737427.0,
558,21773,3,5,,103165562,3440,Unspecified,,,,,volume of urine at 3 mg/kg,Other,6737427.0,
559,21774,3,5,,103165562,3440,Unspecified,,,,,volume of urine at 81 mg/kg,Other,6737427.0,
560,21775,3,5,,103165562,3440,Unspecified,,,,,volume of urine at 9 mg/kg,Other,6737427.0,
561,21776,3,4,,103165562,3440,Unspecified,,,,,volume of urine in dog,Other,6737427.0,
562,21802,5,1,,103165562,3440,Unspecified,,,,,Mean urinary output in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Other,1433206.0,
563,21803,5,1,,103165562,3440,Unspecified,,,,,Mean urinary output in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Other,1433206.0,
564,21807,5,1,,103165562,3440,Unspecified,,,,,Mean urinary output in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Other,1433206.0,
565,21811,5,1,,103165562,3440,Unspecified,,,,,Mean urinary output in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Other,1433206.0,
566,21815,5,1,,103165562,3440,Unspecified,,,,,Mean urinary output in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Other,1433206.0,
567,21819,5,1,,103165562,3440,Unspecified,,,,,Mean urinary output in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Other,1433206.0,
568,21823,5,1,,103165562,3440,Unspecified,,,,,Mean urinary output in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Other,1433206.0,
569,21827,5,1,,103165562,3440,Unspecified,,,,,Mean urinary output in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Other,1433206.0,
570,21909,3,4,,103165562,3440,Unspecified,,,,,"Compound administered at a dose of 6.25 mg/25 mL/kg orally to rats, urine collected for 6 hr and measured for K+ excretion.",Other,1992150.0,
571,21966,4,1,,103165562,3440,Unspecified,,,,,Solubility of compound in water was determined,Other,6876086.0,
572,22025,5,1,,103165562,3440,Unspecified,,,,,Tested for the diuretic activity by measuring the urinary volume after peroral administering 0 uM/Kg of drug in rats,Other,7966129.0,
573,22059,5,1,,103165562,3440,Unspecified,,,,,Tested for the diuretic activity by measuring the urinary volume after peroral administering 30.2 uM/Kg of drug in rats,Other,7966129.0,
574,22060,5,1,,103165562,3440,Unspecified,,,,,Tested for the diuretic activity by measuring the urinary volume after peroral administering 302 uM/Kg of drug in rats,Other,7966129.0,
575,22233,5,1,,103165562,3440,Unspecified,,,,,Tested for the diuretic activity by measuring the urinary volume after peroral administering 9.06 uM/Kg of drug in dogs,Other,7966129.0,
576,22234,5,1,,103165562,3440,Unspecified,,,,,Tested for the diuretic activity by measuring the urinary volume after peroral administering 9.06 uM/Kg of drug in rats,Other,7966129.0,
577,22235,5,1,,103165562,3440,Unspecified,,,,,Tested for the diuretic activity by measuring the urinary volume after peroral administering 9.6 uM/Kg of drug in dogs,Other,7966129.0,
578,22236,5,1,,103165562,3440,Unspecified,,,,,Tested for the diuretic activity by measuring the urinary volume after peroral administering 90.6 uM/Kg of drug in rats,Other,7966129.0,
579,24128,3,4,,103165562,3440,Unspecified,,,,,urate excreted in 4 Cebus monkey''s during 0-6 hr,Other,6431103.0,
580,24132,4,4,,103165562,3440,Unspecified,,,,,urate excreted in female dogs during 0-6 hr,Other,6431103.0,
581,24183,3,5,,103165562,3440,Unspecified,,,,,Distribution coefficient in octanol/water at pH 5.5,Other,9836611.0,
582,24184,3,5,,103165562,3440,Unspecified,,,,,Distribution coefficient in octanol/water at pH 6.5,Other,9836611.0,
583,24185,3,5,,103165562,3440,Unspecified,,,,,Distribution coefficient in octanol/water at pH 7.4,Other,9836611.0,
584,24420,3,3,,103165562,3440,Unspecified,,,,,Partition coefficient (logP),Other,9836611.0,
585,24421,4,4,,103165562,3440,Unspecified,,,,,Partition coefficient (logD),Other,9836611.0,
586,25051,3,4,,103165562,3440,Unspecified,,,,,"Dissociation constant, pK1 was determined using potassium salt",Other,6876086.0,
587,26315,4,3,,103165562,3440,Unspecified,,,,,Dissociation constant (pKa) (determined in 30% EtOH),Other,7086844.0,
588,26400,3,3,,103165562,3440,Unspecified,,,,,pKa value of the compound. (extrapolated value),Other,9836611.0,
589,27167,3,4,,103165562,3440,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
590,28234,3,4,,103165562,3440,Unspecified,,,,,% absorbed in human GI-tract,Other,11300874.0,
591,28679,3,4,,103165562,3440,Unspecified,,,,,Partition coefficient (logD6.8),Other,11300874.0,
592,28681,3,4,,103165562,3440,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
593,28924,3,3,,103165562,3440,Unspecified,,,,,Effective permeability (Pe) across a hexadecane membrane (pH 6.8),Other,11300874.0,
594,28925,3,3,,103165562,3440,Unspecified,,,,,Highest effective permeability across hexadecane membrane (pH 4-8),Other,11300874.0,
595,29359,3,3,,103165562,3440,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
596,29813,3,3,,103165562,3440,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
597,29845,3,4,,103165562,3440,Unspecified,,,,,Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.,Other,10841786.0,
598,32292,8,5,,103165562,3440,Unspecified,1351830.0,100135472.0,100.0,Ki,Binding affinity against adenosine A1 receptor in guinea pig forebrain membranes using N6-[3H]cyclohexyladenosine as radioligand,Confirmatory,1501234.0,
599,33587,7,1,,103165562,3440,Unspecified,,,100.0,Ki,Binding affinity against adenosine A2 receptor in rat striatal membranes using N-[3H]-ethyladenosin-5''-uronamide as radioligand in the presence of 50 nM cyclopentyladenosine,Confirmatory,1501234.0,
600,43581,3,7,,103165562,3440,Unspecified,,,,,Inhibition of beta-lactamase at 100 uM,Other,14521410.0,
601,48338,7,2,,103165562,3440,Active,,,10.0,IC50,In vitro inhibition of HCO3- stimulated swelling in cat cerebrocortical tissue slice,Confirmatory,7086844.0,
602,51591,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for the oral natriuretic activity in chimpanzee at 5 mg/kg by observing the excretion rates of sodium; mequiv of Na+/min,Other,7277396.0,
603,51596,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity in chimpanzee measured as increase in the number of microequivalents of Cl- electrolyte/min at 1 mg/kg,Other,6737427.0,
604,51599,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity in chimpanzee measured as increase in the number of microequivalents of Cl- electrolyte/min at 1 mg/kg,Other,6737427.0,
605,51734,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity in chimpanzee measured as increase in the number of microequivalents of Na+ /min at 1 mg/kg,Other,6737427.0,
606,51737,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity in chimpanzee measured as increase in the number of microequivalents of Na+ /min at 1 mg/kg,Other,6737427.0,
607,51741,3,4,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity in chimpanzee measured as increase in volume of urine at 1 mg/kg,Other,6737427.0,
608,51746,3,4,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity in chimpanzee measured as increase in volume of urine at 1 mg/kg,Other,6737427.0,
609,51748,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity in chimpanzee measured as increase in the number of microequivalents of K+ /min at 1 mg/kg,Other,6737427.0,
610,51751,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity in chimpanzee measured as clearance of insulin and urate after intra venous administration of 1 mg/kg.,Other,6737427.0,
611,51758,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity in chimpanzee measured as clearance of insulin and urate after peroral administration of 5 mg/kg,Other,6737427.0,
612,51760,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity in chimpanzee measured as increase in the number of microequivalents of K+ /min at 1 mg/kg,Other,6737427.0,
613,51904,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for natriuretic activity in chimpanzee at 5 mg/kg dose activity is measured as microequivalent of Na+/minute; muequiv of Na+/min,Other,7277395.0,
614,52075,3,3,,103165562,3440,Active,,,,,Relative salidiuretic efficacy was scored in chimpanzee; very marked,Other,7086844.0,
615,52790,3,7,,103165562,3440,Unspecified,,,,,Inhibition of chymotrypsin at 250 uM,Other,14521410.0,
616,57179,3,3,,103165562,3440,Unspecified,,,,,"Compound was evaluated for diuretic activity, administered orally in female mongrel dogs (5 mg/kg) measured as milliequivalents of Cl-",Other,6737427.0,
617,57180,3,3,,103165562,3440,Unspecified,,,,,"Compound was evaluated for diuretic activity, administered orally in female mongrel dogs (5 mg/kg) measured as milliequivalents of K",Other,6737427.0,
618,57181,3,3,,103165562,3440,Unspecified,,,,,"Compound was evaluated for diuretic activity, administered orally in female mongrel dogs (5 mg/kg) measured as milliequivalents of Na",Other,6737427.0,
619,57182,3,4,,103165562,3440,Unspecified,,,,,"Compound was evaluated for diuretic activity, in female mongrel dogs by measuring amount of Cl- in urine after iv administration of 5 mg/kg (control/compound treatment results) Control = 1",Other,6737427.0,
620,57318,3,4,,103165562,3440,Unspecified,,,,,"Compound was evaluated for diuretic activity, in female mongrel dogs by measuring amount of K+ in urine after iv administration of 5 mg/kg (control/compound treatment results) Control = 18",Other,6737427.0,
621,57323,3,4,,103165562,3440,Unspecified,,,,,"Compound was evaluated for diuretic activity, in female mongrel dogs by measuring amount of Na+ in urine after iv administration of 5 mg/kg (control/compound treatment results) Control = 29",Other,6737427.0,
622,58442,3,3,,103165562,3440,Unspecified,,,,,"Diuretic activity in the dog (2 animals/dose) at (dose 0.78 mg/Kg), when administered perorally",Other,6876086.0,
623,58445,3,3,,103165562,3440,Unspecified,,,,,"Diuretic activity in the dog (2 animals/dose) at (dose 6.25 mg/Kg), when administered perorally",Other,6876086.0,
624,58593,3,4,,103165562,3440,Unspecified,,,,,The saluretic(Cl-) effect of compound was measured in dogs after iv administration at 2 mg/kg dose; Cl-mequiv/min=303,Other,7205867.0,
625,58595,3,4,,103165562,3440,Unspecified,,,,,The saluretic(K+) effect of compound was measured in dogs after iv administration at 2 mg/kg dose; K+mequiv/min=20,Other,7205867.0,
626,58597,3,4,,103165562,3440,Unspecified,,,,,The saluretic(Na+) effect of compound was measured in dogs after iv administration at 2 mg/kg dose; Na+ mequiv/min=279,Other,7205867.0,
627,58923,3,3,,103165562,3440,Active,,,,,Relative salidiuretic efficacy was scored in dog; very marked,Other,7086844.0,
628,59303,4,3,,103165562,3440,Unspecified,,,,,ED5(natriuretic potency) is the oral dose(mg/kg) required to produce an excretion of 5 milliequivalents of Na+per kilogram during 0-6 hr in female dogs (Highest dose tested was 30 mg/kg),Other,6431103.0,
629,59305,3,3,,103165562,3440,Unspecified,,,,,"Natriuretic potency was evaluated as oral dose required to produce an excretion of 2 mequiv of Na+/Kg of dog body weight, ED5 value based on N=2 dogs/dose",Other,3989818.0,
630,60413,3,3,,103165562,3440,Unspecified,,,,,Diuretic activity was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 1 hr,Other,7086820.0,
631,60414,3,3,,103165562,3440,Unspecified,,,,,The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 1 hr; Micro equiv of Na+/kg,Other,7086820.0,
632,60415,3,3,,103165562,3440,Unspecified,,,,,The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 2 hr; Micro equiv of Na+/kg,Other,7086820.0,
633,60416,3,3,,103165562,3440,Unspecified,,,,,The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 3 hr; Micro equiv of Na+/kg,Other,7086820.0,
634,60417,3,3,,103165562,3440,Unspecified,,,,,The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 4 hr; Micro equiv of Na+/kg,Other,7086820.0,
635,60418,3,3,,103165562,3440,Unspecified,,,,,The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 5h; Micro equiv of Na+/kg,Other,7086820.0,
636,60419,3,3,,103165562,3440,Unspecified,,,,,The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 6 h; Micro equiv of Na+/kg,Other,7086820.0,
637,60862,7,1,,103165562,3440,Unspecified,,,,,Effect on (GFR) glomerular filtration rate in dogs was evaluated,Other,6876086.0,
638,61893,3,3,,103165562,3440,Unspecified,,,,,"Sailuric activity in the dog measured as concentration of K+ in urinary excretion (2 animals/dose) at (dose 0.78 mg/Kg, po)",Other,6876086.0,
639,62065,3,3,,103165562,3440,Unspecified,,,,,"Sailuric activity in the dog measured as concentration of Cl - in urinary excretion (2 animals/dose) at (dose 0.78 mg/Kg, po)",Other,6876086.0,
640,62066,3,3,,103165562,3440,Unspecified,,,,,"Sailuric activity in the dog measured as concentration of Cl - in urinary excretion (2 animals/dose) at (dose 6.25 mg/Kg, po)",Other,6876086.0,
641,62068,3,3,,103165562,3440,Unspecified,,,,,"Sailuric activity in the dog measured as concentration of K+ in urinary excretion (2 animals/dose) at (dose 6.25 mg/Kg, po)",Other,6876086.0,
642,62069,3,3,,103165562,3440,Unspecified,,,,,"Sailuric activity in the dog measured as concentration of Na+ in urinary excretion (2 animals/dose) at (dose 0.78 mg/Kg, po)",Other,6876086.0,
643,62071,3,3,,103165562,3440,Unspecified,,,,,"Sailuric activity in the dog measured as concentration of Na+ in urinary excretion (2 animals/dose) at (dose 6.25 mg/Kg, po)",Other,6876086.0,
644,62233,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for the saluretic property in dogs after intravenous administration of 1 mg/kg; >900 micro equivalents of Na+ excreted per minute,Other,7288821.0,
645,62352,3,3,,103165562,3440,Unspecified,,,,,Saluretic property in average of two anesthetized dogs after 1 mg/kg intravenous administration,Other,6834392.0,
646,62699,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for diuretic activity in dogs at 5 mg/kg dose after intravenous administration measured as microequivalent of Na+/minute; 29/960 (Control/Drug treated),Other,7277395.0,
647,63429,7,1,,103165562,3440,Unspecified,,,,,Effect on Urine flow in dogs was evaluated,Other,6876086.0,
648,71809,8,1,,103165562,3440,Unspecified,,,,,Dose required for 50% inhibition of chloride transport in frog cornea was evaluated,Other,6502592.0,
649,90254,3,3,,103165562,3440,Active,,,,,Relative salidiuretic efficacy was scored in human; very marked,Other,7086844.0,
650,91481,4,7,,103165562,3440,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
651,106806,3,8,,103165562,3440,Unspecified,,,,,Inhibition of malate dehydrogenase (MDH) at 400 uM,Other,14521410.0,
652,117497,3,3,,103165562,3440,Unspecified,,,,,The diuretic activity was measured after oral administration in saline loaded mice at 4 mg/kg after 5 hr,Other,7086820.0,
653,117499,3,3,,103165562,3440,Unspecified,,,,,The diuretic activity was measured after oral administration in saline loaded mice at 64 mg/kg after 5 hr,Other,7086820.0,
654,127482,3,3,,103165562,3440,Unspecified,,,,,"Ability to bind to monoclonal antibody IgE (Lb4), expressed as association constant (LogKA)",Other,8831754.0,
655,129601,3,3,,103165562,3440,Unspecified,,,,,Acute toxicity in mice when given po,Other,1433206.0,
656,132826,4,3,,103165562,3440,Unspecified,,,,,ED6 (natriuretic potency) is the oral dose(mg/kg) required to produce an excretion of 6 milliequivalents of Na+per kilogram during 0-4 hr in male mice (Highest dose tested was 50 mg/kg),Other,6431103.0,
657,135327,6,1,,103165562,3440,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
658,156202,3,4,,103165562,3440,Unspecified,,,,,Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system,Other,10841786.0,
659,156204,3,4,,103165562,3440,Unspecified,,,,,Binding to POPC/GMI liposomes using biosensor system,Other,10841786.0,
660,169981,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity administered orally in female rats measured as milliequivalents of Cl-+x 100 / cage at 27 mg/kg,Other,6737427.0,
661,169982,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity administered orally in female rats measured as milliequivalents of Cl-x 100 / cage at 3 mg/kg,Other,6737427.0,
662,169983,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity administered orally in female rats measured as milliequivalents of Cl-x 100 / cage at 81 mg/kg,Other,6737427.0,
663,169984,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity administered orally in female rats measured as milliequivalents of Cl-x 100 / cage at 9 mg/kg,Other,6737427.0,
664,169985,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity administered orally in female rats measured as milliequivalents of K+x 100 / cage at 27 mg/kg,Other,6737427.0,
665,169986,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity administered orally in female rats measured as milliequivalents of K+x 100 / cage at 3 mg/kg,Other,6737427.0,
666,169987,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity administered orally in female rats measured as milliequivalents of K+x 100 / cage at 81 mg/kg,Other,6737427.0,
667,169988,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity administered orally in female rats measured as milliequivalents of K+x 100 / cage at 9 mg/kg,Other,6737427.0,
668,169989,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity administered orally in female rats measured as milliequivalents of Na+x 100 / cage at 27 mg/kg,Other,6737427.0,
669,169990,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity administered orally in female rats measured as milliequivalents of Na+x 100 / cage at 3 mg/kg,Other,6737427.0,
670,169991,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity administered orally in female rats measured as milliequivalents of Na+x 100 / cage at 81 mg/kg,Other,6737427.0,
671,169992,3,3,,103165562,3440,Unspecified,,,,,Compound was evaluated for diuretic activity administered orally in female rats measured as milliequivalents of Na+x 100 / cage at 9 mg/kg,Other,6737427.0,
672,173380,3,4,,103165562,3440,Unspecified,,,,,The saluretic(K+) effect of compound was measured in rats after oral administration at 81 mg/kg dose; K+mequiv*100/cage=14,Other,7205867.0,
673,173381,3,4,,103165562,3440,Unspecified,,,,,The saluretic(K+) effect of compound was measured in rats after oral administration at 9 mg/kg dose; K+mequiv*100/cage=14,Other,7205867.0,
674,173776,5,1,,103165562,3440,Unspecified,,,,,Dose required to produce an excretion of 2 mequiv of Na+/kg bw/6h vs control groups,Other,1433206.0,
675,173777,3,3,,103165562,3440,Unspecified,,,,,ED2(natriuretic potency) is the oral dose(mg/kg) required to produce an excretion of 2 milliequivalents of Na+per kilogram during 0-4 hr in female rats (Highest dose tested was 100 mg/kg),Other,6431103.0,
676,173783,3,3,,103165562,3440,Unspecified,,,,,"Natriuretic potency was evaluated as oral dose required to produce an excretion of 2 mequiv of Na+/Kg of rat body weight, ED2 value based on N=4 rats/dose",Other,3989818.0,
677,173965,3,4,,103165562,3440,Unspecified,,,,,Dose required to produce increase in 200 % in urine production vs control groups,Other,1433206.0,
678,174281,3,5,,103165562,3440,Unspecified,,,,,Compound was tested for antihypertensive activity in rat after 1 hr postdose,Other,3712385.0,
679,174282,3,5,,103165562,3440,Unspecified,,,,,Compound was tested for antihypertensive activity in rat after 24 hr postdose,Other,3712385.0,
680,174283,3,5,,103165562,3440,Unspecified,,,,,Compound was tested for antihypertensive activity in rat after 4 hr postdose,Other,3712385.0,
681,174517,8,1,,103165562,3440,Unspecified,,,,,Serum creatinine concentration measured after intraperitoneal administration of 10 mg/kg of compound to rats(vehicle 3.22+/-0.35),Other,1501234.0,
682,175531,3,3,,103165562,3440,Unspecified,,,,,Diuretic activity by measuring the urinary output at the dose of 20 mg/kg,Other,7086830.0,
683,175534,3,3,,103165562,3440,Unspecified,,,,,Diuretic activity by measuring the urinary output at the dose of 40 mg/kg,Other,7086830.0,
684,175816,3,3,,103165562,3440,Unspecified,,,,,Diuretic activity in rats,Other,3735318.0,
685,175817,3,4,,103165562,3440,Unspecified,,,,,Diuretic activity in rats at time intervals of 0-24 hours,Other,3712385.0,
686,175818,3,4,,103165562,3440,Unspecified,,,,,Diuretic activity in rats at time intervals of 0-5 hours,Other,3712385.0,
687,175819,3,4,,103165562,3440,Unspecified,,,,,Diuretic activity in rats at time intervals of 5-24 hours,Other,3712385.0,
688,175820,4,3,,103165562,3440,Unspecified,,,,,"Diuretic activity in the rats, determined by a modified Lipschitz test",Other,6876086.0,
689,175822,5,3,,103165562,3440,Unspecified,,,,,Diuretic effect was evaluated in the conscious female rat by natriuretic assay involving metabolic caging at dose 20 mg/kg,Other,8632425.0,
690,175823,5,3,,103165562,3440,Unspecified,,,,,Diuretic effect was evaluated in the conscious female rat by natriuretic assay involving metabolic caging at dose 30 mg/kg,Other,8632425.0,
691,175998,3,4,,103165562,3440,Unspecified,,,,,The saluretic (Na+) effect of compound was measured in rats after oral administration at 27 mg/kg dose; Na+ mequiv*100/cage,Other,7205867.0,
692,175999,3,4,,103165562,3440,Unspecified,,,,,The saluretic (Na+) effect of compound was measured in rats after oral administration at 81 mg/kg dose; Na+ mequiv*100/cage,Other,7205867.0,
693,176000,3,4,,103165562,3440,Unspecified,,,,,The saluretic (Na+) effect of compound was measured in rats after oral administration at 9 mg/kg dose; Na+ mequiv*100/cage,Other,7205867.0,
694,176003,4,4,,103165562,3440,Unspecified,,,,,The saluretic(Cl-) effect of compound was measured in rats after oral administration at 27 mg/kg dose; Cl-mequiv*100/cage=14,Other,7205867.0,
695,176009,3,4,,103165562,3440,Unspecified,,,,,The saluretic(Cl-) effect of compound was measured in rats after oral administration at 9 mg/kg dose; Cl-mequiv*100/cage=14,Other,7205867.0,
696,176010,4,4,,103165562,3440,Unspecified,,,,,The saluretic(K+) effect of compound was measured in rats after oral administration at 27 mg/kg dose; K+mequiv*100/cage=14,Other,7205867.0,
697,176936,8,2,,103165562,3440,Unspecified,,,,,Dose required to produce increase in 50 % in urine production vs control groups,Other,1433206.0,
698,180598,4,3,,103165562,3440,Unspecified,,,,,Compound was tested for the oral natriuretic activity in female rats at the dose 27 mg/kg; mequiv of Na+ x 100 / cage,Other,7277396.0,
699,180599,3,3,,103165562,3440,Inconclusive,,,,,Compound was tested for the oral natriuretic activity in female rats at the dose 3 mg/kg( mequiv of Na+ x 100 / cage); Not tested,Other,7277396.0,
700,180602,4,3,,103165562,3440,Unspecified,,,,,Compound was tested for the oral natriuretic activity in female rats at the dose 81 mg/kg; mequiv of Na+ x 100 / cage,Other,7277396.0,
701,180604,4,3,,103165562,3440,Unspecified,,,,,Compound was tested for the oral natriuretic activity in female rats at the dose 9 mg/kg; mequiv of Na+ x 100 / cage,Other,7277396.0,
702,185745,3,4,,103165562,3440,Unspecified,,,,,"Mean arterial pressure was measured in hypertensive rat at dose of 20 mg/kg, po",Other,7205867.0,
703,186699,3,4,,103165562,3440,Unspecified,,,,,Blood pressure change in rats after oral administration of 50 mg/kg dose after 24 hours,Other,3735318.0,
704,186701,3,4,,103165562,3440,Unspecified,,,,,Blood pressure change in rats after oral administration of 50 mg/kg dose after 4 hours,Other,3735318.0,
705,186829,3,4,,103165562,3440,Unspecified,,,,,Potassium salt excretion in conscious rat at the dose of 0.3 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
706,186830,3,4,,103165562,3440,Unspecified,,,,,Potassium salt excretion in conscious rat at the dose of 1.0 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
707,186831,3,4,,103165562,3440,Unspecified,,,,,Potassium salt excretion in conscious rat at the dose of 10 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
708,186832,3,4,,103165562,3440,Unspecified,,,,,Potassium salt excretion in conscious rat at the dose of 100 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
709,186833,3,4,,103165562,3440,Unspecified,,,,,Potassium salt excretion in conscious rat at the dose of 3.0 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
710,186859,3,4,,103165562,3440,Unspecified,,,,,Maximum fall in mean arterial blood pressure was measured in SH rats when compound was administered at 3.75 mg/kg perorally,Other,7452697.0,
711,186860,3,4,,103165562,3440,Unspecified,,,,,Maximum fall in mean arterial blood pressure was measured in SH rats when compound was administered at 30 mg/kg perorally,Other,7452697.0,
712,186862,3,4,,103165562,3440,Unspecified,,,,,Maximum fall in mean arterial blood pressure was measured in SH rats when compound was administered at 7.5 mg/kg perorally,Other,7452697.0,
713,186961,3,4,,103165562,3440,Unspecified,,,,,Potassium salt excretion in conscious rat at the dose of 30 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
714,186985,3,3,,103165562,3440,Unspecified,,,,,Kaliuretic effect was evaluated in the conscious female rat by natriuretic assay involving metabolic caging at dose 20 mg/kg,Other,8632425.0,
715,186986,3,3,,103165562,3440,Unspecified,,,,,Kaliuretic effect was evaluated in the conscious female rat by natriuretic assay involving metabolic caging at dose 30 mg/kg,Other,8632425.0,
716,187642,3,3,,103165562,3440,Active,,,,,Relative salidiuretic efficacy was scored in Rat; very marked,Other,7086844.0,
717,187952,5,1,,103165562,3440,Unspecified,,,,,Effect on urinary excretion potassium and sodium after oral administration of 1.6 mg/kg to rats(potassium and sodium excretion in control rat is 0.161+/-0.013),Other,1501234.0,
718,188112,5,1,,103165562,3440,Unspecified,,,,,Effect on urinary excretion potassium and sodium after oral administration of 25 mg/kg to rats(potassium and sodium excretion in control rat is 0.180+/-0.015),Other,1501234.0,
719,188120,5,1,,103165562,3440,Unspecified,,,,,Effect on urinary excretion potassium and sodium after oral administration of 6.25 mg/kg to rats(potassium and sodium excretion in control rat is 0.079+/-0.007),Other,1501234.0,
720,188263,3,4,,103165562,3440,Unspecified,,,,,Sodium salt excretion in conscious rat at the dose of 0.3 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
721,188264,3,4,,103165562,3440,Unspecified,,,,,Sodium salt excretion in conscious rat at the dose of 1.0 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
722,188265,3,4,,103165562,3440,Unspecified,,,,,Sodium salt excretion in conscious rat at the dose of 10 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
723,188266,3,4,,103165562,3440,Unspecified,,,,,Sodium salt excretion in conscious rat at the dose of 100 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
724,188267,3,4,,103165562,3440,Unspecified,,,,,Sodium salt excretion in conscious rat at the dose of 3.0 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
725,188268,3,4,,103165562,3440,Unspecified,,,,,Sodium salt excretion in conscious rat at the dose of 30 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
726,188280,4,3,,103165562,3440,Unspecified,,,,,"Ratio of sodium ion/potassium ion concentration in treated rats to that in control rats, at a peroral dose of 1.6 mg/Kg",Other,1501234.0,
727,188282,4,3,,103165562,3440,Unspecified,,,,,"Ratio of sodium ion/potassium ion concentration in treated rats to that in control rats, at a peroral dose of 25 mg/Kg",Other,1501234.0,
728,188407,4,4,,103165562,3440,Unspecified,,,,,Ratio of sodium ion/potassium ion concentration in urine of rats following 6.25 mg/kg p.o.,Other,1501234.0,
729,188410,3,3,,103165562,3440,Unspecified,,,,,Natriuretic effect was evaluated in the conscious female rat by natriuretic assay involving metabolic caging at dose 20 mg/kg,Other,8632425.0,
730,188411,3,3,,103165562,3440,Unspecified,,,,,Natriuretic effect was evaluated in the conscious female rat by natriuretic assay involving metabolic caging at dose 30 mg/kg,Other,8632425.0,
731,189923,3,3,,103165562,3440,Unspecified,,,,,"Ratio of urinary excretion value (Na+ concentration) in treated rats to that in control rats, at a peroral dose of 1.6 mg/Kg",Other,1501234.0,
732,189925,4,3,,103165562,3440,Unspecified,,,,,"Ratio of urinary excretion value (Na+ concentration) in treated rats to that in control rats, at a peroral dose of 25 mg/Kg",Other,1501234.0,
733,189927,4,3,,103165562,3440,Unspecified,,,,,"Ratio of urinary excretion value (Na+ concentration) in treated rats to that in control rats, at a peroral dose of 6.25 mg/Kg",Other,1501234.0,
734,189935,4,3,,103165562,3440,Unspecified,,,,,"Ratio of urinary excretion value (urinary volume) in treated rats to that in control rats, at a peroral dose of 1.6 mg/Kg",Other,1501234.0,
735,189937,4,3,,103165562,3440,Unspecified,,,,,"Ratio of urinary excretion value (urinary volume) in treated rats to that in control rats, at a peroral dose of 25 mg/Kg",Other,1501234.0,
736,189939,4,3,,103165562,3440,Unspecified,,,,,"Ratio of urinary excretion value (urinary volume) in treated rats to that in control rats, at a peroral dose of 6.25 mg/Kg",Other,1501234.0,
737,190185,8,1,,103165562,3440,Unspecified,,,,,Urea nitrogen concentration measured after intraperitoneal administration of 10 mg/kg of compound to rats(vehicle 110.7+/-9.4),Other,1501234.0,
738,190283,7,1,,103165562,3440,Unspecified,,,,,"Saluretic activity in rats after 0-24 hours, as chloride ion concentration in urine",Other,3712385.0,
739,190284,7,1,,103165562,3440,Unspecified,,,,,"Saluretic activity in rats after 0-24 hours, as potassium ion concentration in urine",Other,3712385.0,
740,190285,7,1,,103165562,3440,Unspecified,,,,,"Saluretic activity in rats after 0-24 hours, as sodium ion concentration in urine",Other,3712385.0,
741,190286,7,1,,103165562,3440,Unspecified,,,,,"Saluretic activity in rats after 0-5 hours, as chloride ion concentration in urine",Other,3712385.0,
742,190287,7,1,,103165562,3440,Unspecified,,,,,"Saluretic activity in rats after 0-5 hours, as potassium ion concentration in urine",Other,3712385.0,
743,190288,7,1,,103165562,3440,Unspecified,,,,,"Saluretic activity in rats after 0-5 hours, as sodium ion concentration in urine",Other,3712385.0,
744,190289,7,1,,103165562,3440,Unspecified,,,,,"Saluretic activity in rats after 5-24 hours, as chloride ion concentration in urine",Other,3712385.0,
745,190290,7,1,,103165562,3440,Unspecified,,,,,"Saluretic activity in rats after 5-24 hours, as potassium ion concentration in urine",Other,3712385.0,
746,190417,7,1,,103165562,3440,Unspecified,,,,,"Saluretic activity in rats after 5-24 hours, as sodium ion concentration in urine",Other,3712385.0,
747,190418,4,4,,103165562,3440,Unspecified,,,,,Saluretic activity in the rat measured as concentration of chloride in urine,Other,6876086.0,
748,190419,4,4,,103165562,3440,Unspecified,,,,,Saluretic activity in the rat measured as concentration of K+ in urine,Other,6876086.0,
749,190420,4,4,,103165562,3440,Unspecified,,,,,Saluretic activity in the rat measured as concentration of Na+ in urine,Other,6876086.0,
750,190428,3,3,,103165562,3440,Unspecified,,,,,Evaluated for the saluretic property in rats after oral administration; score represents micro equivalents of Na+ excreted at a given mg/kg dose,Other,7288821.0,
751,190442,3,3,,103165562,3440,Unspecified,,,,,Saluretic property after 50 mg/kg oral administration in rats,Other,6834392.0,
752,190622,3,3,,103165562,3440,Unspecified,,,,,Post dosing time interval of maximum activity,Other,1433206.0,
753,190850,8,1,,103165562,3440,Unspecified,,,,,Compound was evaluated for Urea Nitrogen concentration in glycerol injected rats treated with 10 mg/kg administered intraperitoneally.,Other,1992150.0,
754,190863,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for urinary volume excretion in conscious rat at the dose of 0.3 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
755,190864,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for urinary volume excretion in conscious rat at the dose of 1.0 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
756,190865,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for urinary volume excretion in conscious rat at the dose of 10 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
757,190866,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for urinary volume excretion in conscious rat at the dose of 100 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
758,190867,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for urinary volume excretion in conscious rat at the dose of 3.0 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
759,190869,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for urinary volume excretion in conscious rat at the dose of 30 mg/kg expressed as urinary excretion in treated rats/urinary excretion in control rats,Other,3735318.0,
760,191185,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was measured after oral administration of 1.6 mg/kg to rats(control volume is 0.85+/-0.10),Other,1501234.0,
761,191283,8,1,,103165562,3440,Unspecified,,,,,Compound was evaluated for Serum creatinine concentration in glycerol injected rats treated with 10 mg/kg administered intraperitoneally.,Other,1992150.0,
762,191346,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was measured after oral administration of 25 mg/kg to rats(control volume is 1.21+/-0.08),Other,1501234.0,
763,191350,3,3,,103165562,3440,Unspecified,,,,,Oral diuretic activity was measured after oral administration of 6.25 mg/kg to rats(control volume is 0.69+/-0.03),Other,1501234.0,
764,192672,4,2,,103165562,3440,Unspecified,,,,,Percent inhibition of serum creatinine by the compound given as ratio of Cr value in treated to vehicle treated ones after intraperitoneal administration of 10 mg/kg of compound to rats(vehicle 3.22+/-0.35),Other,1501234.0,
765,194796,4,2,,103165562,3440,Unspecified,,,,,Percent inhibition of Urea nitrogen by the compound given as ratio of UN value in treated to vehicle treated ones after intraperitoneal administration of 10 mg/kg of compound to rats(vehicle 110.7+/-9.4),Other,1501234.0,
766,195372,3,3,,103165562,3440,Unspecified,,,,,Reduction of Astrocyte intracellular chloride concentration at 0.1 mM.,Other,3656355.0,
767,195375,5,2,,103165562,3440,Inconclusive,,,,,Reduction of Astrocyte intracellular chloride concentration at 0.05 mM; No data.,Other,3656355.0,
768,195377,3,3,,103165562,3440,Unspecified,,,,,Reduction of Astrocyte intracellular chloride concentration at 1 mM.,Other,3656355.0,
769,196138,4,3,,103165562,3440,Unspecified,,,,,Natriuretic activity in rats at 27 mg/kg of dosage; mequiv of Na,Other,7277395.0,
770,196139,4,3,,103165562,3440,Unspecified,,,,,Natriuretic activity in rats at 3 mg/kg of dosage; mequiv of Na,Other,7277395.0,
771,196141,4,3,,103165562,3440,Unspecified,,,,,Natriuretic activity in rats at 81 mg/kg of dosage; mequiv of Na,Other,7277395.0,
772,196142,4,3,,103165562,3440,Unspecified,,,,,Natriuretic activity in rats at 9 mg/kg of dosage; mequiv of Na,Other,7277395.0,
773,220699,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for diuretic activity in dogs at 5 mg/kg dose after intravenous administration measured as microequivalent of Cl-/minute; 1/1081 (Control/Drug treated),Other,7277395.0,
774,220700,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for diuretic activity in dogs at 5 mg/kg dose after intravenous administration measured as microequivalent of K+/minute; 18/141 (Control/Drug treated),Other,7277395.0,
775,220704,3,4,,103165562,3440,Unspecified,,,,,"Compound was tested for diuretic activity in dogs at 5 mg/kg dose after intravenous administration, activity is expressed as urine volume",Other,7277395.0,
776,220705,3,4,,103165562,3440,Unspecified,,,,,"Compound was tested for diuretic activity in dogs at 5 mg/kg dose after intravenous administration, activity is expressed as urine volume; 1/3",Other,7277395.0,
777,220706,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for diuretic activity in dogs at 5 mg/kg dose after oral administration measured as microequivalent of Cl-/minute,Other,7277395.0,
778,220707,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for diuretic activity in dogs at 5 mg/kg dose after oral administration measured as microequivalent of K+/minute,Other,7277395.0,
779,220708,3,3,,103165562,3440,Unspecified,,,,,Compound was tested for diuretic activity in dogs at 5 mg/kg dose after oral administration measured as microequivalent of Na+/minute,Other,7277395.0,
780,230247,4,2,,103165562,3440,Unspecified,,,,,Ratio of Na+ to K+ excretion,Other,1992150.0,
781,230248,4,3,,103165562,3440,Unspecified,,,,,Ratio of Na+ to K+ excretion at dose,Other,1433206.0,
782,230249,3,3,,103165562,3440,Unspecified,,,,,Ratio of Na+ to k+ excretion at above dose,Other,1433206.0,
783,230280,3,4,,103165562,3440,Unspecified,,,,,Ratio of Total electrolytic excretion of sodium and potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Other,7966129.0,
784,230281,3,4,,103165562,3440,Unspecified,,,,,Ratio of Total electrolytic excretion of sodium and potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Other,7966129.0,
785,230295,3,4,,103165562,3440,Unspecified,,,,,Ratio of Total electrolytic excretion of sodium and potassium in urine of rats after peroral administration of 0 uM/Kg of drug,Other,7966129.0,
786,230407,3,3,,103165562,3440,Unspecified,,,,,It is ratio of Insulin U/P,Other,6876086.0,
787,230470,3,4,,103165562,3440,Unspecified,,,,,Ratio of Total electrolytic excretion of sodium and potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,Other,7966129.0,
788,230471,3,4,,103165562,3440,Unspecified,,,,,Ratio of Total electrolytic excretion of sodium and potassium in urine of rats after peroral administration of 302 uM/Kg of drug,Other,7966129.0,
789,230657,3,4,,103165562,3440,Unspecified,,,,,Ratio of Total electrolytic excretion of sodium and potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Other,7966129.0,
790,230658,3,4,,103165562,3440,Unspecified,,,,,Ratio of Total electrolytic excretion of sodium and potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Other,7966129.0,
791,232279,4,4,,103165562,3440,Unspecified,,,,,Compound was tested for the ratio of clearance of urate to clearance of inulin levels at 5 mg/kg in Chimpanzee,Other,7277396.0,
792,232282,3,5,,103165562,3440,Unspecified,,,,,"Saluretic activity in rats after 0-24 hours, as ratio of Na+/K+ ion concentration in urine",Other,3712385.0,
793,232283,3,5,,103165562,3440,Unspecified,,,,,"Saluretic activity in rats after 0-5 hours, as ratio of Na+/K+ ion concentration in urine",Other,3712385.0,
794,232284,3,5,,103165562,3440,Unspecified,,,,,"Saluretic activity in rats after 5-24 hours, as ratio of Na+/K+ ion concentration in urine",Other,3712385.0,
795,233748,3,4,,103165562,3440,Unspecified,,,,,Compound was tested for natriuretic activity in chimpanzee at 5 mg/kg dose activity is measured as ratio of clearance of urate / insulin; Curate/Cinulin,Other,7277395.0,
796,236918,3,5,,103165562,3440,Unspecified,,,,,Apparent permeability of the compound was determined in MDCK (madin darby canine kidney) strain I; Activity = Papp 10e-6,Other,15689164.0,
797,236919,4,4,,103165562,3440,Unspecified,,,,,Apparent permeability of the compound was determined inCaco-2 (human colon carcinoma) cells; Activity = Papp 10e-6 (ND =Not determined),Other,15689164.0,
798,237416,3,4,,103165562,3440,Unspecified,,,,,Log D value against bovine serum albumin,Other,15267234.0,
799,237474,3,3,,103165562,3440,Unspecified,,,,,Percentage of drug bound in bovine plasma albumin,Other,15267234.0,
800,237685,4,3,,103165562,3440,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
801,239780,3,9,,103165562,3440,Unspecified,113576.0,213.0,,,Percentage plasma protein binding towards human serum albumin,Other,15801837.0,
802,239884,4,2,,103165562,3440,Unspecified,,,,,pKa value of the compound,Other,15267234.0,
803,243230,4,1,,103165562,3440,Unspecified,113576.0,213.0,138038000000.0,Ki,Binding affinity towards human serum albumin,Confirmatory,15801837.0,
804,257101,12,2,,103165562,3440,Unspecified,6225000.0,938194.0,,IC50,Inhibitory activity against Bacillus subtilis AcpS by HTRF assay,Confirmatory,16335920.0,
805,275284,6,2,,103165562,3440,Inconclusive,,,,EC50,Reduction of PrPSC accumulation in ScN2a cells,Confirmatory,17201410.0,
806,275285,8,1,,103165562,3440,Inconclusive,,,,LD50,Cytotoxicity against ScN2a cells,Confirmatory,17201410.0,
807,275286,6,2,,103165562,3440,Unspecified,,,,,Solubility in phosphate buffer at pH 6.5 at 500 uM,Other,17201410.0,
808,275287,3,4,,103165562,3440,Unspecified,,,,,Permeability across DOPC lipid membrane by PAMPA,Other,17201410.0,
809,288184,9,1,,103165562,3440,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
810,288185,7,1,,103165562,3440,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
811,288192,3,4,,103165562,3440,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
812,311367,3,6,,103165562,3440,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
813,328974,3,9,,103165562,3440,Active,115449.0,759.0,,,Inhibition of human full length carbonic anhydrase 1,Other,18374572.0,
814,328975,3,9,,103165562,3440,Active,115456.0,760.0,,,Inhibition of human full length carbonic anhydrase 2,Other,18374572.0,
815,328976,9,1,,103165562,3440,Unspecified,134047703.0,761.0,,,Inhibition of human full length carbonic anhydrase 3,Other,18374572.0,
816,328977,4,9,,103165562,3440,Active,115465.0,762.0,,,Inhibition of human full length carbonic anhydrase 4,Other,18374572.0,
817,328978,4,9,,103165562,3440,Active,461680.0,763.0,,,Inhibition of human full length carbonic anhydrase 5A,Other,18374572.0,
818,328979,4,9,,103165562,3440,Active,8928041.0,11238.0,,,Inhibition of human full length carbonic anhydrase 5B,Other,18374572.0,
819,328980,4,9,,103165562,3440,Active,116241278.0,765.0,,,Inhibition of human full length carbonic anhydrase 6,Other,18374572.0,
820,328981,4,9,,103165562,3440,Active,1168744.0,766.0,,,Inhibition of human full length carbonic anhydrase 7,Other,18374572.0,
821,328982,4,10,,103165562,3440,Active,83300925.0,768.0,,,Inhibition of human catalytic domain carbonic anhydrase 9,Other,18374572.0,
822,328983,4,9,,103165562,3440,Active,5915866.0,771.0,,,Inhibition of human catalytic domain carbonic anhydrase 12,Other,18374572.0,
823,328984,4,9,,103165562,3440,Active,30580372.0,71934.0,,,Inhibition of mouse full length carbonic anhydrase 13,Other,18374572.0,
824,328985,4,9,,103165562,3440,Active,8928036.0,23632.0,,,Inhibition of human full length carbonic anhydrase 14,Other,18374572.0,
825,346025,3,3,,103165562,3440,Unspecified,,,,,Binding affinity to beta cyclodextrin,Other,19056282.0,
826,352313,9,6,,103165562,3440,Unspecified,118569.0,3290.0,,IC50,Inhibition of human 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH,Confirmatory,18653260.0,
827,352314,9,5,,103165562,3440,Unspecified,1706408.0,15483.0,,IC50,Inhibition of mouse 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH,Confirmatory,18653260.0,
828,352315,4,10,,103165562,3440,Inactive,30316367.0,3291.0,,,Inhibition of human 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol at 100 uM by scintillation proximity assay in presence of NADPH,Other,18653260.0,
829,352316,4,9,,103165562,3440,Inactive,30316364.0,15484.0,,,Inhibition of mouse 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol at 100 uM by scintillation proximity assay in presence of NADPH,Other,18653260.0,
830,354122,9,1,,103165562,3440,Unspecified,,,,,"Effect on acute renal function in rat assessed as change in urine sodium level per 100 gm body weight at 30 mg/kg, po (RVb= 55.4+/-5.2 mg/dl)",Other,19361209.0,
831,354123,8,1,,103165562,3440,Unspecified,,,,,"Effect on acute renal function in rat assessed as change in urine protein level per 100 gm body weight at 30 mg/kg, po (RVb= 11.4+/-1.7 mg/dl)",Other,19361209.0,
832,354124,8,1,,103165562,3440,Unspecified,,,,,"Effect on acute renal function in rat assessed as change in urine phosphate level per 100 gm body weight at 30 mg/kg, po (RVb= 11.7+/-3.3 mg/dl)",Other,19361209.0,
833,354125,8,1,,103165562,3440,Unspecified,,,,,"Effect on acute renal function in rat assessed as change in urine creatinine level per 100 gm body weight at 30 mg/kg, po (RVb= 17.8+/-1.1 mg/dl)",Other,19361209.0,
834,354126,8,1,,103165562,3440,Unspecified,,,,,"Effect on acute renal function in rat assessed as change in urine urea level per 100 gm body weight at 30 mg/kg, po (RVb= 347+/-27 mg/dl)",Other,19361209.0,
835,354127,8,1,,103165562,3440,Unspecified,,,,,"Effect on acute renal function in rat assessed as change in glucose level in urine per 100 gm body weight at 30 mg/kg, po (RVb= 10.1+/-0.7 mg/dl)",Other,19361209.0,
836,354128,7,1,,103165562,3440,Unspecified,,,,,"Effect on acute renal function in rat assessed as change in osmolality in urine per 100 gm body weight at 30 mg/kg, po (RVb= 372+/-25 mg/dl)",Other,19361209.0,
837,354129,3,4,,103165562,3440,Unspecified,,,,,"Effect on acute renal function in rat assessed as change in urine volume at 30 mg/kg, po (RVb= 1.9+/-0.1 ml/100g)",Other,19361209.0,
838,354342,3,3,,103165562,3440,Unspecified,,,,,"Effect on gastrointestinal motility in fasted Sprague-Dawley rat assessed as distance of charcoal moved from stomach to cecum at 30 mg/kg, ip (RVb =36.4+/-2.9)",Other,19361209.0,
839,354345,9,1,,103165562,3440,Unspecified,,,,,"Effect on acute renal function in rat assessed as change in urine potassium level per 100 gm body weight at 30 mg/kg, po (RVb= 59.2+/-3.1 mg/dl)",Other,19361209.0,
840,354346,9,1,,103165562,3440,Unspecified,,,,,"Effect on acute renal function in rat assessed as change in urine chloride level per 100 gm body weight at 30 mg/kg, po (RVb= 89.6+/-5.7 mg/dl)",Other,19361209.0,
841,354347,3,4,,103165562,3440,Unspecified,,,,,"Effect on acute renal function in rat assessed as change in urine pH per 100 gm body weight at 30 mg/kg, po (RVb= 7.32+/-0.13 mg/dl)",Other,19361209.0,
842,367608,8,5,,103165562,3440,Active,115449.0,759.0,0.062,Ki,Inhibition of human recombinant full length CA1 by stopped-flow CO2 hydration method,Confirmatory,19119014.0,
843,367609,8,5,,103165562,3440,Active,115456.0,760.0,0.065,Ki,Inhibition of human recombinant full length CA2 by stopped-flow CO2 hydration method,Confirmatory,19119014.0,
844,367610,13,2,,103165562,3440,Unspecified,134047703.0,761.0,3200.0,Ki,Inhibition of human recombinant full length CA3 by stopped-flow CO2 hydration method,Confirmatory,19119014.0,
845,367611,8,5,,103165562,3440,Active,115465.0,762.0,0.564,Ki,Inhibition of human recombinant full length CA4 by stopped-flow CO2 hydration method,Confirmatory,19119014.0,
846,367612,8,5,,103165562,3440,Active,461680.0,763.0,0.499,Ki,Inhibition of human recombinant full length CA5A by stopped-flow CO2 hydration method,Confirmatory,19119014.0,
847,367613,8,5,,103165562,3440,Active,8928041.0,11238.0,0.322,Ki,Inhibition of human recombinant full length CA5B by stopped-flow CO2 hydration method,Confirmatory,19119014.0,
848,367614,8,5,,103165562,3440,Active,116241278.0,765.0,0.245,Ki,Inhibition of human recombinant full length CA6 by stopped-flow CO2 hydration method,Confirmatory,19119014.0,
849,367615,8,5,,103165562,3440,Active,1168744.0,766.0,0.513,Ki,Inhibition of human recombinant full length CA7 by stopped-flow CO2 hydration method,Confirmatory,19119014.0,
850,367616,8,5,,103165562,3440,Active,83300925.0,768.0,0.42,Ki,Inhibition of human recombinant CA9 catalytic domain by stopped-flow CO2 hydration method,Confirmatory,19119014.0,
851,367617,8,5,,103165562,3440,Active,5915866.0,771.0,0.261,Ki,Inhibition of human recombinant CA12 catalytic domain by stopped-flow CO2 hydration method,Confirmatory,19119014.0,
852,367618,8,5,,103165562,3440,Active,30580372.0,71934.0,0.55,Ki,Inhibition of mouse recombinant full length CA13 by stopped-flow CO2 hydration method,Confirmatory,19119014.0,
853,367619,8,5,,103165562,3440,Active,8928036.0,23632.0,0.052000000000000005,Ki,Inhibition of human recombinant full length CA14 by stopped-flow CO2 hydration method,Confirmatory,19119014.0,
854,373867,6,3,,103165562,3440,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
855,384955,4,4,,103165562,3440,Unspecified,,,,,Intrinsic aqueous solubility at pH 10 by shake-flask method,Other,18396854.0,
856,386623,4,8,,103165562,3440,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
857,404304,3,10,,103165562,3440,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
858,409958,3,9,,103165562,3440,Inactive,124028637.0,281293.0,,,Inhibition of bovine brain MAOA,Other,18834112.0,
859,409960,3,9,,103165562,3440,Inactive,124028638.0,338445.0,,,Inhibition of bovine brain MAOB,Other,18834112.0,
860,425652,7,2,,103165562,3440,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
861,425653,7,2,,103165562,3440,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
862,432063,8,1,,103165562,3440,Unspecified,,,,,Apparent permeability at pH 7.4 after 24 hrs by PAMPA method,Other,19410338.0,
863,434955,1,2,,47193739,3440,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
864,434959,1,1,,85788855,3440,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
865,434962,1,2,,47193739,3440,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
866,434973,1,3,,47193739,3440,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
867,434989,1,1,,47193739,3440,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
868,435003,1,3,,47193739,3440,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
869,435005,1,1,,47193739,3440,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
870,435022,2,2,,47193739,3440,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
871,435030,1,2,,47193739,3440,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
872,435030,1,2,,47193739,3440,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
873,436208,3,4,,103165562,3440,Inconclusive,,,,,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in type B+ human erythrocytes assessed as reduction of hemozoin formation at IC50 after 48 hrs relative to control,Other,19269069.0,
874,436212,3,4,,103165562,3440,Unspecified,,,,,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in type B+ human erythrocytes assessed as inhibition of sorbitol-induced hemolysis at 10 uM after 15 min by spectrophotometry,Other,19269069.0,
875,444050,7,1,,103165562,3440,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
876,444051,6,2,,103165562,3440,Unspecified,,,,,Total clearance in human,Other,20070106.0,
877,444052,6,2,,103165562,3440,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
878,444053,6,2,,103165562,3440,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
879,444054,6,1,,103165562,3440,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
880,444055,3,3,,103165562,3440,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
881,444056,3,3,,103165562,3440,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
882,444057,3,3,,103165562,3440,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
883,444058,6,2,,103165562,3440,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
884,449728,1,2,,47193739,3440,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
885,449739,1,2,,47193739,3440,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
886,449762,1,2,,47193739,3440,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
887,449763,1,3,,47193739,3440,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
888,449768,1,1,,47193739,3440,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
889,453203,3,4,,103165562,3440,Unspecified,,,,,"Lipophilicity, log D of the compound",Other,19963379.0,
890,453204,3,6,,103165562,3440,Unspecified,,,,,Permeability in human skin after 48 hrs by Franz cell permeability assay,Other,19963379.0,
891,455986,3,5,,103165562,3440,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
892,463079,1,2,,47193739,3440,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
893,463082,1,1,,47193739,3440,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
894,463104,1,2,,47193739,3440,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
895,463111,1,1,,47193739,3440,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
896,463141,1,2,,47193739,3440,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
897,463165,1,1,,47193739,3440,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
898,463190,1,2,,47193739,3440,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
899,463195,1,2,,47193739,3440,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
900,463210,1,2,,47193739,3440,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
901,463212,1,1,,47193739,3440,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
902,467611,3,6,,103165562,3440,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
903,467612,3,6,,103165562,3440,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
904,467613,5,3,,103165562,3440,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
905,475125,3,4,,103165562,3440,Unspecified,,,,,Antagonist activity to dog NKCC1 transporter expressed in MDCK cells assessed as inhibition of Cl- free medium-stimulated Rb+ influx at 100 uM after 45 mins by atomic absorption spectroscopy,Other,20299216.0,
906,475126,6,2,,103165562,3440,Inconclusive,,,,,Intrinsic clearance in rat hepatocytes assessed per 10^6 cells,Other,20299216.0,
907,475127,6,1,,103165562,3440,Inconclusive,,,,,Aqueous solubility in PBS buffer at pH 7.4,Other,20299216.0,
908,475128,6,2,,103165562,3440,Inconclusive,,,,,Intrinsic clearance in rat microsomes assessed per mg of protein,Other,20299216.0,
909,476929,3,3,,103165562,3440,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
910,481439,3,4,,103165562,3440,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
911,481440,3,4,,103165562,3440,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,20373811.0,
912,481441,3,6,,103165562,3440,Unspecified,,,,,Aqueous diffusivity at 37C,Other,20373811.0,
913,481442,3,6,,103165562,3440,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
914,481444,3,4,,103165562,3440,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20373811.0,
915,481446,5,1,,103165562,3440,Unspecified,,,,,Effective permeability across human jejunum,Other,20373811.0,
916,485270,1,1,,47193739,3440,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
917,485272,1,1,,47193739,3440,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
918,485273,2,1,,47193739,3440,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
919,485275,1,3,,47193739,3440,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
920,485281,1,1,,11112125,3440,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
921,485290,1,1,,11112125,3440,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
922,485290,1,1,,17389872,3440,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
923,485290,1,1,,26747275,3440,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
924,485290,1,1,,26752834,3440,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
925,485290,1,1,,26752835,3440,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
926,485317,1,2,,47193739,3440,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
927,485346,1,1,,47193739,3440,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
928,485346,1,1,,47193739,3440,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
929,485350,1,2,,92123947,3440,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
930,485350,1,2,,92125367,3440,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
931,488839,1,1,,50085981,3440,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
932,488839,1,1,,50085981,3440,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
933,488847,1,3,,47193739,3440,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
934,488862,1,1,,50085981,3440,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
935,488890,1,2,,47193739,3440,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
936,488895,1,2,,50085981,3440,Active,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
937,488896,1,1,,50085981,3440,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
938,488899,1,1,,50085981,3440,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
939,488922,1,2,,47193739,3440,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
940,488965,1,2,,50085981,3440,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
941,488966,1,1,,50085981,3440,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
942,488975,1,2,,47193739,3440,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
943,488977,1,2,,47193739,3440,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
944,489030,2,1,,47193739,3440,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
945,489031,2,1,,47193739,3440,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
946,492953,1,1,,50085981,3440,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
947,492956,1,1,,50085981,3440,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
948,492967,1,2,,92125367,3440,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
949,492967,1,2,,99301663,3440,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
950,492972,1,1,,50085981,3440,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
951,493005,1,1,,47193739,3440,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
952,493008,1,1,,50085981,3440,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
953,493008,1,1,,50085981,3440,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
954,493008,1,1,,50085981,3440,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
955,493008,1,1,,50085981,3440,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
956,493011,1,1,,47193739,3440,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
957,493012,1,1,,47193739,3440,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
958,493033,1,2,,92123947,3440,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
959,493033,1,2,,92125367,3440,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
960,493036,1,2,,47193739,3440,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
961,493087,1,1,,50085981,3440,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
962,493091,1,1,,47193739,3440,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
963,493098,1,1,,47193739,3440,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
964,493131,1,1,,50085981,3440,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
965,493140,1,1,,103914190,3440,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
966,493160,1,1,,47193739,3440,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
967,493162,1,2,,99301663,3440,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
968,493187,1,2,,47193739,3440,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
969,493244,1,1,,50085981,3440,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
970,493244,1,1,,50085981,3440,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
971,493244,1,1,,50085981,3440,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
972,493244,1,1,,50085981,3440,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
973,496817,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
974,496818,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
975,496819,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
976,496820,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
977,496821,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
978,496823,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
979,496824,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
980,496825,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
981,496826,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
982,496827,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
983,496828,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
984,496829,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
985,496830,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
986,496831,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
987,496832,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
988,497005,4,2,,103165562,3440,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
989,504326,1,2,,50085981,3440,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
990,504326,1,2,,50085981,3440,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
991,504327,1,1,,11112125,3440,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
992,504329,1,1,,50085981,3440,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
993,504332,1,1,,11112125,3440,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
994,504339,1,1,,47193739,3440,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
995,504357,1,1,,50085981,3440,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
996,504357,1,1,,50085981,3440,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
997,504406,1,1,,47193739,3440,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
998,504408,2,1,,47193739,3440,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
999,504411,1,1,,50085981,3440,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1000,504414,1,1,,50085981,3440,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1001,504414,1,1,,50085981,3440,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1002,504423,1,1,,50085981,3440,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1003,504441,1,1,,50085981,3440,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1004,504444,1,1,,47193739,3440,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1005,504454,1,3,,50085981,3440,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1006,504462,1,1,,47193739,3440,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1007,504490,1,2,,50085981,3440,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1008,504523,1,1,,50085981,3440,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1009,504523,1,1,,50085981,3440,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1010,504558,1,1,,50085981,3440,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1011,504577,2,2,,50085981,3440,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1012,504582,2,1,,50085981,3440,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1013,504621,1,1,,50085981,3440,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1014,504634,1,1,,50085981,3440,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1015,504648,1,1,,47193739,3440,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1016,504690,1,3,,47193739,3440,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1017,504692,2,2,,50085981,3440,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1018,504700,1,1,,50085981,3440,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1019,504700,1,1,,50085981,3440,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1020,504707,1,1,,50085981,3440,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1021,504707,1,1,,50085981,3440,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1022,504720,1,1,,47193739,3440,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1023,504734,1,1,,50085981,3440,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1024,504749,1,3,,26752835,3440,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1025,504749,1,3,,104171270,3440,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1026,504749,1,3,1.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1027,504749,1,3,2.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1028,504749,1,3,3.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1029,504749,1,3,4.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1030,504749,1,3,5.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1031,504749,1,3,6.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1032,504749,1,3,7.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1033,504749,1,3,8.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1034,504749,1,3,9.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1035,504749,1,3,10.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1036,504749,1,3,11.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1037,504749,1,3,12.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1038,504749,1,3,13.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1039,504749,1,3,14.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1040,504749,1,3,15.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1041,504749,1,3,16.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1042,504749,1,3,17.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1043,504749,1,3,18.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1044,504749,1,3,19.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1045,504749,1,3,20.0,104171270,3440,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1046,504749,1,3,21.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1047,504749,1,3,22.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1048,504749,1,3,23.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1049,504749,1,3,24.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1050,504749,1,3,25.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1051,504749,1,3,26.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1052,504749,1,3,27.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1053,504749,1,3,28.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1054,504749,1,3,29.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1055,504749,1,3,30.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1056,504749,1,3,31.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1057,504749,1,3,32.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1058,504749,1,3,33.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1059,504749,1,3,34.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1060,504749,1,3,35.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1061,504749,1,3,36.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1062,504749,1,3,37.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1063,504749,1,3,38.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1064,504749,1,3,39.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1065,504749,1,3,40.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1066,504749,1,3,41.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1067,504749,1,3,42.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1068,504749,1,3,43.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1069,504749,1,3,44.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1070,504749,1,3,45.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1071,504749,1,3,46.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1072,504749,1,3,47.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1073,504749,1,3,48.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1074,504749,1,3,49.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1075,504749,1,3,50.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1076,504749,1,3,51.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1077,504749,1,3,52.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1078,504749,1,3,53.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1079,504749,1,3,54.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1080,504749,1,3,55.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1081,504749,1,3,56.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1082,504749,1,3,57.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1083,504749,1,3,58.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1084,504749,1,3,59.0,104171270,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1085,504749,1,3,60.0,104171270,3440,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1086,504749,1,3,61.0,26752835,3440,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1087,504766,2,1,,50085981,3440,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1088,504770,1,2,,92123947,3440,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
1089,504775,1,1,,50085981,3440,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1090,504803,1,1,,50085981,3440,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1091,504832,1,1,,104171270,3440,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1092,504834,1,1,,104171270,3440,Inconclusive,,,1.9012,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1093,504843,1,1,,50085981,3440,Inactive,,,,AC50_uM,Bacterial Growth Inhibition Counterscreen using BacTiter-Glo Measured in Microorganism System Using Plate Reader - 2093-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1094,504845,1,1,,47193739,3440,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1095,504847,1,1,,11112125,3440,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1096,504847,1,1,,47193739,3440,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1097,504847,1,1,,104171270,3440,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1098,504865,1,1,,11112125,3440,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1099,504865,1,1,,104171270,3440,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1100,504884,1,2,,50085981,3440,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1101,504891,1,1,,47193739,3440,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1102,504894,1,1,,47193739,3440,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1103,504937,1,2,,47193739,3440,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1104,504941,1,1,,50085981,3440,Inactive,90111653.0,948321.0,,AC50_uM,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_Dose_CherryPick_Activity_Set2,Confirmatory,,
1105,515780,5,1,,103165562,3440,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
1106,521220,3,3,,103165562,3440,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
1107,524792,7,2,,103165562,3440,Active,,,15.8489,IC50,Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1108,524794,7,1,,103165562,3440,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1109,524796,7,1,,103165562,3440,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1110,540209,4,3,,103165562,3440,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
1111,540210,4,3,,103165562,3440,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
1112,540211,2,5,,103165562,3440,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
1113,540212,4,3,,103165562,3440,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
1114,540213,4,3,,103165562,3440,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
1115,540214,4,3,,103165562,3440,Unspecified,,,,,Clearance in rat after iv administration,Other,15920768.0,
1116,540215,3,2,,103165562,3440,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,15920768.0,
1117,540216,4,3,,103165562,3440,Unspecified,,,,,Clearance in dog after iv administration,Other,15920768.0,
1118,540217,4,3,,103165562,3440,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,15920768.0,
1119,540218,4,3,,103165562,3440,Unspecified,,,,,Clearance in monkey after iv administration,Other,15920768.0,
1120,540219,4,3,,103165562,3440,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,15920768.0,
1121,540220,4,3,,103165562,3440,Unspecified,,,,,Clearance in human after iv administration,Other,15920768.0,
1122,540221,4,3,,103165562,3440,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,15920768.0,
1123,540230,2,5,,103165562,3440,Unspecified,,,,,Dose normalised AUC in rat after po administration,Other,16019946.0,
1124,540231,2,5,,103165562,3440,Unspecified,,,,,Dose normalised AUC in dog after po administration,Other,16019946.0,
1125,540232,2,5,,103165562,3440,Unspecified,,,,,Dose normalised AUC in monkey after po administration,Other,16019946.0,
1126,540233,2,5,,103165562,3440,Unspecified,,,,,Dose normalised AUC in human after po administration,Other,16019946.0,
1127,540253,1,1,,47193739,3440,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1128,540253,1,1,,47193739,3440,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1129,540253,1,1,,47193739,3440,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1130,540263,1,1,,47193739,3440,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1131,540263,1,1,,47193739,3440,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1132,540267,1,1,,47193739,3440,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1133,540295,1,1,,50085981,3440,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1134,540299,1,2,,92123947,3440,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1135,540299,1,2,,92125367,3440,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1136,540303,1,1,,47193739,3440,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1137,540303,1,1,,47193739,3440,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1138,540303,1,1,,47193739,3440,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1139,540308,1,1,,50085981,3440,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1140,540317,1,1,,47193739,3440,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1141,540336,1,1,,50085981,3440,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1142,540336,1,1,,50085981,3440,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1143,540364,1,2,,50085981,3440,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1144,567091,2,6,,103165562,3440,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
1145,582094,3,4,,103165562,3440,Active,,,,,Inhibition of PSAC-mediated sorbitol uptake in erythrocytes infected with Plasmodium falciparum HB3 at 100 to 5000 uM by osmotic lysis half-time determination assay,Other,18443109.0,
1146,582095,3,4,,103165562,3440,Inactive,,,,,Inhibition of PSAC-mediated sorbitol uptake in erythrocytes infected with leupeptin resistant-Plasmodium falciparum HB3-leuR1 by osmotic lysis half-time determination assay,Other,18443109.0,
1147,588208,2,3,,103165562,3440,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
1148,588209,2,3,,103165562,3440,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
1149,588210,2,4,,103165562,3440,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
1150,588211,2,3,,103165562,3440,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
1151,588212,2,3,,103165562,3440,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
1152,588213,2,3,,103165562,3440,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
1153,588214,2,3,,103165562,3440,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
1154,588215,2,3,,103165562,3440,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
1155,588216,2,3,,103165562,3440,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
1156,588217,2,3,,103165562,3440,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
1157,588218,2,3,,103165562,3440,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
1158,588219,2,3,,103165562,3440,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
1159,588220,2,3,,103165562,3440,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
1160,588334,1,1,,50085981,3440,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1161,588335,1,1,,50085981,3440,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1162,588352,1,2,,50085981,3440,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1163,588354,1,1,,50085981,3440,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1164,588358,1,2,,50085981,3440,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1165,588391,1,1,,50085981,3440,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1166,588405,1,1,,50085981,3440,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1167,588413,1,2,,47193739,3440,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1168,588436,1,1,,50085981,3440,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1169,588453,1,1,,47193739,3440,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1170,588456,1,1,,47193739,3440,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1171,588458,1,1,,50085981,3440,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1172,588473,1,1,,47193739,3440,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1173,588473,1,1,,47193739,3440,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1174,588475,1,2,,47193739,3440,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1175,588475,1,2,,47193739,3440,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1176,588478,1,2,,124800495,3440,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1177,588489,1,1,,50085981,3440,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1178,588492,1,1,,50085981,3440,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1179,588493,1,2,,50085981,3440,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1180,588497,1,2,,50085981,3440,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1181,588497,1,2,,50085981,3440,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1182,588497,1,2,,50085981,3440,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1183,588499,1,3,,50085981,3440,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1184,588499,1,3,,50085981,3440,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1185,588499,1,3,,50085981,3440,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1186,588501,1,2,,50085981,3440,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1187,588501,1,2,,50085981,3440,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1188,588501,1,2,,50085981,3440,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1189,588511,1,2,,47193739,3440,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1190,588513,1,1,,17389872,3440,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1191,588513,1,1,,26752835,3440,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1192,588514,1,1,,17389872,3440,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1193,588514,1,1,,26752835,3440,Inconclusive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1194,588515,1,1,,17389872,3440,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1195,588515,1,1,,26752835,3440,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1196,588516,1,1,,17389872,3440,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1197,588516,1,1,,26752835,3440,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1198,588519,1,2,,92123947,3440,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1199,588519,1,2,,92125367,3440,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1200,588526,1,1,,17389872,3440,Inconclusive,325495553.0,9971.0,0.2239,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1201,588526,1,1,,26752835,3440,Inconclusive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1202,588527,1,1,,17389872,3440,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1203,588527,1,1,,26752835,3440,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1204,588532,1,1,,17389872,3440,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1205,588532,1,1,,26752835,3440,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1206,588533,1,1,,17389872,3440,Inconclusive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1207,588533,1,1,,26752835,3440,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1208,588534,1,1,,17389872,3440,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1209,588534,1,1,,26752835,3440,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1210,588535,1,1,,17389872,3440,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1211,588535,1,1,,26752835,3440,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1212,588536,1,1,,17389872,3440,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1213,588536,1,1,,26752835,3440,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1214,588537,1,1,,17389872,3440,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1215,588537,1,1,,26752835,3440,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1216,588541,1,1,,17389872,3440,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1217,588541,1,1,,26752835,3440,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1218,588543,1,1,,17389872,3440,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1219,588543,1,1,,26752835,3440,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1220,588544,1,1,,17389872,3440,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1221,588544,1,1,,26752835,3440,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1222,588545,1,1,,17389872,3440,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1223,588545,1,1,,26752835,3440,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1224,588546,1,1,,17389872,3440,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1225,588546,1,1,,26752835,3440,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1226,588547,1,1,,17389872,3440,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1227,588547,1,1,,26752835,3440,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1228,588549,1,1,,50085981,3440,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1229,588579,1,1,,11112125,3440,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1230,588579,1,1,,47193739,3440,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1231,588579,1,1,,104171270,3440,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1232,588579,1,1,,124881920,3440,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1233,588579,1,1,,124881922,3440,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1234,588590,1,1,,47193739,3440,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1235,588591,1,1,,47193739,3440,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1236,588621,1,1,,50085981,3440,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1237,588627,1,1,,47193739,3440,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1238,588664,1,2,,50085981,3440,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1239,588664,1,2,,50085981,3440,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1240,588674,1,2,,50085981,3440,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1241,588675,1,1,,47193739,3440,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1242,588676,1,1,,47193739,3440,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1243,588689,1,1,,50085981,3440,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1244,588692,2,1,,50085981,3440,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1245,588726,1,2,,50085981,3440,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1246,588727,1,1,,50085981,3440,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1247,588795,1,1,,47193739,3440,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1248,588814,1,3,,50085981,3440,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1249,588819,1,4,,50085981,3440,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1250,588834,2,1,,17389872,3440,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1251,588834,2,1,,26752835,3440,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1252,588850,1,1,,50085981,3440,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1253,588852,1,3,,50085981,3440,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1254,588855,1,1,,47193739,3440,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1255,588856,1,1,,47193739,3440,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1256,588965,1,9,,103165562,3440,Unspecified,74730587.0,9376.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT3",Other,20190787.0,
1257,588979,1,9,,103165562,3440,Unspecified,206729914.0,10257.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, MRP4",Other,20190787.0,
1258,589073,1,10,,103165562,3440,Unspecified,29839637.0,54576.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A8,Other,,
1259,589074,1,10,,103165562,3440,Unspecified,29839451.0,54600.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A9,Other,,
1260,589075,1,10,,103165562,3440,Unspecified,29839636.0,54575.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A10,Other,,
1261,592681,1,4,,103165562,3440,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
1262,598525,1,3,,103165562,3440,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,21601448.0,
1263,598526,1,3,,103165562,3440,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake-flask method",Other,21601448.0,
1264,598527,1,3,,103165562,3440,Unspecified,,,,,"1-Octanol-sodium citrate buffer distribution coefficient, log D of the compound at pH 5.5 by shake-flask method",Other,21601448.0,
1265,599064,1,4,,103165562,3440,Unspecified,,,,,Plasma protein binding in human,Other,21601448.0,
1266,602123,1,1,,50085981,3440,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1267,602141,1,1,,50085981,3440,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1268,602162,1,1,,50085981,3440,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1269,602163,1,1,,50085981,3440,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1270,602179,1,2,,47193739,3440,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1271,602229,1,1,,50085981,3440,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1272,602233,1,1,,47193739,3440,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1273,602244,1,2,,50085981,3440,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1274,602247,1,2,,50085981,3440,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1275,602248,1,2,,50085981,3440,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1276,602250,1,2,,50085981,3440,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1277,602252,1,1,,50085981,3440,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1278,602252,1,1,,50085981,3440,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1279,602261,1,1,,50085981,3440,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1280,602274,1,2,,50085981,3440,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1281,602281,1,1,,50085981,3440,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1282,602281,1,1,,50085981,3440,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1283,602310,1,2,,47193739,3440,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1284,602313,1,1,,47193739,3440,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1285,602314,1,2,,92123947,3440,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1286,602314,1,2,,92125367,3440,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1287,602329,1,1,,50085981,3440,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1288,602332,1,1,,11112125,3440,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1289,602332,1,1,,47193739,3440,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1290,602332,1,1,,104171270,3440,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1291,602332,1,1,,124881920,3440,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1292,602332,1,1,,124881922,3440,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1293,602340,1,2,,50085981,3440,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1294,602342,2,1,,50085981,3440,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1295,602346,1,1,,50085981,3440,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1296,602363,1,1,,50085981,3440,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1297,602393,1,1,,50085981,3440,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1298,602396,1,2,,50085981,3440,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1299,602399,1,2,,50085981,3440,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1300,602405,1,1,,50085981,3440,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1301,602410,1,1,,50085981,3440,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1302,602429,1,1,,50085981,3440,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1303,602438,1,1,,50085981,3440,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1304,602440,1,1,,50085981,3440,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1305,602449,1,2,,50085981,3440,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1306,602481,1,1,,50085981,3440,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1307,604741,1,9,,103165562,3440,Unspecified,113576.0,213.0,,,Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
1308,604742,1,9,,103165562,3440,Unspecified,113576.0,213.0,,,Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
1309,604743,1,9,,103165562,3440,Unspecified,113576.0,213.0,,,Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
1310,604744,1,9,,103165562,3440,Unspecified,113576.0,213.0,,,Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
1311,623870,1,1,,50085981,3440,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1312,623870,1,1,,50085981,3440,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1313,623877,1,1,,50085981,3440,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1314,623901,1,1,,50085981,3440,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1315,624030,1,2,,104171270,3440,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1316,624031,1,2,,104171270,3440,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
1317,624032,1,2,,104171270,3440,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
1318,624037,1,3,,50085981,3440,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1319,624038,1,3,,50085981,3440,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1320,624040,1,3,,50085981,3440,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1321,624044,1,2,,104171270,3440,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
1322,624101,1,2,,85788855,3440,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1323,624125,1,4,,50085981,3440,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1324,624126,1,3,,50085981,3440,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1325,624127,1,2,,50085981,3440,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1326,624151,1,1,,85788855,3440,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
1327,624156,1,1,,85788855,3440,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1328,624168,1,1,,50085981,3440,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1329,624169,1,1,,50085981,3440,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1330,624170,1,1,,47193739,3440,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1331,624170,1,1,,104171270,3440,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1332,624171,1,1,,47193739,3440,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1333,624172,1,1,,47193739,3440,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1334,624172,1,1,,104171270,3440,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1335,624173,1,3,,47193739,3440,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1336,624173,1,3,,104171270,3440,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1337,624178,1,1,,47193739,3440,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1338,624202,1,1,,47193739,3440,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1339,624204,1,2,,50085981,3440,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1340,624246,1,1,,47193739,3440,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1341,624256,1,2,,50085981,3440,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1342,624263,1,1,,47193739,3440,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1343,624263,1,1,,47193739,3440,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1344,624267,1,2,,50085981,3440,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1345,624267,1,2,,50085981,3440,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1346,624268,1,3,,50085981,3440,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1347,624288,1,1,,47193739,3440,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1348,624296,1,1,,47193739,3440,Inconclusive,7705682.0,51053.0,16.3601,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1349,624296,1,1,,104171270,3440,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1350,624297,1,1,,47193739,3440,Inactive,7705682.0,51053.0,0.5623,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1351,624297,1,1,,104171270,3440,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1352,624304,1,2,,50085981,3440,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1353,624330,1,2,,50085981,3440,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1354,624349,1,2,,92123947,3440,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1355,624349,1,2,,92125367,3440,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1356,624349,1,2,,92307335,3440,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1357,624349,1,2,,92309202,3440,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1358,624349,1,2,,121362568,3440,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1359,624349,1,2,,121363038,3440,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1360,624352,1,1,,50085981,3440,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1361,624354,1,1,,50085981,3440,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1362,624377,1,1,,50085981,3440,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1363,624414,1,1,,47193739,3440,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1364,624415,1,2,,47193739,3440,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1365,624416,1,1,,50085981,3440,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1366,624417,1,1,,47193739,3440,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1367,624418,1,1,,47193739,3440,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1368,624463,1,1,,47193739,3440,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1369,624464,1,1,,47193739,3440,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1370,624465,1,1,,47193739,3440,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1371,624466,1,3,,50085981,3440,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1372,624467,1,1,,50085981,3440,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1373,624483,1,1,,50085981,3440,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1374,624606,1,9,,103165562,3440,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
1375,624611,1,9,,103165562,3440,Unspecified,29839637.0,54576.0,,,Specific activity of expressed human recombinant UGT1A8,Other,10836148.0,
1376,624612,1,9,,103165562,3440,Unspecified,29839451.0,54600.0,,,Specific activity of expressed human recombinant UGT1A9,Other,10836148.0,
1377,624613,1,9,,103165562,3440,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
1378,624647,3,4,,103165562,3440,Unspecified,,,1700.0,Ki,Inhibition of AZT glucuronidation by human UGT enzymes from liver microsomes,Confirmatory,15781124.0,
1379,625144,5,5,,103165562,3440,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1380,625145,4,7,,103165562,3440,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1381,625146,5,5,,103165562,3440,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1382,625147,4,7,,103165562,3440,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1383,625148,4,7,,103165562,3440,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1384,625149,4,7,,103165562,3440,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1385,625150,5,5,,103165562,3440,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1386,625151,4,7,,103165562,3440,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1387,625152,4,7,,103165562,3440,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1388,625153,4,7,,103165562,3440,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1389,625154,4,7,,103165562,3440,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1390,625155,4,7,,103165562,3440,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1391,625156,1,9,,103165562,3440,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1392,625157,6,2,,103165562,3440,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1393,625158,3,4,,103165562,3440,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1394,625159,5,5,,103165562,3440,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1395,625160,1,9,,103165562,3440,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1396,625161,4,7,,103165562,3440,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1397,625162,4,7,,103165562,3440,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1398,625163,4,7,,103165562,3440,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1399,625164,1,6,,103165562,3440,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1400,625165,3,4,,103165562,3440,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1401,625166,3,4,,103165562,3440,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1402,625167,5,5,,103165562,3440,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1403,625168,4,7,,103165562,3440,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1404,625169,1,6,,103165562,3440,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1405,625170,3,4,,103165562,3440,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1406,625171,4,7,,103165562,3440,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1407,625172,4,7,,103165562,3440,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1408,625173,5,5,,103165562,3440,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1409,625174,5,5,,103165562,3440,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1410,625175,5,5,,103165562,3440,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1411,625176,1,9,,103165562,3440,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1412,625177,5,5,,103165562,3440,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1413,625178,5,5,,103165562,3440,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1414,625179,1,9,,103165562,3440,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1415,625180,5,5,,103165562,3440,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1416,625181,5,5,,103165562,3440,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1417,625182,5,5,,103165562,3440,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1418,625183,5,5,,103165562,3440,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1419,625184,5,5,,103165562,3440,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1420,625185,5,5,,103165562,3440,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1421,625186,5,5,,103165562,3440,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1422,625187,5,5,,103165562,3440,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1423,625188,1,9,,103165562,3440,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1424,625189,1,7,,103165562,3440,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1425,625190,4,5,,103165562,3440,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1426,625191,4,7,,103165562,3440,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1427,625192,4,7,,103165562,3440,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1428,625193,5,5,,103165562,3440,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1429,625194,4,7,,103165562,3440,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1430,625195,4,7,,103165562,3440,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1431,625196,5,6,,103165562,3440,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1432,625197,3,4,,103165562,3440,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1433,625198,4,7,,103165562,3440,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1434,625199,4,7,,103165562,3440,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1435,625200,4,7,,103165562,3440,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1436,625201,4,7,,103165562,3440,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1437,625202,4,7,,103165562,3440,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1438,625203,4,7,,103165562,3440,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1439,625204,4,7,,103165562,3440,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1440,625205,4,7,,103165562,3440,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1441,625206,4,7,,103165562,3440,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1442,625207,4,7,,103165562,3440,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1443,625208,5,5,,103165562,3440,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1444,625209,4,7,,103165562,3440,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1445,625210,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1446,625211,1,6,,103165562,3440,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1447,625212,3,4,,103165562,3440,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1448,625213,4,7,,103165562,3440,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1449,625214,1,9,,103165562,3440,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1450,625215,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1451,625216,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1452,625217,4,7,,103165562,3440,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1453,625218,4,7,,103165562,3440,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1454,625219,3,4,,103165562,3440,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1455,625220,4,7,,103165562,3440,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1456,625221,4,7,,103165562,3440,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1457,625222,4,7,,103165562,3440,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1458,625223,4,7,,103165562,3440,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1459,625224,3,4,,103165562,3440,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1460,625225,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1461,625226,4,7,,103165562,3440,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1462,625227,4,7,,103165562,3440,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1463,625228,4,7,,103165562,3440,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1464,625229,5,5,,103165562,3440,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1465,625230,1,6,,103165562,3440,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1466,625231,4,7,,103165562,3440,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1467,625232,1,9,,103165562,3440,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1468,625233,4,7,,103165562,3440,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1469,625234,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1470,625235,4,7,,103165562,3440,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1471,625236,5,5,,103165562,3440,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1472,625237,4,7,,103165562,3440,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1473,625238,4,7,,103165562,3440,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1474,625239,4,7,,103165562,3440,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1475,625240,1,9,,103165562,3440,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1476,625241,4,7,,103165562,3440,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1477,625242,4,7,,103165562,3440,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1478,625243,5,5,,103165562,3440,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1479,625244,5,5,,103165562,3440,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1480,625245,5,5,,103165562,3440,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1481,625246,1,9,,103165562,3440,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1482,625247,5,5,,103165562,3440,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1483,625248,5,5,,103165562,3440,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1484,625249,5,5,,103165562,3440,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1485,625250,5,5,,103165562,3440,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1486,625251,5,5,,103165562,3440,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1487,625252,4,7,,103165562,3440,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1488,625253,4,7,,103165562,3440,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1489,625254,4,7,,103165562,3440,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1490,625255,4,7,,103165562,3440,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1491,625256,4,7,,103165562,3440,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1492,625257,4,7,,103165562,3440,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1493,625258,4,7,,103165562,3440,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1494,625259,4,7,,103165562,3440,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1495,625260,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1496,625261,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1497,625262,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1498,625263,4,7,,103165562,3440,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1499,625264,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1500,625265,1,6,,103165562,3440,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1501,625266,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1502,625267,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1503,625268,4,2,,103165562,3440,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1504,625268,4,2,,103165562,3440,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1505,625268,4,2,,103165562,3440,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1506,625268,4,2,,103165562,3440,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1507,625269,4,7,,103165562,3440,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1508,625270,4,7,,103165562,3440,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1509,625271,5,5,,103165562,3440,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1510,625272,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1511,625273,4,6,,103165562,3440,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1512,625274,1,6,,103165562,3440,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1513,625275,3,4,,103165562,3440,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1514,625277,1,3,,103165562,3440,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
1515,625279,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1516,625280,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1517,625281,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1518,625282,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1519,625283,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1520,625284,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1521,625285,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1522,625286,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1523,625287,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1524,625288,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1525,625289,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1526,625290,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1527,625291,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1528,625292,1,3,,103165562,3440,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1529,651550,1,1,,47193739,3440,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1530,651560,1,1,,50085981,3440,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1531,651572,1,2,,50085981,3440,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1532,651582,1,1,,50085981,3440,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1533,651602,1,1,,50085981,3440,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1534,651602,1,1,,50085981,3440,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1535,651602,1,1,,50085981,3440,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1536,651610,2,1,,50085981,3440,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1537,651631,4,1,,144203873,3440,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1538,651631,4,1,,144209411,3440,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1539,651631,4,1,,144213288,3440,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1540,651632,4,1,,144203873,3440,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1541,651632,4,1,,144209411,3440,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1542,651632,4,1,,144213288,3440,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1543,651633,4,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1544,651633,4,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1545,651633,4,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1546,651634,4,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1547,651634,4,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1548,651634,4,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1549,651635,1,3,,11112125,3440,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1550,651635,1,3,,47193739,3440,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1551,651636,1,1,,50085981,3440,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1552,651640,1,1,,50085981,3440,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1553,651644,1,1,,47193739,3440,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1554,651647,1,1,,50085981,3440,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1555,651654,1,1,,50085981,3440,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1556,651658,1,1,,50085981,3440,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1557,651661,2,1,,50085981,3440,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1558,651699,1,1,,50085981,3440,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1559,651699,1,1,,50085981,3440,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1560,651702,1,2,,50085981,3440,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1561,651704,2,1,,50085981,3440,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1562,651710,1,1,,50085981,3440,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1563,651711,2,1,,50085981,3440,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1564,651718,1,2,,50085981,3440,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1565,651719,1,2,,50085981,3440,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1566,651724,1,1,,47193739,3440,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1567,651725,1,1,,47193739,3440,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1568,651741,1,1,,17389872,3440,Inconclusive,20149576.0,4780.0,74.97800000000001,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1569,651741,1,1,,144203873,3440,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1570,651743,1,1,,17389872,3440,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1571,651743,1,1,,26752835,3440,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1572,651749,1,1,,17389872,3440,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1573,651749,1,1,,26752835,3440,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1574,651751,1,1,,17389872,3440,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1575,651751,1,1,,26752835,3440,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1576,651754,1,1,,17389872,3440,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
1577,651755,1,1,,17389872,3440,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
1578,651757,1,1,,17389872,3440,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
1579,651758,1,1,,17389872,3440,Inconclusive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
1580,651768,1,2,,47193739,3440,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1581,651777,1,1,,17389872,3440,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1582,651777,1,1,,26752835,3440,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1583,651778,1,1,,17389872,3440,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1584,651778,1,1,,26752835,3440,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1585,651784,1,1,,124881919,3440,Inactive,4826730.0,2475.0,,Potency,"Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Hit Validation",Confirmatory,,
1586,651789,1,1,,124881919,3440,Inactive,4826730.0,2475.0,,Potency,Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in WT MEF Cells: Hit Validation,Confirmatory,,
1587,651800,1,1,,50085981,3440,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1588,651802,1,1,,17389872,3440,Inactive,49066040.0,6097.0,,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1589,651819,1,1,,47193739,3440,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1590,651820,1,1,,47193739,3440,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1591,651821,2,4,,50085981,3440,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1592,651828,1,2,,92309202,3440,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1593,651828,1,2,,121362568,3440,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1594,651838,1,1,,17389872,3440,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1595,651838,1,1,,26752835,3440,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1596,651838,1,1,1.0,17389872,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1597,651838,1,1,1.0,26752835,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1598,651838,1,1,2.0,17389872,3440,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1599,651838,1,1,2.0,26752835,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1600,651838,1,1,3.0,17389872,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1601,651838,1,1,3.0,26752835,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1602,651838,1,1,4.0,17389872,3440,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1603,651838,1,1,4.0,26752835,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1604,651838,1,1,5.0,17389872,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1605,651838,1,1,5.0,26752835,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1606,651838,1,1,6.0,17389872,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1607,651838,1,1,6.0,26752835,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1608,651838,1,1,7.0,17389872,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1609,651838,1,1,7.0,26752835,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1610,651838,1,1,8.0,17389872,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1611,651838,1,1,8.0,26752835,3440,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1612,651957,1,1,,50085981,3440,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1613,651958,1,1,,50085981,3440,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1614,651965,1,1,,47193739,3440,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1615,651999,1,1,,50085981,3440,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1616,652010,1,1,,50085981,3440,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1617,652017,1,1,,50085981,3440,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1618,652025,1,1,,47193739,3440,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1619,652039,1,1,,50085981,3440,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1620,652048,1,2,,47193739,3440,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1621,652048,1,2,,144203873,3440,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1622,652051,1,1,,47193739,3440,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1623,652051,1,1,,144203873,3440,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1624,652054,1,1,,47193739,3440,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1625,652067,1,4,,50085981,3440,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1626,652104,1,1,,47193739,3440,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1627,652105,1,1,,47193739,3440,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1628,652106,1,1,,47193739,3440,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1629,652115,1,1,,50085981,3440,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1630,652126,1,3,,50085981,3440,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1631,652154,1,1,,50085981,3440,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1632,652162,2,1,,50085981,3440,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1633,652163,1,1,,50085981,3440,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1634,652197,1,1,,50085981,3440,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1635,652257,1,1,,50085981,3440,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1636,678712,1,8,,103165562,3440,Inconclusive,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
1637,678713,1,8,,103165562,3440,Inconclusive,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
1638,678714,1,8,,103165562,3440,Inconclusive,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1639,678715,1,8,,103165562,3440,Inconclusive,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1640,678716,1,8,,103165562,3440,Inconclusive,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
1641,678717,1,8,,103165562,3440,Inconclusive,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
1642,678722,1,5,,103165562,3440,Unspecified,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
1643,679000,2,7,,103165562,3440,Unspecified,357529156.0,24546.0,47.0,Ki,TP_TRANSPORTER: inhibition of PGF2alpha uptake in PGT-expressing HeLa cells,Confirmatory,7754369.0,
1644,679485,2,7,,103165562,3440,Unspecified,81886651.0,29509.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,10991988.0,
1645,679520,1,8,,103165562,3440,Unspecified,74762955.0,9356.0,,,"TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Furosemide: 2000 uM) in Xenopus laevis oocytes",Other,9887087.0,
1646,679532,1,8,,103165562,3440,Unspecified,74762955.0,9356.0,,,TP_TRANSPORTER: inhibition of PAH uptake (Furosemide: 200 uM) in OAT1-expressing HeLa cells,Other,9950961.0,
1647,680193,1,7,,103165562,3440,Unspecified,74734337.0,55867.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Furosemide: 500 uM) in Xenopus laevis oocytes",Other,10660625.0,
1648,680799,1,8,,103165562,3440,Unspecified,308153583.0,1244.0,,,"TP_TRANSPORTER: inhibition of NEM-GS uptake (NEM-GS: 4 uM, Furosemide: 5000 uM) in membrane vesicles from MRP2-expressing Sf9 cells",Other,10727523.0,
1649,681057,1,7,,103165562,3440,Unspecified,74730587.0,9376.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Furosemide: 5 uM) in Xenopus laevis oocytes",Other,11306713.0,
1650,681378,3,6,,103165562,3440,Unspecified,2498046.0,6554.0,15.0,IC50,TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells,Confirmatory,10565843.0,
1651,681388,3,6,,103165562,3440,Unspecified,81886651.0,29509.0,9.5,Ki,TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes,Confirmatory,10991988.0,
1652,681432,1,7,,103165562,3440,Unspecified,81872813.0,83500.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 40 uM, Furosemide: 1000 uM) in Xenopus laevis oocytes",Other,10224140.0,
1653,681745,1,7,,103165562,3440,Unspecified,81886651.0,29509.0,,,"TP_TRANSPORTER: quantitative PCR in vivo, SD rat, kidney",Other,12897087.0,
1654,681818,1,7,,103165562,3440,Unspecified,81886651.0,29509.0,,,"TP_TRANSPORTER: Western in vivo, SD rat, kidney",Other,12897087.0,
1655,682311,1,7,,103165562,3440,Unspecified,8928257.0,6584.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Furosemide: 500 uM) in OCTN2-expressing HEK293 cells",Other,10525100.0,
1656,686940,1,1,,50085981,3440,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1657,686947,2,2,,162108257,3440,Inactive,4885661.0,7525.0,,Potency,qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen,Confirmatory,23787099.0,
1658,686950,1,1,,162108257,3440,Inactive,,,,Potency,qHTS for small molecule inhibitors of Yes1 kinase: Counter Assay,Other,,
1659,686964,1,1,,50085981,3440,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1660,686970,1,2,,47193739,3440,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1661,686971,1,2,,47193739,3440,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1662,686977,2,1,,49698703,3440,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
1663,686978,1,1,,47193739,3440,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1664,686978,1,1,,124881920,3440,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1665,686978,1,1,,144203873,3440,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1666,686979,1,1,,47193739,3440,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1667,686979,1,1,,124881920,3440,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1668,686979,1,1,,144203873,3440,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1669,686992,2,1,,50085981,3440,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1670,686996,1,1,,50085981,3440,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1671,687014,1,1,,50085981,3440,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1672,687016,1,1,,50085981,3440,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1673,699539,1,7,,103165562,3440,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
1674,699540,1,7,,103165562,3440,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1675,699541,1,7,,103165562,3440,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1676,720504,1,1,,47193739,3440,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1677,720508,1,1,,50085981,3440,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1678,720509,1,1,,50085981,3440,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1679,720511,1,1,,50085981,3440,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1680,720516,2,1,,144203873,3440,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1681,720516,2,1,,144209411,3440,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1682,720516,2,1,,144213288,3440,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1683,720532,1,1,,11112125,3440,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1684,720532,1,1,,124881920,3440,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1685,720532,1,1,,124881922,3440,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1686,720532,1,1,,144203873,3440,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1687,720533,1,1,,11112125,3440,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1688,720533,1,1,,124881920,3440,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1689,720533,1,1,,124881922,3440,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1690,720533,1,1,,144203873,3440,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1691,720542,1,2,,47193739,3440,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1692,720543,1,1,,50085981,3440,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1693,720551,1,2,,47193739,3440,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1694,720552,2,1,,144203873,3440,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1695,720552,2,1,,144209411,3440,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1696,720552,2,1,,144213288,3440,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1697,720553,1,2,,47193739,3440,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1698,720554,1,3,,121362568,3440,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
1699,720579,2,1,,47193739,3440,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1700,720579,2,1,,124881920,3440,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1701,720580,1,1,,47193739,3440,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1702,720580,1,1,,124881920,3440,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1703,720582,1,1,,50085981,3440,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1704,720596,1,1,,50085981,3440,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1705,720634,2,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1706,720634,2,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1707,720634,2,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1708,720635,2,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1709,720635,2,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1710,720635,2,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1711,720636,1,1,,17389872,3440,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1712,720636,1,1,,144203873,3440,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1713,720637,2,1,,144203873,3440,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1714,720637,2,1,,144209411,3440,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1715,720637,2,1,,144213288,3440,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1716,720641,1,2,,92307335,3440,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1717,720641,1,2,,92309202,3440,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1718,720648,1,1,,50085981,3440,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1719,720652,1,1,,17389872,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1720,720653,1,1,,17389872,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1721,720653,1,1,,26752835,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1722,720659,1,1,,17389872,3440,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1723,720659,1,1,,26752835,3440,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1724,720674,2,2,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1725,720674,2,2,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1726,720674,2,2,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1727,720675,2,2,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1728,720675,2,2,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1729,720675,2,2,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1730,720678,2,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1731,720678,2,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1732,720678,2,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1733,720679,2,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1734,720679,2,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1735,720679,2,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1736,720680,2,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1737,720680,2,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1738,720680,2,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1739,720681,2,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1740,720681,2,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1741,720681,2,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1742,720682,2,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1743,720682,2,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1744,720682,2,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1745,720683,2,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1746,720683,2,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1747,720683,2,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1748,720684,2,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1749,720684,2,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1750,720684,2,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1751,720685,2,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1752,720685,2,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1753,720685,2,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1754,720686,2,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1755,720686,2,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1756,720686,2,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1757,720687,2,2,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1758,720687,2,2,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1759,720687,2,2,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1760,720691,4,1,,144203873,3440,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1761,720691,4,1,,144209411,3440,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1762,720691,4,1,,144213288,3440,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1763,720692,3,1,,144203873,3440,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1764,720692,3,1,,144209411,3440,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1765,720692,3,1,,144213288,3440,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1766,720693,3,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1767,720693,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1768,720693,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1769,720700,1,4,,50085981,3440,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1770,720702,1,1,,50085981,3440,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1771,720704,1,4,,50085981,3440,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1772,720707,1,2,,47193739,3440,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1773,720708,1,2,,47193739,3440,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1774,720709,1,2,,47193739,3440,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1775,720711,1,2,,47193739,3440,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1776,720717,1,3,,92123947,3440,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1777,720717,1,3,,92125367,3440,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1778,720717,1,3,,92307335,3440,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1779,720717,1,3,,92309202,3440,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1780,720719,2,1,,144203873,3440,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1781,720719,2,1,,144209411,3440,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1782,720719,2,1,,144213288,3440,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1783,720725,2,1,,144203873,3440,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1784,720725,2,1,,144209411,3440,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1785,720725,2,1,,144213288,3440,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1786,721753,1,6,,103165562,3440,Unspecified,74731723.0,55244.0,,,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay,Other,23241029.0,
1787,721754,2,5,,103165562,3440,Unspecified,74731723.0,55244.0,500.0,IC50,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
1788,743012,3,1,,144203873,3440,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1789,743012,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1790,743012,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1791,743014,3,1,,144203873,3440,Inconclusive,,,21.1317,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1792,743014,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1793,743014,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1794,743015,3,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1795,743015,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1796,743015,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1797,743033,3,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1798,743033,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1799,743033,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1800,743035,2,1,,144203873,3440,Inconclusive,124375976.0,367.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1801,743035,2,1,,144209411,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1802,743035,2,1,,144213288,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1803,743036,2,1,,144203873,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1804,743036,2,1,,144209411,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1805,743036,2,1,,144213288,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1806,743040,3,1,,144203873,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1807,743040,3,1,,144209411,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1808,743040,3,1,,144213288,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1809,743041,3,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1810,743041,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1811,743041,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1812,743042,3,1,,144203873,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1813,743042,3,1,,144209411,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1814,743042,3,1,,144213288,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1815,743053,2,1,,144203873,3440,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1816,743053,2,1,,144209411,3440,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1817,743053,2,1,,144213288,3440,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1818,743054,2,1,,144203873,3440,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1819,743054,2,1,,144209411,3440,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1820,743054,2,1,,144213288,3440,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1821,743063,2,1,,144203873,3440,Active,124375976.0,367.0,26.8325,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1822,743063,2,1,,144209411,3440,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1823,743063,2,1,,144213288,3440,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1824,743064,3,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1825,743064,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1826,743064,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1827,743065,3,1,,144203873,3440,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1828,743065,3,1,,144209411,3440,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1829,743065,3,1,,144213288,3440,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1830,743066,3,1,,144203873,3440,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1831,743066,3,1,,144209411,3440,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1832,743066,3,1,,144213288,3440,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1833,743067,2,1,,144203873,3440,Inconclusive,399498506.0,24831.0,17.7801,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1834,743067,2,1,,144209411,3440,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1835,743067,2,1,,144213288,3440,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1836,743069,2,1,,144203873,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1837,743069,2,1,,144209411,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1838,743069,2,1,,144213288,3440,Inactive,348019627.0,2099.0,1.9496,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1839,743074,2,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1840,743074,2,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1841,743074,2,1,,144213288,3440,Inconclusive,,,24.5442,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1842,743075,2,1,,144203873,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1843,743075,2,1,,144209411,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1844,743075,2,1,,144213288,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1845,743077,2,1,,144203873,3440,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1846,743077,2,1,,144209411,3440,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1847,743077,2,1,,144213288,3440,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1848,743078,2,1,,144203873,3440,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1849,743078,2,1,,144209411,3440,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1850,743078,2,1,,144213288,3440,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1851,743079,3,1,,144203873,3440,Active,348019627.0,2099.0,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1852,743079,3,1,,144209411,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1853,743079,3,1,,144213288,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1854,743080,3,1,,144203873,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1855,743080,3,1,,144209411,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1856,743080,3,1,,144213288,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1857,743081,3,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1858,743081,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1859,743081,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1860,743083,3,1,,144203873,3440,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1861,743083,3,1,,144209411,3440,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1862,743083,3,1,,144213288,3440,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1863,743084,3,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1864,743084,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1865,743084,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1866,743085,3,1,,144203873,3440,Inconclusive,51095037.0,196.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1867,743085,3,1,,144209411,3440,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1868,743085,3,1,,144213288,3440,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1869,743086,3,1,,144203873,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1870,743086,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1871,743086,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1872,743091,2,1,,144203873,3440,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1873,743091,2,1,,144209411,3440,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1874,743091,2,1,,144213288,3440,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1875,743094,3,1,,144203873,3440,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1876,743094,3,1,,144209411,3440,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1877,743094,3,1,,144213288,3440,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1878,743122,2,1,,144203873,3440,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1879,743122,2,1,,144209411,3440,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1880,743122,2,1,,144213288,3440,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1881,743126,1,1,,50085981,3440,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1882,743139,2,1,,144203873,3440,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1883,743139,2,1,,144209411,3440,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1884,743139,2,1,,144213288,3440,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1885,743140,2,1,,144203873,3440,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1886,743140,2,1,,144209411,3440,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1887,743140,2,1,,144213288,3440,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1888,743191,3,1,,144209411,3440,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1889,743191,3,1,,144213288,3440,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1890,743191,3,1,,170464879,3440,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1891,743194,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1892,743194,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1893,743194,3,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1894,743199,2,1,,144209411,3440,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1895,743199,2,1,,144213288,3440,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1896,743199,2,1,,170464879,3440,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1897,743202,4,1,,144209411,3440,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1898,743202,4,1,,144213288,3440,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1899,743202,4,1,,170464879,3440,Inconclusive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1900,743203,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1901,743203,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1902,743203,3,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1903,743209,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1904,743209,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1905,743209,3,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1906,743210,4,1,,144209411,3440,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1907,743210,4,1,,144213288,3440,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1908,743210,4,1,,170464879,3440,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1909,743211,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1910,743211,3,1,,144213288,3440,Inconclusive,,,0.0389,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1911,743211,3,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1912,743212,3,1,,144209411,3440,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1913,743212,3,1,,144213288,3440,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1914,743212,3,1,,170464879,3440,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1915,743213,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1916,743213,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1917,743213,3,1,,170464879,3440,Inconclusive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1918,743215,3,1,,144209411,3440,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1919,743215,3,1,,144213288,3440,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1920,743215,3,1,,170464879,3440,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1921,743217,3,1,,144209411,3440,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1922,743217,3,1,,144213288,3440,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1923,743217,3,1,,170464879,3440,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1924,743218,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1925,743218,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1926,743218,3,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1927,743219,3,1,,144209411,3440,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1928,743219,3,1,,144213288,3440,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1929,743219,3,1,,170464879,3440,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1930,743220,3,1,,144209411,3440,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1931,743220,3,1,,144213288,3440,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1932,743220,3,1,,170464879,3440,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1933,743221,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1934,743221,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1935,743221,3,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1936,743222,3,1,,144209411,3440,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1937,743222,3,1,,144213288,3440,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1938,743222,3,1,,170464879,3440,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1939,743223,3,1,,144209411,3440,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1940,743223,3,1,,144213288,3440,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1941,743223,3,1,,170464879,3440,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1942,743224,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1943,743224,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1944,743224,3,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1945,743225,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1946,743225,3,1,,144213288,3440,Inconclusive,,,0.195,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1947,743225,3,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1948,743226,2,1,,144209411,3440,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1949,743226,2,1,,144213288,3440,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1950,743226,2,1,,170464879,3440,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1951,743227,2,1,,144209411,3440,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1952,743227,2,1,,144213288,3440,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1953,743227,2,1,,170464879,3440,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1954,743228,3,1,,144209411,3440,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1955,743228,3,1,,144213288,3440,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1956,743228,3,1,,170464879,3440,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1957,743238,1,1,,50085981,3440,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
1958,743239,2,1,,144209411,3440,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1959,743239,2,1,,144213288,3440,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1960,743239,2,1,,170464879,3440,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1961,743240,2,1,,144209411,3440,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1962,743240,2,1,,144213288,3440,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1963,743240,2,1,,170464879,3440,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1964,743241,2,1,,144209411,3440,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1965,743241,2,1,,144213288,3440,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1966,743241,2,1,,170464879,3440,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1967,743242,2,1,,144209411,3440,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1968,743242,2,1,,144213288,3440,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1969,743242,2,1,,170464879,3440,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1970,743244,1,1,,144203873,3440,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1971,743247,1,2,,50085981,3440,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1972,743255,1,1,,47193739,3440,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1973,743266,1,2,,47193739,3440,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1974,743268,1,1,,172080576,3440,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
1975,743269,1,1,,50085981,3440,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1976,743269,1,1,,50085981,3440,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1977,743270,1,1,,172080576,3440,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
1978,743271,1,1,,172080576,3440,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
1979,743272,1,1,,172080576,3440,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
1980,743279,1,2,,47193739,3440,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1981,743288,1,1,,17389872,3440,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
1982,743288,1,1,,26752835,3440,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
1983,743292,1,1,,17389872,3440,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
1984,743292,1,1,,26752835,3440,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
1985,743344,1,1,,162108257,3440,Inactive,,,18.8212,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
1986,743345,1,1,,162108257,3440,Inactive,,,0.0013,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
1987,743346,1,1,,162108257,3440,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
1988,743347,1,1,,162108257,3440,Inactive,,,11.8754,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
1989,743397,1,1,,50085981,3440,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1990,743398,1,1,,50085981,3440,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1991,769720,1,5,,103165562,3440,Unspecified,68068087.0,2859.0,,,Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells at 100 uM after 90 mins by beta-arrestin recruitment assay relative to zaprinast,Other,23888932.0,
1992,769723,4,2,,103165562,3440,Active,68068087.0,2859.0,11.2,EC50,Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells after 90 mins by beta-arrestin recruitment assay,Confirmatory,23888932.0,
1993,769725,2,3,,103165562,3440,Active,68068087.0,2859.0,3.27,Ki,Displacement of [3H]PSB-13253 from human recombinant GPR35 exprssed in CHO cells by liquid scintillation counting analysis,Confirmatory,23888932.0,
1994,769740,2,3,,103165562,3440,Active,68068087.0,2859.0,6.2,EC50,Agonist activity at human GPR35 by Ca+2 release assay,Confirmatory,23888932.0,
1995,781325,1,2,,103165562,3440,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 2009,Other,24249037.0,
1996,781326,1,2,,103165562,3440,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
1997,781329,1,2,,103165562,3440,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by other workers,Other,24249037.0,
1998,781330,1,2,,103165562,3440,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by potentiometric titration,Other,24249037.0,
1999,817074,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 392/12,Other,,
2000,817075,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 392/12,Other,,
2001,817076,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 392/12,Other,,
2002,817077,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 392/12,Other,,
2003,817078,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 392/12,Other,,
2004,817079,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 392/12,Other,,
2005,817080,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 392/12,Other,,
2006,817081,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 392/12,Other,,
2007,817082,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 392/12,Other,,
2008,817083,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 392/12,Other,,
2009,817084,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 392/12,Other,,
2010,817085,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 392/12,Other,,
2011,817086,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 392/13,Other,,
2012,817087,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 392/13,Other,,
2013,817088,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 392/13,Other,,
2014,817089,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 392/13,Other,,
2015,817090,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 392/13,Other,,
2016,817091,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 392/13,Other,,
2017,817092,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 392/13,Other,,
2018,817093,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 392/13,Other,,
2019,817094,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 392/13,Other,,
2020,817095,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 392/13,Other,,
2021,817096,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 392/13,Other,,
2022,817097,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 392/13,Other,,
2023,817098,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 392/13,Other,,
2024,817099,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 392/13,Other,,
2025,817100,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 392/13,Other,,
2026,817101,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 392/13,Other,,
2027,817102,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 392/13,Other,,
2028,817773,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 392/14,Other,,
2029,817774,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 392/14,Other,,
2030,817775,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 392/14,Other,,
2031,817776,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 392/14,Other,,
2032,817777,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 392/14,Other,,
2033,817778,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 392/14,Other,,
2034,817779,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 392/14,Other,,
2035,817780,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 392/14,Other,,
2036,817781,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 392/14,Other,,
2037,817782,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 392/14,Other,,
2038,817783,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 392/14,Other,,
2039,817784,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 392/14,Other,,
2040,817785,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 392/14,Other,,
2041,817786,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 392/14,Other,,
2042,817787,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 392/14,Other,,
2043,817788,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 392/14,Other,,
2044,817789,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 392/14,Other,,
2045,817790,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 392/15,Other,,
2046,817791,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 392/15,Other,,
2047,817827,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 393/11,Other,,
2048,817828,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 393/11,Other,,
2049,817829,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 393/11,Other,,
2050,817830,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 393/11,Other,,
2051,817831,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 393/11,Other,,
2052,817832,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 393/11,Other,,
2053,817833,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 393/11,Other,,
2054,817834,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 393/11,Other,,
2055,817835,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 393/11,Other,,
2056,817836,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 393/11,Other,,
2057,817837,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 393/11,Other,,
2058,817838,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 393/12,Other,,
2059,817839,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 393/12,Other,,
2060,817840,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 393/12,Other,,
2061,817841,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 393/12,Other,,
2062,817842,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 393/12,Other,,
2063,817843,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 393/12,Other,,
2064,817844,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 393/12,Other,,
2065,817845,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 393/12,Other,,
2066,817846,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 393/12,Other,,
2067,817847,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 393/12,Other,,
2068,817848,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 393/12,Other,,
2069,817849,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 393/12,Other,,
2070,817850,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 393/12,Other,,
2071,817851,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 393/12,Other,,
2072,817852,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 393/12,Other,,
2073,817853,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 393/12,Other,,
2074,817854,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 393/12,Other,,
2075,817855,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 393/13,Other,,
2076,817856,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 393/13,Other,,
2077,817857,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 393/13,Other,,
2078,817858,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 393/13,Other,,
2079,817859,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 393/13,Other,,
2080,817860,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 393/13,Other,,
2081,817861,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 393/13,Other,,
2082,818533,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 393/13,Other,,
2083,818534,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 393/13,Other,,
2084,818535,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 393/13,Other,,
2085,818536,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 393/13,Other,,
2086,818537,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 393/13,Other,,
2087,818538,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 393/13,Other,,
2088,818539,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 393/13,Other,,
2089,818540,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 393/13,Other,,
2090,818541,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 393/13,Other,,
2091,818542,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 393/13,Other,,
2092,818543,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 393/14,Other,,
2093,819932,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 392/15,Other,,
2094,819933,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 392/15,Other,,
2095,819934,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 392/15,Other,,
2096,819935,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 392/15,Other,,
2097,819936,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 392/15,Other,,
2098,819937,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 392/15,Other,,
2099,819938,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 392/15,Other,,
2100,819939,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 392/15,Other,,
2101,819940,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 392/15,Other,,
2102,819941,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 392/15,Other,,
2103,819942,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 392/15,Other,,
2104,819943,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 392/15,Other,,
2105,819944,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 392/15,Other,,
2106,819945,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 392/15,Other,,
2107,819946,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 392/15,Other,,
2108,819947,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 392/16,Other,,
2109,819948,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 392/16,Other,,
2110,819949,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 392/16,Other,,
2111,819950,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 392/16,Other,,
2112,820619,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 392/16,Other,,
2113,820620,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 392/16,Other,,
2114,820621,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 392/16,Other,,
2115,820622,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 392/16,Other,,
2116,820623,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 392/16,Other,,
2117,820624,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 392/16,Other,,
2118,820625,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 392/16,Other,,
2119,820626,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 392/16,Other,,
2120,820627,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 392/16,Other,,
2121,820628,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 392/16,Other,,
2122,820629,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 392/16,Other,,
2123,820630,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 392/16,Other,,
2124,820631,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 392/16,Other,,
2125,820632,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 393/5,Other,,
2126,820633,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 393/5,Other,,
2127,820634,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 393/5,Other,,
2128,820635,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 393/5,Other,,
2129,820636,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 393/5,Other,,
2130,820637,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 393/5,Other,,
2131,820638,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 393/5,Other,,
2132,820639,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 393/5,Other,,
2133,820640,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 393/5,Other,,
2134,820641,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 393/5,Other,,
2135,820642,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 393/5,Other,,
2136,820643,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 393/5,Other,,
2137,820644,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 393/5,Other,,
2138,820645,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 393/5,Other,,
2139,820646,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 393/5,Other,,
2140,820682,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 393/14,Other,,
2141,820683,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 393/14,Other,,
2142,820684,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 393/14,Other,,
2143,820685,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 393/14,Other,,
2144,820686,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 393/14,Other,,
2145,820687,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 393/14,Other,,
2146,820688,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 393/14,Other,,
2147,820689,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 393/14,Other,,
2148,820690,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 393/14,Other,,
2149,820691,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 393/14,Other,,
2150,820692,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 393/14,Other,,
2151,820693,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 393/14,Other,,
2152,820694,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 393/14,Other,,
2153,820695,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 393/14,Other,,
2154,820696,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 393/14,Other,,
2155,820697,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 393/14,Other,,
2156,820698,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 393/15,Other,,
2157,820699,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 393/15,Other,,
2158,820700,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 393/15,Other,,
2159,820701,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 393/15,Other,,
2160,820702,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 393/15,Other,,
2161,820703,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 393/15,Other,,
2162,820704,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 393/15,Other,,
2163,820705,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 393/15,Other,,
2164,820706,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 393/15,Other,,
2165,820707,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 393/15,Other,,
2166,820708,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 393/15,Other,,
2167,821382,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 393/15,Other,,
2168,821383,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 393/15,Other,,
2169,821384,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 393/15,Other,,
2170,821385,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 393/15,Other,,
2171,821386,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 393/15,Other,,
2172,821387,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 393/15,Other,,
2173,821388,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 393/16,Other,,
2174,821389,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 393/16,Other,,
2175,821390,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 393/16,Other,,
2176,821391,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 393/16,Other,,
2177,821392,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 393/16,Other,,
2178,821393,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 393/16,Other,,
2179,821394,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 393/16,Other,,
2180,821395,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 393/16,Other,,
2181,821396,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 393/16,Other,,
2182,821397,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 393/16,Other,,
2183,821398,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 393/16,Other,,
2184,821399,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 393/16,Other,,
2185,821400,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 393/16,Other,,
2186,821491,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 392/5,Other,,
2187,821492,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 392/5,Other,,
2188,821493,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 392/5,Other,,
2189,821494,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 392/5,Other,,
2190,821495,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 392/5,Other,,
2191,821496,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 392/5,Other,,
2192,821497,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 392/5,Other,,
2193,821498,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 392/5,Other,,
2194,821499,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 392/5,Other,,
2195,821500,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 392/5,Other,,
2196,821501,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 392/5,Other,,
2197,821502,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 392/5,Other,,
2198,821503,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 392/5,Other,,
2199,821504,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 392/5,Other,,
2200,821505,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 392/5,Other,,
2201,821506,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 392/5,Other,,
2202,821507,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 392/5,Other,,
2203,821508,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 392/6,Other,,
2204,821509,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 392/6,Other,,
2205,821510,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 392/6,Other,,
2206,821511,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 392/6,Other,,
2207,821512,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 392/6,Other,,
2208,821513,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 392/6,Other,,
2209,821514,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 392/6,Other,,
2210,821515,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 392/6,Other,,
2211,822179,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 392/6,Other,,
2212,822180,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 392/6,Other,,
2213,822181,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 392/6,Other,,
2214,822182,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 392/6,Other,,
2215,822786,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 393/5,Other,,
2216,822787,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 393/5,Other,,
2217,822788,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 393/6,Other,,
2218,822789,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 393/6,Other,,
2219,822790,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 393/6,Other,,
2220,822791,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 393/6,Other,,
2221,822792,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 393/6,Other,,
2222,822793,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 393/6,Other,,
2223,822794,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 393/6,Other,,
2224,822795,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 393/6,Other,,
2225,823464,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 393/6,Other,,
2226,823465,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 393/6,Other,,
2227,823466,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 393/6,Other,,
2228,823467,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 393/6,Other,,
2229,823468,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 393/6,Other,,
2230,823469,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 393/6,Other,,
2231,823470,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 393/6,Other,,
2232,823471,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 393/6,Other,,
2233,823472,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 393/6,Other,,
2234,823473,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 393/7,Other,,
2235,823474,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 393/7,Other,,
2236,823475,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 393/7,Other,,
2237,823476,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 393/7,Other,,
2238,823477,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 393/7,Other,,
2239,823478,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 393/7,Other,,
2240,823479,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 393/7,Other,,
2241,823480,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 393/7,Other,,
2242,823481,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 393/7,Other,,
2243,823482,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 393/7,Other,,
2244,823483,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 393/7,Other,,
2245,823484,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 393/7,Other,,
2246,823485,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 393/7,Other,,
2247,823486,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 393/7,Other,,
2248,823487,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 393/7,Other,,
2249,823488,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 393/7,Other,,
2250,823489,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 393/7,Other,,
2251,823490,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 393/8,Other,,
2252,823491,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 393/8,Other,,
2253,823492,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 393/8,Other,,
2254,823493,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 393/8,Other,,
2255,823494,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 393/8,Other,,
2256,823495,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 393/8,Other,,
2257,823496,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 393/8,Other,,
2258,823497,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 393/8,Other,,
2259,823498,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 393/8,Other,,
2260,823499,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 393/8,Other,,
2261,823500,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 393/8,Other,,
2262,823534,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 393/16,Other,,
2263,823535,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 393/16,Other,,
2264,823536,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 393/16,Other,,
2265,823537,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 393/16,Other,,
2266,824328,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 392/6,Other,,
2267,824329,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 392/6,Other,,
2268,824330,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 392/6,Other,,
2269,824331,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 392/6,Other,,
2270,824332,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 392/6,Other,,
2271,824333,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 392/7,Other,,
2272,824334,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 392/7,Other,,
2273,824335,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 392/7,Other,,
2274,824336,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 392/7,Other,,
2275,824337,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 392/7,Other,,
2276,824338,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 392/7,Other,,
2277,824339,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 392/7,Other,,
2278,824340,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 392/7,Other,,
2279,824341,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 392/7,Other,,
2280,824342,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 392/7,Other,,
2281,824343,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 392/7,Other,,
2282,824344,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 392/7,Other,,
2283,824345,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 392/7,Other,,
2284,824346,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 392/7,Other,,
2285,824347,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 392/7,Other,,
2286,824348,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 392/7,Other,,
2287,824349,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 392/7,Other,,
2288,824350,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 392/8,Other,,
2289,824351,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 392/8,Other,,
2290,824352,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 392/8,Other,,
2291,824353,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 392/8,Other,,
2292,824354,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 392/8,Other,,
2293,824355,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 392/8,Other,,
2294,824356,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 392/8,Other,,
2295,824357,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 392/8,Other,,
2296,824358,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 392/8,Other,,
2297,824359,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 392/8,Other,,
2298,824360,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 392/8,Other,,
2299,824361,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 392/8,Other,,
2300,825030,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 392/8,Other,,
2301,825031,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 392/8,Other,,
2302,825032,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 392/8,Other,,
2303,825033,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 392/8,Other,,
2304,825034,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 392/8,Other,,
2305,825035,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 392/9,Other,,
2306,825036,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 392/9,Other,,
2307,825037,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 392/9,Other,,
2308,825038,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 392/9,Other,,
2309,825039,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 392/9,Other,,
2310,825040,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 392/9,Other,,
2311,825041,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 392/9,Other,,
2312,825042,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 392/9,Other,,
2313,825043,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 392/9,Other,,
2314,825566,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 392/9,Other,,
2315,825567,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 392/9,Other,,
2316,825568,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 392/9,Other,,
2317,825569,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 392/9,Other,,
2318,825570,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 392/9,Other,,
2319,825571,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 392/9,Other,,
2320,825572,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 392/9,Other,,
2321,825573,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 392/9,Other,,
2322,825574,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 392/10,Other,,
2323,825575,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 392/10,Other,,
2324,825576,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 392/10,Other,,
2325,825577,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 392/10,Other,,
2326,825578,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 392/10,Other,,
2327,825579,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 392/10,Other,,
2328,825580,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 392/10,Other,,
2329,825581,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 392/10,Other,,
2330,825582,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 392/10,Other,,
2331,825583,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 392/10,Other,,
2332,825584,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 392/10,Other,,
2333,825585,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 392/10,Other,,
2334,825586,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 392/10,Other,,
2335,825587,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 392/10,Other,,
2336,825588,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 392/10,Other,,
2337,825589,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 392/10,Other,,
2338,825590,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 392/10,Other,,
2339,825591,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 392/11,Other,,
2340,825592,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 392/11,Other,,
2341,825593,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 392/11,Other,,
2342,825594,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 392/11,Other,,
2343,825595,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 392/11,Other,,
2344,825596,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 392/11,Other,,
2345,825597,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 392/11,Other,,
2346,825598,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 392/11,Other,,
2347,825599,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 392/11,Other,,
2348,825600,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 392/11,Other,,
2349,825601,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 392/11,Other,,
2350,825602,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 392/11,Other,,
2351,825645,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 393/8,Other,,
2352,825646,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 393/8,Other,,
2353,826269,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 392/11,Other,,
2354,826270,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 392/11,Other,,
2355,826271,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 392/11,Other,,
2356,826272,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 392/11,Other,,
2357,826273,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 392/11,Other,,
2358,826274,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 392/12,Other,,
2359,826275,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 392/12,Other,,
2360,826276,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 392/12,Other,,
2361,826277,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 392/12,Other,,
2362,826278,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 392/12,Other,,
2363,826314,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 393/8,Other,,
2364,826315,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 393/8,Other,,
2365,826316,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 393/8,Other,,
2366,826317,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 393/8,Other,,
2367,826318,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 393/9,Other,,
2368,826319,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 393/9,Other,,
2369,826320,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 393/9,Other,,
2370,826321,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 393/9,Other,,
2371,826322,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 393/9,Other,,
2372,826323,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 393/9,Other,,
2373,826324,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 393/9,Other,,
2374,826325,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 393/9,Other,,
2375,826326,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 393/9,Other,,
2376,826327,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 393/9,Other,,
2377,826328,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 393/9,Other,,
2378,826329,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 393/9,Other,,
2379,826330,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 393/9,Other,,
2380,826331,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 393/9,Other,,
2381,826332,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 393/9,Other,,
2382,826333,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 393/9,Other,,
2383,826334,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 393/9,Other,,
2384,826335,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 393/10,Other,,
2385,826336,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 393/10,Other,,
2386,826337,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 393/10,Other,,
2387,826338,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 393/10,Other,,
2388,826339,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 393/10,Other,,
2389,826340,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 393/10,Other,,
2390,826341,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 393/10,Other,,
2391,826342,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 393/10,Other,,
2392,826343,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 393/10,Other,,
2393,826344,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 393/10,Other,,
2394,826345,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 393/10,Other,,
2395,826346,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 393/10,Other,,
2396,826347,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 393/10,Other,,
2397,826348,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 393/10,Other,,
2398,826349,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 393/10,Other,,
2399,826350,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 393/10,Other,,
2400,826351,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 393/10,Other,,
2401,826352,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 393/11,Other,,
2402,826353,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 393/11,Other,,
2403,826354,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 393/11,Other,,
2404,826355,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 393/11,Other,,
2405,826356,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 393/11,Other,,
2406,826357,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 393/11,Other,,
2407,849024,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 393/5,Other,,
2408,849025,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 393/5,Other,,
2409,849026,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 393/5,Other,,
2410,849027,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 393/5,Other,,
2411,849028,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 393/5,Other,,
2412,849029,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 393/5,Other,,
2413,849030,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 393/5,Other,,
2414,849031,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 393/5,Other,,
2415,849032,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 393/5,Other,,
2416,849033,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 393/5,Other,,
2417,849034,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 393/5,Other,,
2418,849035,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 393/5,Other,,
2419,849036,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 393/5,Other,,
2420,849037,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 393/5,Other,,
2421,849038,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 393/5,Other,,
2422,849039,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 393/5,Other,,
2423,849040,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 393/5,Other,,
2424,849041,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 393/5,Other,,
2425,849042,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 393/5,Other,,
2426,849043,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 393/5,Other,,
2427,849044,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 393/6,Other,,
2428,849045,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 393/6,Other,,
2429,849046,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 393/6,Other,,
2430,849047,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 393/6,Other,,
2431,849048,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 393/6,Other,,
2432,849049,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 393/6,Other,,
2433,849050,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 393/6,Other,,
2434,849051,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 393/6,Other,,
2435,849052,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 393/6,Other,,
2436,849053,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 393/6,Other,,
2437,849054,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 393/6,Other,,
2438,849055,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 393/6,Other,,
2439,849056,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 393/6,Other,,
2440,849057,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 393/6,Other,,
2441,849092,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 393/13,Other,,
2442,849093,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 393/13,Other,,
2443,849094,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 393/13,Other,,
2444,849095,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 393/13,Other,,
2445,849096,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 393/13,Other,,
2446,849097,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 393/13,Other,,
2447,849098,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 393/13,Other,,
2448,849099,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 393/13,Other,,
2449,849100,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 393/13,Other,,
2450,849101,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 393/13,Other,,
2451,849102,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 393/13,Other,,
2452,849103,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 393/13,Other,,
2453,849104,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 393/13,Other,,
2454,849105,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 393/14,Other,,
2455,849106,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 393/14,Other,,
2456,849107,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 393/14,Other,,
2457,849108,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 393/14,Other,,
2458,849109,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 393/14,Other,,
2459,849110,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 393/14,Other,,
2460,849111,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 393/14,Other,,
2461,849112,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 393/14,Other,,
2462,849113,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 393/14,Other,,
2463,849792,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 393/14,Other,,
2464,849793,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 393/14,Other,,
2465,849794,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 393/14,Other,,
2466,849795,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 393/14,Other,,
2467,849796,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 393/14,Other,,
2468,849797,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 393/14,Other,,
2469,849798,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 393/14,Other,,
2470,849799,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 393/14,Other,,
2471,849800,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 393/14,Other,,
2472,849801,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 393/14,Other,,
2473,849802,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 393/14,Other,,
2474,849803,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 393/14,Other,,
2475,849804,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 393/15,Other,,
2476,849805,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 393/15,Other,,
2477,849806,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 393/15,Other,,
2478,849807,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 393/15,Other,,
2479,849808,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 393/15,Other,,
2480,849809,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 393/15,Other,,
2481,849810,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 393/15,Other,,
2482,849811,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 393/15,Other,,
2483,849812,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 393/15,Other,,
2484,849813,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 393/15,Other,,
2485,849814,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 393/15,Other,,
2486,849815,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 393/15,Other,,
2487,849816,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 393/15,Other,,
2488,849887,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 392/7,Other,,
2489,849888,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 392/7,Other,,
2490,849889,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 392/7,Other,,
2491,849890,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 392/7,Other,,
2492,849891,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 392/7,Other,,
2493,849892,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 392/7,Other,,
2494,849893,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 392/7,Other,,
2495,849894,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 392/7,Other,,
2496,849895,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 392/7,Other,,
2497,849896,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 392/7,Other,,
2498,849897,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 392/7,Other,,
2499,849898,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 392/7,Other,,
2500,849899,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 392/7,Other,,
2501,849900,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 392/7,Other,,
2502,849901,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 392/7,Other,,
2503,849902,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 392/7,Other,,
2504,849903,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 392/8,Other,,
2505,849904,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 392/8,Other,,
2506,849905,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 392/8,Other,,
2507,849906,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 392/8,Other,,
2508,849907,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 392/8,Other,,
2509,849908,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 392/8,Other,,
2510,849909,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 392/8,Other,,
2511,849910,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 392/8,Other,,
2512,849911,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 392/8,Other,,
2513,849912,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 392/8,Other,,
2514,849913,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 392/8,Other,,
2515,849914,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 392/8,Other,,
2516,849915,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 392/8,Other,,
2517,849916,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 392/8,Other,,
2518,849917,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 392/8,Other,,
2519,849918,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 392/8,Other,,
2520,849919,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 392/8,Other,,
2521,849920,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 392/8,Other,,
2522,849921,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 392/8,Other,,
2523,849922,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 392/8,Other,,
2524,849923,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 392/8,Other,,
2525,849924,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 392/9,Other,,
2526,849925,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 392/9,Other,,
2527,849926,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 392/9,Other,,
2528,849927,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 392/9,Other,,
2529,850599,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 392/9,Other,,
2530,850600,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 392/9,Other,,
2531,850601,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 392/9,Other,,
2532,850602,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 392/9,Other,,
2533,850603,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 392/9,Other,,
2534,850604,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 392/9,Other,,
2535,850605,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 392/9,Other,,
2536,851137,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 392/9,Other,,
2537,851138,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 392/9,Other,,
2538,851139,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 392/9,Other,,
2539,851140,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 392/9,Other,,
2540,851141,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 392/9,Other,,
2541,851142,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 392/9,Other,,
2542,851143,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 392/9,Other,,
2543,851144,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 392/9,Other,,
2544,851145,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 392/9,Other,,
2545,851146,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 392/9,Other,,
2546,851147,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 392/10,Other,,
2547,851148,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 392/10,Other,,
2548,851149,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 392/10,Other,,
2549,851150,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 392/10,Other,,
2550,851151,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 392/10,Other,,
2551,851152,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 392/10,Other,,
2552,851153,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 392/10,Other,,
2553,851154,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 392/10,Other,,
2554,851155,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 392/10,Other,,
2555,851156,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 392/10,Other,,
2556,851157,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 392/10,Other,,
2557,851158,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 392/10,Other,,
2558,851159,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 392/10,Other,,
2559,851160,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 392/10,Other,,
2560,851161,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 392/10,Other,,
2561,851162,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 392/10,Other,,
2562,851163,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 392/10,Other,,
2563,851164,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 392/10,Other,,
2564,851165,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 392/10,Other,,
2565,851166,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 392/10,Other,,
2566,851167,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 392/10,Other,,
2567,851168,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 392/11,Other,,
2568,851169,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 392/11,Other,,
2569,851170,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 392/11,Other,,
2570,851171,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 392/11,Other,,
2571,851172,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 392/11,Other,,
2572,851173,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 392/11,Other,,
2573,851174,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 392/11,Other,,
2574,851175,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 392/11,Other,,
2575,851176,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 392/11,Other,,
2576,851177,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 392/11,Other,,
2577,851178,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 392/11,Other,,
2578,851220,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 393/6,Other,,
2579,851221,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 393/6,Other,,
2580,851222,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 393/6,Other,,
2581,851223,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 393/6,Other,,
2582,851224,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 393/6,Other,,
2583,851857,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 392/11,Other,,
2584,851858,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 392/11,Other,,
2585,851859,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 392/11,Other,,
2586,851860,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 392/11,Other,,
2587,851861,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 392/11,Other,,
2588,851862,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 392/11,Other,,
2589,851902,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 393/6,Other,,
2590,851903,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 393/6,Other,,
2591,851904,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 393/7,Other,,
2592,851905,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 393/7,Other,,
2593,851906,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 393/7,Other,,
2594,851907,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 393/7,Other,,
2595,851908,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 393/7,Other,,
2596,851909,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 393/7,Other,,
2597,851910,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 393/7,Other,,
2598,851911,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 393/7,Other,,
2599,851912,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 393/7,Other,,
2600,851913,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 393/7,Other,,
2601,851914,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 393/7,Other,,
2602,851915,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 393/7,Other,,
2603,851916,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 393/7,Other,,
2604,851917,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 393/7,Other,,
2605,851918,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 393/7,Other,,
2606,851919,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 393/7,Other,,
2607,851920,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 393/7,Other,,
2608,851921,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 393/7,Other,,
2609,851922,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 393/7,Other,,
2610,851923,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 393/7,Other,,
2611,851924,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 393/7,Other,,
2612,851925,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 393/8,Other,,
2613,851926,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 393/8,Other,,
2614,851927,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 393/8,Other,,
2615,851928,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 393/8,Other,,
2616,851929,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 393/8,Other,,
2617,851930,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 393/8,Other,,
2618,851931,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 393/8,Other,,
2619,851932,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 393/8,Other,,
2620,851933,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 393/8,Other,,
2621,851934,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 393/8,Other,,
2622,851935,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 393/8,Other,,
2623,851936,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 393/8,Other,,
2624,851937,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 393/8,Other,,
2625,851938,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 393/8,Other,,
2626,851939,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 393/8,Other,,
2627,851940,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 393/8,Other,,
2628,851941,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 393/8,Other,,
2629,851942,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 393/8,Other,,
2630,851943,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 393/8,Other,,
2631,851980,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 393/15,Other,,
2632,851981,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 393/15,Other,,
2633,851982,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 393/15,Other,,
2634,851983,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 393/15,Other,,
2635,851984,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 393/15,Other,,
2636,851985,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 393/15,Other,,
2637,851986,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 393/15,Other,,
2638,851987,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 393/15,Other,,
2639,851988,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 393/16,Other,,
2640,851989,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 393/16,Other,,
2641,851990,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 393/16,Other,,
2642,851991,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 393/16,Other,,
2643,852670,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 393/16,Other,,
2644,852671,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 393/16,Other,,
2645,852672,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 393/16,Other,,
2646,852673,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 393/16,Other,,
2647,852674,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 393/16,Other,,
2648,852675,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 393/16,Other,,
2649,852676,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 393/16,Other,,
2650,852677,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 393/16,Other,,
2651,852678,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 393/16,Other,,
2652,852679,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 393/16,Other,,
2653,852680,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 393/16,Other,,
2654,852681,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 393/16,Other,,
2655,852682,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 393/16,Other,,
2656,852683,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 393/16,Other,,
2657,852684,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 393/16,Other,,
2658,852685,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 393/16,Other,,
2659,852686,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 393/16,Other,,
2660,854028,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 392/11,Other,,
2661,854029,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 392/11,Other,,
2662,854030,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 392/11,Other,,
2663,854031,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 392/11,Other,,
2664,854032,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 392/12,Other,,
2665,854033,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 392/12,Other,,
2666,854034,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 392/12,Other,,
2667,854035,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 392/12,Other,,
2668,854036,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 392/12,Other,,
2669,854037,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 392/12,Other,,
2670,854038,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 392/12,Other,,
2671,854039,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 392/12,Other,,
2672,854040,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 392/12,Other,,
2673,854041,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 392/12,Other,,
2674,854042,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 392/12,Other,,
2675,854043,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 392/12,Other,,
2676,854044,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 392/12,Other,,
2677,854045,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 392/12,Other,,
2678,854046,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 392/12,Other,,
2679,854047,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 392/12,Other,,
2680,854048,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 392/12,Other,,
2681,854049,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 392/12,Other,,
2682,854050,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 392/12,Other,,
2683,854051,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 392/12,Other,,
2684,854052,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 392/12,Other,,
2685,854053,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 392/13,Other,,
2686,854054,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 392/13,Other,,
2687,854055,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 392/13,Other,,
2688,854056,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 392/13,Other,,
2689,854057,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 392/13,Other,,
2690,854058,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 392/13,Other,,
2691,854059,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 392/13,Other,,
2692,854060,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 392/13,Other,,
2693,854738,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 392/13,Other,,
2694,854739,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 392/13,Other,,
2695,854740,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 392/13,Other,,
2696,854741,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 392/13,Other,,
2697,854742,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 392/13,Other,,
2698,854743,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 392/13,Other,,
2699,854744,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 392/13,Other,,
2700,854745,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 392/13,Other,,
2701,854746,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 392/13,Other,,
2702,854747,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 392/13,Other,,
2703,854748,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 392/13,Other,,
2704,854749,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 392/13,Other,,
2705,854750,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 392/13,Other,,
2706,854751,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 392/14,Other,,
2707,854752,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 392/14,Other,,
2708,854786,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 393/8,Other,,
2709,854787,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 393/8,Other,,
2710,854788,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 393/9,Other,,
2711,854789,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 393/9,Other,,
2712,854790,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 393/9,Other,,
2713,854791,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 393/9,Other,,
2714,854792,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 393/9,Other,,
2715,854793,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 393/9,Other,,
2716,854794,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 393/9,Other,,
2717,854795,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 393/9,Other,,
2718,854796,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 393/9,Other,,
2719,854797,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 393/9,Other,,
2720,854798,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 393/9,Other,,
2721,854799,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 393/9,Other,,
2722,854800,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 393/9,Other,,
2723,854801,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 393/9,Other,,
2724,854802,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 393/9,Other,,
2725,854803,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 393/9,Other,,
2726,854804,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 393/9,Other,,
2727,854805,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 393/9,Other,,
2728,854806,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 393/9,Other,,
2729,854807,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 393/9,Other,,
2730,854808,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 393/9,Other,,
2731,854809,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 393/10,Other,,
2732,854810,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 393/10,Other,,
2733,854811,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 393/10,Other,,
2734,854812,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 393/10,Other,,
2735,854813,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 393/10,Other,,
2736,854814,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 393/10,Other,,
2737,854815,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 393/10,Other,,
2738,854816,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 393/10,Other,,
2739,854817,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 393/10,Other,,
2740,854818,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 393/10,Other,,
2741,854819,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 393/10,Other,,
2742,854820,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 393/10,Other,,
2743,854821,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 393/10,Other,,
2744,854822,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 393/10,Other,,
2745,854823,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 393/10,Other,,
2746,854824,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 393/10,Other,,
2747,854825,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 393/10,Other,,
2748,854826,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 393/10,Other,,
2749,854827,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 393/10,Other,,
2750,855504,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 393/10,Other,,
2751,855505,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 393/10,Other,,
2752,855506,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 393/11,Other,,
2753,855507,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 393/11,Other,,
2754,855508,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 393/11,Other,,
2755,856914,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 392/14,Other,,
2756,856915,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 392/14,Other,,
2757,856916,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 392/14,Other,,
2758,856917,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 392/14,Other,,
2759,856918,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 392/14,Other,,
2760,856919,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 392/14,Other,,
2761,856920,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 392/14,Other,,
2762,856921,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 392/14,Other,,
2763,856922,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 392/14,Other,,
2764,856923,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 392/14,Other,,
2765,856924,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 392/14,Other,,
2766,856925,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 392/14,Other,,
2767,856926,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 392/14,Other,,
2768,856927,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 392/14,Other,,
2769,856928,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 392/14,Other,,
2770,856929,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 392/14,Other,,
2771,856930,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 392/14,Other,,
2772,856931,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 392/14,Other,,
2773,856932,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 392/14,Other,,
2774,856933,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 392/15,Other,,
2775,856934,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 392/15,Other,,
2776,856935,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 392/15,Other,,
2777,856936,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 392/15,Other,,
2778,857614,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 392/15,Other,,
2779,857615,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 392/15,Other,,
2780,857616,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 392/15,Other,,
2781,857617,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 392/15,Other,,
2782,857618,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 392/15,Other,,
2783,857619,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 392/15,Other,,
2784,857620,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 392/15,Other,,
2785,857621,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 392/15,Other,,
2786,857622,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 392/15,Other,,
2787,857623,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 392/15,Other,,
2788,857624,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 392/15,Other,,
2789,857625,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 392/15,Other,,
2790,857626,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 392/15,Other,,
2791,857627,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 392/15,Other,,
2792,857628,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 392/15,Other,,
2793,857629,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 392/15,Other,,
2794,857630,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 392/15,Other,,
2795,857631,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 392/16,Other,,
2796,857632,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 392/16,Other,,
2797,857633,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 392/16,Other,,
2798,857634,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 392/16,Other,,
2799,857635,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 392/16,Other,,
2800,857636,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 392/16,Other,,
2801,857637,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 392/16,Other,,
2802,857638,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 392/16,Other,,
2803,857672,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 393/11,Other,,
2804,857673,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 393/11,Other,,
2805,857674,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 393/11,Other,,
2806,857675,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 393/11,Other,,
2807,857676,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 393/11,Other,,
2808,857677,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 393/11,Other,,
2809,857678,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 393/11,Other,,
2810,857679,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 393/11,Other,,
2811,857680,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 393/11,Other,,
2812,857681,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 393/11,Other,,
2813,857682,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 393/11,Other,,
2814,857683,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 393/11,Other,,
2815,857684,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 393/11,Other,,
2816,857685,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 393/11,Other,,
2817,857686,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 393/11,Other,,
2818,857687,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 393/11,Other,,
2819,857688,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 393/11,Other,,
2820,857689,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 393/11,Other,,
2821,857690,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 393/12,Other,,
2822,857691,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 393/12,Other,,
2823,857692,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 393/12,Other,,
2824,857693,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 393/12,Other,,
2825,857694,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 393/12,Other,,
2826,857695,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 393/12,Other,,
2827,857696,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 393/12,Other,,
2828,857697,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 393/12,Other,,
2829,857698,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 393/12,Other,,
2830,857699,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 393/12,Other,,
2831,857700,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 393/12,Other,,
2832,857701,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 393/12,Other,,
2833,857702,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 393/12,Other,,
2834,857703,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 393/12,Other,,
2835,857792,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 392/5,Other,,
2836,857793,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 392/5,Other,,
2837,858379,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 393/12,Other,,
2838,858380,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 393/12,Other,,
2839,858381,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 393/12,Other,,
2840,858382,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 393/12,Other,,
2841,858383,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 393/12,Other,,
2842,858384,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 393/12,Other,,
2843,858385,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 393/12,Other,,
2844,858386,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 393/13,Other,,
2845,858387,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 393/13,Other,,
2846,858388,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 393/13,Other,,
2847,858389,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 393/13,Other,,
2848,858390,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 393/13,Other,,
2849,858391,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 393/13,Other,,
2850,858392,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 393/13,Other,,
2851,858393,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 393/13,Other,,
2852,858470,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 392/5,Other,,
2853,858471,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 392/5,Other,,
2854,858472,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 392/5,Other,,
2855,858473,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 392/5,Other,,
2856,858474,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 392/5,Other,,
2857,858475,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 392/5,Other,,
2858,858476,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 392/5,Other,,
2859,858477,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 392/5,Other,,
2860,858478,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 392/5,Other,,
2861,858479,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 392/5,Other,,
2862,858480,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 392/5,Other,,
2863,858481,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 392/5,Other,,
2864,858482,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 392/5,Other,,
2865,858483,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 392/5,Other,,
2866,858484,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 392/5,Other,,
2867,858485,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 392/5,Other,,
2868,858486,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 392/5,Other,,
2869,858487,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 392/5,Other,,
2870,858488,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 392/5,Other,,
2871,858489,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 392/6,Other,,
2872,858490,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 392/6,Other,,
2873,858491,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 392/6,Other,,
2874,858492,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 392/6,Other,,
2875,858493,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 392/6,Other,,
2876,858494,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 392/6,Other,,
2877,858495,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 392/6,Other,,
2878,858496,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 392/6,Other,,
2879,858497,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 392/6,Other,,
2880,858498,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 392/6,Other,,
2881,858499,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 392/6,Other,,
2882,858500,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 392/6,Other,,
2883,858501,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 392/6,Other,,
2884,858502,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 392/6,Other,,
2885,858503,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 392/6,Other,,
2886,858504,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 392/6,Other,,
2887,858505,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 392/6,Other,,
2888,858506,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 392/6,Other,,
2889,858507,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 392/6,Other,,
2890,858508,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 392/6,Other,,
2891,858509,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 392/6,Other,,
2892,858510,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 392/7,Other,,
2893,858511,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 392/7,Other,,
2894,858512,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 392/7,Other,,
2895,858513,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 392/7,Other,,
2896,858514,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 392/7,Other,,
2897,859804,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 392/16,Other,,
2898,859805,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 392/16,Other,,
2899,859806,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 392/16,Other,,
2900,859807,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 392/16,Other,,
2901,859808,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 392/16,Other,,
2902,859809,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 392/16,Other,,
2903,859810,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 392/16,Other,,
2904,859811,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 392/16,Other,,
2905,859812,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 392/16,Other,,
2906,859813,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 392/16,Other,,
2907,859814,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 392/16,Other,,
2908,859815,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 392/16,Other,,
2909,859816,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 392/16,Other,,
2910,859817,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 393/5,Other,,
2911,925994,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020708,Other,,
2912,925995,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020708,Other,,
2913,925996,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020708,Other,,
2914,925997,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020708,Other,,
2915,925998,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020708,Other,,
2916,925999,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020708,Other,,
2917,926000,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020708,Other,,
2918,926001,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020708,Other,,
2919,926002,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020708,Other,,
2920,926003,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020708,Other,,
2921,926004,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020708,Other,,
2922,926005,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020708,Other,,
2923,926006,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020708,Other,,
2924,926007,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020708,Other,,
2925,926008,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020708,Other,,
2926,926009,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020708,Other,,
2927,926010,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020708,Other,,
2928,926011,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020708,Other,,
2929,926012,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020708,Other,,
2930,926013,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020708,Other,,
2931,926014,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020708",Other,,
2932,926015,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020708,Other,,
2933,926016,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020708,Other,,
2934,926017,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020708,Other,,
2935,926018,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020708,Other,,
2936,926019,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020708,Other,,
2937,926020,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020708,Other,,
2938,926021,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020708,Other,,
2939,926022,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020708,Other,,
2940,926023,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020708,Other,,
2941,934012,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020708,Other,,
2942,936030,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020708,Other,,
2943,936031,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020708,Other,,
2944,936032,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020708,Other,,
2945,936033,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020708",Other,,
2946,936034,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020708,Other,,
2947,936035,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020708,Other,,
2948,936036,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020708,Other,,
2949,963402,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020708,Other,,
2950,963403,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020708,Other,,
2951,963404,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020708,Other,,
2952,967047,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020708,Other,,
2953,967048,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020708,Other,,
2954,967049,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020708,Other,,
2955,967050,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020708,Other,,
2956,967051,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020708,Other,,
2957,967052,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020708,Other,,
2958,967053,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020708,Other,,
2959,967684,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020708,Other,,
2960,967685,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020708,Other,,
2961,967686,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020708,Other,,
2962,967687,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020708,Other,,
2963,967688,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020708,Other,,
2964,967689,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020708,Other,,
2965,967690,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020708,Other,,
2966,967691,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020708,Other,,
2967,975719,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020708,Other,,
2968,975720,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020708,Other,,
2969,975721,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020708,Other,,
2970,975722,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020708,Other,,
2971,975723,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020708,Other,,
2972,975724,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020708,Other,,
2973,975725,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020708,Other,,
2974,975726,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020708,Other,,
2975,975727,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020708,Other,,
2976,975728,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020708,Other,,
2977,975729,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020708,Other,,
2978,975730,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020708,Other,,
2979,975731,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020708,Other,,
2980,975732,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020708,Other,,
2981,975733,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020708,Other,,
2982,975734,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020708,Other,,
2983,975735,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020708,Other,,
2984,975736,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020708,Other,,
2985,975737,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020708,Other,,
2986,975738,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020708,Other,,
2987,977599,1,1,,103165562,3440,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2988,977602,1,2,,103165562,3440,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2989,977610,3,1,,208012082,3440,Active,,,0.065,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,19119014.0,
2990,1005894,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S020708",Other,,
2991,1005895,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S020708",Other,,
2992,1005896,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S020708",Other,,
2993,1005897,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S020708",Other,,
2994,1005898,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020708,Other,,
2995,1005899,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S020708",Other,,
2996,1005900,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020708",Other,,
2997,1007759,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020708",Other,,
2998,1007760,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020708",Other,,
2999,1007761,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020708",Other,,
3000,1007762,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020708,Other,,
3001,1007763,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020708",Other,,
3002,1007764,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020708",Other,,
3003,1007765,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S020708",Other,,
3004,1007766,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S020708",Other,,
3005,1007767,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020708",Other,,
3006,1007768,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020708",Other,,
3007,1007769,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020708",Other,,
3008,1007770,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020708",Other,,
3009,1007771,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S020708",Other,,
3010,1007772,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S020708",Other,,
3011,1007773,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S020708",Other,,
3012,1007774,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S020708",Other,,
3013,1007775,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S020708",Other,,
3014,1007776,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020708",Other,,
3015,1007777,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020708,Other,,
3016,1007778,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020708",Other,,
3017,1007779,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020708",Other,,
3018,1007780,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S020708",Other,,
3019,1007781,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020708,Other,,
3020,1007782,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020708",Other,,
3021,1007783,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020708",Other,,
3022,1007784,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020708",Other,,
3023,1007785,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020708",Other,,
3024,1007786,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020708",Other,,
3025,1007787,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020708",Other,,
3026,1008373,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S020708",Other,,
3027,1015169,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020708,Other,,
3028,1015170,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020708",Other,,
3029,1015171,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020708",Other,,
3030,1015172,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020708",Other,,
3031,1015173,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020708",Other,,
3032,1015174,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020708",Other,,
3033,1015175,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020708",Other,,
3034,1015176,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020708",Other,,
3035,1015177,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020708",Other,,
3036,1015178,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020708",Other,,
3037,1015179,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020708",Other,,
3038,1015180,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S020708",Other,,
3039,1015181,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S020708",Other,,
3040,1015182,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S020708,Other,,
3041,1015183,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020708",Other,,
3042,1015184,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020708",Other,,
3043,1015185,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020708",Other,,
3044,1015186,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020708",Other,,
3045,1015187,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020708",Other,,
3046,1015188,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020708",Other,,
3047,1015189,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020708",Other,,
3048,1015190,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020708",Other,,
3049,1015191,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020708",Other,,
3050,1015192,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020708",Other,,
3051,1015193,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020708",Other,,
3052,1015194,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S020708",Other,,
3053,1015195,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S020708",Other,,
3054,1015196,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S020708",Other,,
3055,1015197,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020708,Other,,
3056,1015198,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020708,Other,,
3057,1015199,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020708",Other,,
3058,1015200,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020708",Other,,
3059,1015201,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020708",Other,,
3060,1015202,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S020708",Other,,
3061,1019308,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S020708,Other,,
3062,1019309,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020708",Other,,
3063,1019310,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020708",Other,,
3064,1019311,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020708",Other,,
3065,1019312,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020708",Other,,
3066,1019313,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020708",Other,,
3067,1019314,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020708",Other,,
3068,1019315,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020708",Other,,
3069,1019316,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S020708",Other,,
3070,1019317,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S020708",Other,,
3071,1019318,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S020708",Other,,
3072,1019319,1,3,,103165562,3440,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020708,Other,,
3073,1019320,1,3,,103165562,3440,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020708",Other,,
3074,1038012,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 392/5,Other,,
3075,1038013,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 392/5,Other,,
3076,1038014,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 392/5,Other,,
3077,1038015,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 392/5,Other,,
3078,1038016,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 392/5,Other,,
3079,1040166,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 392/6,Other,,
3080,1040167,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 392/6,Other,,
3081,1040168,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 392/6,Other,,
3082,1040169,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 392/6,Other,,
3083,1040170,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 392/6,Other,,
3084,1040171,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 392/7,Other,,
3085,1040172,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 392/7,Other,,
3086,1040173,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 392/7,Other,,
3087,1040174,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 392/7,Other,,
3088,1040175,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 392/7,Other,,
3089,1040176,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 392/8,Other,,
3090,1040177,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 392/8,Other,,
3091,1040178,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 392/8,Other,,
3092,1040179,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 392/8,Other,,
3093,1040180,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 392/8,Other,,
3094,1040181,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 392/9,Other,,
3095,1040182,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 392/9,Other,,
3096,1040183,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 392/9,Other,,
3097,1040184,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 392/9,Other,,
3098,1040185,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 392/9,Other,,
3099,1040186,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 392/10,Other,,
3100,1040187,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 392/10,Other,,
3101,1040188,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 392/10,Other,,
3102,1040189,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 392/10,Other,,
3103,1040190,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 392/10,Other,,
3104,1040191,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 392/11,Other,,
3105,1040192,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 392/11,Other,,
3106,1040193,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 392/11,Other,,
3107,1040194,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 392/11,Other,,
3108,1040195,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 392/11,Other,,
3109,1040861,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 392/12,Other,,
3110,1040862,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 392/12,Other,,
3111,1040863,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 392/12,Other,,
3112,1040864,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 392/12,Other,,
3113,1040865,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 392/12,Other,,
3114,1040866,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 392/13,Other,,
3115,1040867,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 392/13,Other,,
3116,1040868,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 392/13,Other,,
3117,1040869,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 392/13,Other,,
3118,1040870,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 392/13,Other,,
3119,1040871,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 392/14,Other,,
3120,1040872,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 392/14,Other,,
3121,1040873,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 392/14,Other,,
3122,1040874,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 392/14,Other,,
3123,1040875,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 392/14,Other,,
3124,1040876,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 392/15,Other,,
3125,1040877,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 392/15,Other,,
3126,1043024,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 392/15,Other,,
3127,1043025,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 392/15,Other,,
3128,1043026,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 392/15,Other,,
3129,1043027,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 392/16,Other,,
3130,1043028,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 392/16,Other,,
3131,1043029,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 392/16,Other,,
3132,1043030,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 392/16,Other,,
3133,1043031,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 392/16,Other,,
3134,1043032,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 393/5,Other,,
3135,1043033,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 393/5,Other,,
3136,1043034,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 393/5,Other,,
3137,1043035,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 393/5,Other,,
3138,1043036,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 393/5,Other,,
3139,1043037,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 393/6,Other,,
3140,1043038,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 393/6,Other,,
3141,1043039,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 393/6,Other,,
3142,1043040,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 393/6,Other,,
3143,1043041,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 393/6,Other,,
3144,1043042,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 393/7,Other,,
3145,1043043,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 393/7,Other,,
3146,1043044,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 393/7,Other,,
3147,1043714,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 393/7,Other,,
3148,1043715,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 393/7,Other,,
3149,1043716,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 393/8,Other,,
3150,1043717,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 393/8,Other,,
3151,1043718,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 393/8,Other,,
3152,1043719,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 393/8,Other,,
3153,1043720,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 393/8,Other,,
3154,1043721,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 393/9,Other,,
3155,1043722,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 393/9,Other,,
3156,1043723,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 393/9,Other,,
3157,1043724,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 393/9,Other,,
3158,1043725,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 393/9,Other,,
3159,1043726,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 393/10,Other,,
3160,1043727,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 393/10,Other,,
3161,1043728,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 393/10,Other,,
3162,1043729,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 393/10,Other,,
3163,1043730,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 393/10,Other,,
3164,1043731,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 393/11,Other,,
3165,1043732,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 393/11,Other,,
3166,1043733,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 393/11,Other,,
3167,1043734,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 393/11,Other,,
3168,1043735,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 393/11,Other,,
3169,1043736,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 393/12,Other,,
3170,1043737,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 393/12,Other,,
3171,1043738,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 393/12,Other,,
3172,1045879,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 393/12,Other,,
3173,1045880,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 393/12,Other,,
3174,1045881,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 393/13,Other,,
3175,1045882,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 393/13,Other,,
3176,1045883,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 393/13,Other,,
3177,1045884,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 393/13,Other,,
3178,1045885,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 393/13,Other,,
3179,1045886,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 393/14,Other,,
3180,1045887,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 393/14,Other,,
3181,1045888,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 393/14,Other,,
3182,1045889,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 393/14,Other,,
3183,1045890,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 393/14,Other,,
3184,1045891,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 393/15,Other,,
3185,1045892,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 393/15,Other,,
3186,1046560,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 393/15,Other,,
3187,1046561,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 393/15,Other,,
3188,1046562,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 393/15,Other,,
3189,1046563,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 393/16,Other,,
3190,1046564,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 393/16,Other,,
3191,1046565,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 393/16,Other,,
3192,1046566,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 393/16,Other,,
3193,1046567,1,2,,103165562,3440,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 393/16,Other,,
3194,1053175,2,1,,178126081,3440,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
3195,1053197,1,1,,50085981,3440,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
3196,1053269,1,4,,103165562,3440,Unspecified,317373262.0,5742.0,,,Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control,Other,24088053.0,
3197,1079931,1,1,,103165562,3440,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3198,1079932,1,1,,103165562,3440,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3199,1079933,1,1,,103165562,3440,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3200,1079934,1,1,,103165562,3440,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3201,1079935,1,1,,103165562,3440,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3202,1079936,1,1,,103165562,3440,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3203,1079937,1,1,,103165562,3440,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3204,1079938,1,1,,103165562,3440,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3205,1079939,1,1,,103165562,3440,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3206,1079940,1,1,,103165562,3440,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3207,1079941,1,1,,103165562,3440,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3208,1079942,1,1,,103165562,3440,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3209,1079943,1,1,,103165562,3440,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3210,1079944,1,1,,103165562,3440,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3211,1079945,1,1,,103165562,3440,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3212,1079946,1,1,,103165562,3440,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3213,1079947,1,1,,103165562,3440,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3214,1079948,1,1,,103165562,3440,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3215,1079949,1,1,,103165562,3440,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3216,1091955,1,2,,103165562,3440,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
3217,1091956,1,1,,103165562,3440,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
3218,1091957,1,1,,103165562,3440,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
3219,1091958,2,1,,103165562,3440,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
3220,1094681,2,1,,103165562,3440,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,,
3221,1106384,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis activity in Rattus norvegicus albino (rat) assessed as urinary excretion at 20 mg/kg, po measured at 5-18 hr after drug administration by standard Lipschitz method against frusemide-treated control (Rvb = 0.2 no unit)",Other,,
3222,1106386,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis action in Rattus norvegicus albino (rat) assessed as urinary excretion at 20 mg/kg, po measured at 5-18 hr after drug administration by standard Lipschitz method against untreated control (Rvb = 1 no unit)",Other,,
3223,1106388,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis activity in Rattus norvegicus albino (rat) assessed as urinary excretion at 20 mg/kg, po measured at 0-5 hr after drug administration by standard Lipschitz method against frusemide-treated control (Rvb = 0.5 no unit)",Other,,
3224,1106390,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis action in Rattus norvegicus albino (rat) assessed as urinary excretion at 20 mg/kg, po measured at 0-5 hr after drug administration by standard Lipschitz method against untreated control (Rvb = 1 no unit)",Other,,
3225,1106392,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis in Rattus norvegicus albino (rat) assessed as urinary Cl- excretion at 20 mg/kg, po measured at 5-18 hr after drug administration by standard Lipschitz method (Rvb = 0.38 +/-0.011 mEq/L)",Other,,
3226,1106394,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis in Rattus norvegicus albino (rat) assessed as urinary K+ excretion at 20 mg/kg, po measured at 5-18 hr after drug administration by standard Lipschitz method (Rvb = 0.22 +/-0.004 mEq/L)",Other,,
3227,1106396,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis in Rattus norvegicus albino (rat) assessed as urinary Na+ excretion at 20 mg/kg, po measured at 5-18 hr after drug administration by standard Lipschitz method (Rvb = 0.65+/-0.006 mEq/L)",Other,,
3228,1106397,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis in Rattus norvegicus albino (rat) assessed as urinary Cl- excretion at 20 mg/kg, po measured at 0-5 hr after drug administration by standard Lipschitz method (Rvb = 0.46 +/-0.005 mEq/L)",Other,,
3229,1106400,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis in Rattus norvegicus albino (rat) assessed as urinary K+ excretion at 20 mg/kg, po measured at 0-5 hr after drug administration by standard Lipschitz method (Rvb = 0.46 +/-0.006 mEq/L)",Other,,
3230,1106402,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis in Rattus norvegicus albino (rat) assessed as urinary Na+ excretion at 20 mg/kg, po measured at 0-5 hr after drug administration by standard Lipschitz method (Rvb = 0.90 +/-0.003 mEq/L)",Other,,
3231,1106404,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis in Rattus norvegicus albino (rat) assessed as urinary excretion at 20 mg/kg, po measured at 5-18 hr after drug administration by standard Lipschitz method (Rvb = 50.4%)",Other,,
3232,1106406,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis in Rattus norvegicus albino (rat) assessed as normal saline intake at 20 mg/kg, po measured at 5-18 hr after drug administration by standard Lipschitz method (Rvb = 2.50 +/-0.036 ml)",Other,,
3233,1106408,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis in Rattus norvegicus albino (rat) assessed as total urinary output at 20 mg/kg, po measured at 5-18 hr after drug administration by standard Lipschitz method (Rvb = 1.26 +/-0.049 ml)",Other,,
3234,1106411,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis in Rattus norvegicus albino (rat) assessed as urinary excretion at 20 mg/kg, po measured at 0-5 hr after drug administration by standard Lipschitz method (Rvb = 98.40%)",Other,,
3235,1106412,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis in Rattus norvegicus albino (rat) assessed as normal saline intake at 20 mg/kg, po measured at 0-5 hr after drug administration by standard Lipschitz method (Rvb = 2.50 +/-0.036 ml)",Other,,
3236,1106414,1,2,,103165562,3440,Unspecified,,,,,"Induction of diuresis in Rattus norvegicus albino (rat) assessed as total urinary output at 20 mg/kg, po measured at 0-5 hr after drug administration by standard Lipschitz method (Rvb = 2.46 +/-0.125 ml)",Other,,
3237,1117298,1,2,,170464879,3440,Inactive,,,11.2202,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
3238,1117304,1,2,,170464879,3440,Inactive,,,0.631,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
3239,1117305,1,2,,170464879,3440,Inactive,,,1.4125,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
3240,1117310,1,1,,170464879,3440,Inactive,,,11.2202,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
3241,1117312,1,1,,170464879,3440,Inactive,,,1.41254,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
3242,1117314,1,1,,170464879,3440,Inactive,,,0.630957,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
3243,1117326,1,1,,170464879,3440,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
3244,1117329,1,1,,170464879,3440,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
3245,1117336,1,1,,170464879,3440,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
3246,1117340,1,1,,170464879,3440,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
3247,1117341,1,1,,170464879,3440,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
3248,1117342,1,1,,170464879,3440,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
3249,1117343,1,1,,170464879,3440,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
3250,1117346,1,1,,170464879,3440,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
3251,1123562,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in Wistar rat assessed as volume of excreted urine at 50 mg/kg, po measured after 0 to 5 hrs relative to urea-treated control",Other,423171.0,
3252,1123563,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in Wistar rat assessed as sodium level in excreted urine at 50 mg/kg, po measured after 0 to 5 hrs by flame photometric analysis relative to urea-treated control",Other,423171.0,
3253,1123564,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in Wistar rat assessed as potassium level in excreted urine at 50 mg/kg, po measured after 0 to 5 hrs by flame photometric analysis relative to urea-treated control",Other,423171.0,
3254,1123565,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in Wistar rat assessed as volume of excreted urine at 50 mg/kg, po measured after 5 to 24 hrs relative to urea-treated control",Other,423171.0,
3255,1123566,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in Wistar rat assessed as sodium level in excreted urine at 50 mg/kg, po measured after 5 to 24 hrs by flame photometric analysis relative to urea-treated control",Other,423171.0,
3256,1123567,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in Wistar rat assessed as potassium level in excreted urine at 50 mg/kg, po measured after 5 to 24 hrs by flame photometric analysis relative to urea-treated control",Other,423171.0,
3257,1124840,1,2,,103165562,3440,Unspecified,,,,,Apparent permeability coefficient in Sprague-Dawley rat jejunum,Other,24630695.0,
3258,1132616,1,1,,103165562,3440,Inconclusive,,,,,"Natriuretic activity in rat assessed as per cage at 3 mg/kg, po",Other,660587.0,
3259,1132617,1,1,,103165562,3440,Unspecified,,,,,"Natriuretic activity in rat assessed as per cage at 9 mg/kg, po",Other,660587.0,
3260,1132618,1,1,,103165562,3440,Unspecified,,,,,"Natriuretic activity in rat assessed as per cage at 27 mg/kg, po",Other,660587.0,
3261,1132619,1,1,,103165562,3440,Unspecified,,,,,"Natriuretic activity in rat assessed as per cage at 81 mg/kg, po",Other,660587.0,
3262,1132620,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in dog assessed as sodium level in urine per min at 1 mg/kg, iv relative to control",Other,660587.0,
3263,1132621,1,1,,103165562,3440,Unspecified,,,,,"Natriuretic activity in chimpanzee assessed as per min at 5 mg/kg, po",Other,660587.0,
3264,1132622,1,1,,103165562,3440,Unspecified,,,,,"Natriuretic activity in chimpanzee assessed as change in Curate to Cinsulin ratio at 5 mg/kg, po",Other,660587.0,
3265,1132625,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in dog assessed as potassium level in urine per min at 1 mg/kg, iv relative to control",Other,660587.0,
3266,1132626,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in dog assessed as chloride level in urine per min at 1 mg/kg, iv relative to control",Other,660587.0,
3267,1132628,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in dog assessed as chloride level in urine volume at 1 mg/kg, iv relative to control",Other,660587.0,
3268,1145359,1,1,,103165562,3440,Unspecified,,,,,"Diuretic activity in mongrel dog assessed as excretion of sodium ion per 6 hrs at 1 mg/kg, po (Rvb = 2 mequiv/min)",Other,1263208.0,
3269,1145361,1,1,,103165562,3440,Unspecified,,,,,"Diuretic activity in mongrel dog assessed as excretion of potassium ion per 6 hrs at 1 mg/kg, po (Rvb = 1 mequiv/min)",Other,1263208.0,
3270,1145363,1,1,,103165562,3440,Unspecified,,,,,"Diuretic activity in mongrel dog assessed as excretion of chloride ion per 6 hrs at 1 mg/kg, po (Rvb = 2 mequiv/min)",Other,1263208.0,
3271,1145365,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in mongrel dog assessed as urine volume per 6 hrs at 1 mg/kg, po (Rvb = 180 ml)",Other,1263208.0,
3272,1149924,1,2,,103165562,3440,Unspecified,,,,,"Natriuretic activity in Charles River rat assessed as sodium level in urine per cage collected 0.5 hrs interval at 9 mg/kg, po",Other,915900.0,
3273,1149925,1,2,,103165562,3440,Unspecified,,,,,"Natriuretic activity in Charles River rat assessed as sodium level in urine per cage collected 0.5 hrs interval at 27 mg/kg, po",Other,915900.0,
3274,1149926,1,2,,103165562,3440,Unspecified,,,,,"Natriuretic activity in Charles River rat assessed as sodium level in urine per cage collected 0.5 hrs interval at 81 mg/kg, po",Other,915900.0,
3275,1149927,3,2,,103165562,3440,Unspecified,,,,,"Natriuretic activity in chimpanzee assessed as change sodium level in urine measured per min at 5 mg/kg, po",Other,915900.0,
3276,1149928,1,2,,103165562,3440,Unspecified,,,,,"Ratio of change in urate excretion to change in inulin excretion in chimpanzee in urine at 5 mg/kg, po",Other,915900.0,
3277,1149935,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in dog assessed as sodium level in urine collected for 2 hrs at 1.5 mg/kg, iv over a period of 5 mins (Rvb = 29 microEq)",Other,915900.0,
3278,1149936,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in dog assessed as potassium level in urine collected for 2 hrs at 1.5 mg/kg, iv over a period of 5 mins (Rvb = 18 microEq)",Other,915900.0,
3279,1149937,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in dog assessed as chloride level in urine collected for 2 hrs at 1.5 mg/kg, iv over a period of 5 mins (Rvb = 1 microEq)",Other,915900.0,
3280,1149938,1,2,,103165562,3440,Unspecified,,,,,"Diuretic activity in dog assessed as urine volume collected for 2 hrs at 1.5 mg/kg, iv over a period of 5 mins (Rvb = 1 mL)",Other,915900.0,
3281,1150368,1,1,,103165562,3440,Unspecified,,,,,Diuretic activity in po dosed albino Wistar-TNO rat assessed as 100% increase in urinary volume measured for 5 hrs,Other,940121.0,
3282,1150383,1,1,,103165562,3440,Unspecified,,,,,Diuretic activity in po dosed albino Wistar-TNO rat assessed as increase in urinary volume measured for 5 hrs,Other,940121.0,
3283,1159387,1,2,,103165562,3440,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
3284,1159389,1,2,,103165562,3440,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
3285,1159390,1,2,,103165562,3440,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
3286,1159391,1,2,,103165562,3440,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole dog plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
3287,1159394,1,2,,103165562,3440,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
3288,1159396,1,2,,103165562,3440,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
3289,1159399,1,2,,103165562,3440,Unspecified,,,,,ASTRAZENECA: Most acidic pKa value (pKa A1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Acids: <= 11.,Other,,
3290,1159400,1,2,,103165562,3440,Unspecified,,,,,ASTRAZENECA: Second most acidic pKa value (pKa A2) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Acids: <= 11.,Other,,
3291,1159509,1,1,,144209411,3440,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3292,1159509,1,1,,144213288,3440,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3293,1159509,1,1,,170464879,3440,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3294,1159515,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3295,1159515,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3296,1159515,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3297,1159516,1,1,,144209411,3440,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3298,1159516,1,1,,144213288,3440,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3299,1159516,1,1,,170464879,3440,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3300,1159517,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3301,1159517,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3302,1159517,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3303,1159518,1,1,,144209411,3440,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3304,1159518,1,1,,144213288,3440,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3305,1159518,1,1,,170464879,3440,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3306,1159519,1,1,,144209411,3440,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3307,1159519,1,1,,144213288,3440,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3308,1159519,1,1,,170464879,3440,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3309,1159520,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3310,1159520,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3311,1159520,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3312,1159521,1,1,,144209411,3440,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3313,1159521,1,1,,144213288,3440,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3314,1159521,1,1,,170464879,3440,Inactive,15928672.0,19885.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3315,1159523,1,1,,144209411,3440,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3316,1159523,1,1,,144213288,3440,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3317,1159523,1,1,,170464879,3440,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3318,1159524,1,1,,47193739,3440,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3319,1159524,1,1,,124881920,3440,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3320,1159525,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3321,1159525,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3322,1159525,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3323,1159526,1,1,,144209411,3440,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3324,1159526,1,1,,144213288,3440,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3325,1159526,1,1,,170464879,3440,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3326,1159527,1,1,,144209411,3440,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3327,1159527,1,1,,144213288,3440,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3328,1159527,1,1,,170464879,3440,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3329,1159528,1,1,,144209411,3440,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3330,1159528,1,1,,144213288,3440,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3331,1159528,1,1,,170464879,3440,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3332,1159529,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3333,1159529,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3334,1159529,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3335,1159531,1,1,,144209411,3440,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3336,1159531,1,1,,144213288,3440,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3337,1159531,1,1,,170464879,3440,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3338,1159550,3,1,,252401462,3440,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
3339,1159551,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3340,1159551,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3341,1159551,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3342,1159552,1,1,,144209411,3440,Inactive,325495463.0,5914.0,19.4098,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3343,1159552,1,1,,144213288,3440,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3344,1159552,1,1,,170464879,3440,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3345,1159553,2,1,,144209411,3440,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3346,1159553,2,1,,144213288,3440,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3347,1159553,2,1,,170464879,3440,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3348,1159555,1,1,,144209411,3440,Inconclusive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3349,1159555,1,1,,144213288,3440,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3350,1159555,1,1,,170464879,3440,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3351,1159580,2,1,,268734555,3440,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
3352,1159583,2,1,,178126081,3440,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
3353,1159606,1,1,,50085981,3440,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
3354,1159607,2,1,,312309791,3440,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
3355,1159614,1,2,,170464879,3440,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
3356,1159620,1,1,,103165562,3440,Active,,,,,Summary of drug indications.,Other,,
3357,1169140,1,1,,103165562,3440,Unspecified,,,,,Retention time of the compound by EPSA supercritical fluid chromatography,Other,25313332.0,
3358,1203133,1,1,,103165562,3440,Unspecified,,,,,Apparent permeability of the compound at RT after 24 hrs by PAMPA,Other,25730130.0,
3359,1209455,1,2,,103165562,3440,Unspecified,262527527.0,8647.0,1000.0,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
3360,1209456,1,2,,103165562,3440,Unspecified,12585136.0,83569.0,1000.0,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
3361,1209457,1,1,,103165562,3440,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
3362,1210069,1,2,,103165562,3440,Unspecified,21264413.0,1573.0,50.0,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
3363,1211791,1,1,,103165562,3440,Unspecified,,,,,Fraction unbound in human hepatocytes,Other,21998403.0,
3364,1211792,1,1,,103165562,3440,Unspecified,,,,,Hepatic clearance in human,Other,21998403.0,
3365,1211793,1,1,,103165562,3440,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,21998403.0,
3366,1211794,1,2,,103165562,3440,Unspecified,,,,,Fraction unbound in blood (not specified),Other,21998403.0,
3367,1211795,1,1,,103165562,3440,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21998403.0,
3368,1211797,1,1,,103165562,3440,Unspecified,,,,,Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
3369,1211798,1,1,,103165562,3440,Unspecified,,,,,Intrinsic clearance in human using well stirred liver model by LC-MS/MS method,Other,21998403.0,
3370,1217704,1,2,,103165562,3440,Unspecified,117144.0,1544.0,,,Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3371,1217705,1,2,,103165562,3440,Unspecified,117205.0,1555.0,,,Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3372,1217706,1,2,,103165562,3440,Unspecified,6686268.0,1559.0,,,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3373,1217707,1,2,,103165562,3440,Unspecified,60416369.0,1557.0,,,Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system,Other,21467212.0,
3374,1217708,1,2,,103165562,3440,Unspecified,84028191.0,1565.0,,,Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3375,1217709,1,2,,103165562,3440,Unspecified,116241312.0,1576.0,,,Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3376,1217710,1,2,,103165562,3440,Unspecified,,,,,Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting,Other,21467212.0,
3377,1217711,1,2,,103165562,3440,Unspecified,,,,,Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
3378,1217712,1,2,,103165562,3440,Unspecified,117225.0,1558.0,,,Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3379,1217727,1,2,,103165562,3440,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
3380,1217728,1,1,,103165562,3440,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay,Other,21467212.0,
3381,1217729,1,1,,103165562,3440,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation,Other,21467212.0,
3382,1220783,1,1,,103165562,3440,Unspecified,,,,,Drug metabolism in human assessed as glucuronide concentration in bile and urine,Other,21282406.0,
3383,1220784,1,2,,103165562,3440,Unspecified,,,,,Fraction unbound in mouse plasma by ultracentrifugation method,Other,21282406.0,
3384,1220785,1,2,,103165562,3440,Unspecified,,,,,Fraction unbound in rat plasma by ultracentrifugation method,Other,21282406.0,
3385,1220786,1,2,,103165562,3440,Unspecified,,,,,Fraction unbound in monkey plasma by ultracentrifugation method,Other,21282406.0,
3386,1220787,1,2,,103165562,3440,Unspecified,,,,,Fraction unbound in dog plasma by ultracentrifugation method,Other,21282406.0,
3387,1220788,1,2,,103165562,3440,Unspecified,,,,,Fraction unbound in human plasma by ultracentrifugation method,Other,21282406.0,
3388,1220789,1,2,,103165562,3440,Unspecified,,,,,Ratio of drug level in blood to plasma in mouse,Other,21282406.0,
3389,1220790,1,2,,103165562,3440,Unspecified,,,,,Ratio of drug level in blood to plasma in rat,Other,21282406.0,
3390,1220791,1,2,,103165562,3440,Unspecified,,,,,Ratio of drug level in blood to plasma in monkey,Other,21282406.0,
3391,1220792,1,2,,103165562,3440,Unspecified,,,,,Ratio of drug level in blood to plasma in dog,Other,21282406.0,
3392,1220793,1,2,,103165562,3440,Unspecified,,,,,Ratio of drug level in blood to plasma in human,Other,21282406.0,
3393,1220794,1,1,,103165562,3440,Unspecified,,,,,Plasma clearance in human,Other,21282406.0,
3394,1220795,1,1,,103165562,3440,Unspecified,,,,,Plasma clearance in po dosed human,Other,21282406.0,
3395,1220796,1,1,,103165562,3440,Unspecified,,,,,"Drug metabolism in bile duct-cannulated rat assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
3396,1220797,1,1,,103165562,3440,Unspecified,,,,,Volume of distribution at steady state in human,Other,21282406.0,
3397,1220798,1,1,,103165562,3440,Unspecified,,,,,Half life in human,Other,21282406.0,
3398,1220799,1,1,,103165562,3440,Unspecified,,,,,"Drug metabolism in gallbladder-cannulated mouse assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
3399,1220800,1,1,,103165562,3440,Unspecified,,,,,"Drug metabolism in bile duct-cannulated monkey assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
3400,1220801,1,1,,103165562,3440,Unspecified,,,,,"Drug metabolism in bile duct-cannulated dog assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
3401,1221821,1,1,,103165562,3440,Unspecified,,,,,Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay,Other,20926620.0,
3402,1221956,1,1,,103165562,3440,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
3403,1221957,1,1,,103165562,3440,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
3404,1221958,1,1,,103165562,3440,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
3405,1221959,1,1,,103165562,3440,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral over basolateral to apical side of MDCK cells expressing MDR1,Other,21051535.0,
3406,1221960,1,1,,103165562,3440,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3407,1221961,1,1,,103165562,3440,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3408,1221962,1,1,,103165562,3440,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3409,1221963,1,1,,103165562,3440,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3410,1221964,1,1,,103165562,3440,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3411,1221965,1,1,,103165562,3440,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3412,1221968,1,1,,103165562,3440,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
3413,1221969,1,1,,103165562,3440,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
3414,1221970,1,1,,103165562,3440,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
3415,1221971,1,1,,103165562,3440,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
3416,1221972,1,1,,103165562,3440,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
3417,1221973,1,1,,103165562,3440,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
3418,1221975,1,1,,103165562,3440,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
3419,1221976,1,1,,103165562,3440,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
3420,1221977,1,1,,103165562,3440,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
3421,1221978,1,1,,103165562,3440,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
3422,1221979,1,1,,103165562,3440,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
3423,1221980,1,1,,103165562,3440,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
3424,1221982,1,1,,103165562,3440,Unspecified,,,,,Fraction absorbed in human,Other,21051535.0,
3425,1224824,1,1,,162108257,3440,Inactive,,,7.4266,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
3426,1224825,1,1,,162108257,3440,Inactive,,,0.0372,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
3427,1224834,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3428,1224834,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3429,1224834,3,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3430,1224835,1,1,,144209411,3440,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3431,1224835,1,1,,144213288,3440,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3432,1224835,1,1,,170464879,3440,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3433,1224836,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3434,1224836,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3435,1224836,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3436,1224837,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3437,1224837,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3438,1224837,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3439,1224838,1,1,,144209411,3440,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3440,1224838,1,1,,144213288,3440,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3441,1224838,1,1,,170464879,3440,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3442,1224839,1,1,,144209411,3440,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3443,1224839,1,1,,144213288,3440,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3444,1224839,1,1,,170464879,3440,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3445,1224840,3,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3446,1224840,3,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3447,1224840,3,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3448,1224841,3,1,,144209411,3440,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3449,1224841,3,1,,144213288,3440,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3450,1224841,3,1,,170464879,3440,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3451,1224842,3,1,,144209411,3440,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3452,1224842,3,1,,144213288,3440,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3453,1224842,3,1,,170464879,3440,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3454,1224843,1,1,,144209411,3440,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3455,1224843,1,1,,144213288,3440,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3456,1224843,1,1,,170464879,3440,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3457,1224844,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3458,1224844,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3459,1224844,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3460,1224845,1,1,,144209411,3440,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3461,1224845,1,1,,144213288,3440,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3462,1224845,1,1,,170464879,3440,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3463,1224846,1,1,,144209411,3440,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3464,1224846,1,1,,144213288,3440,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3465,1224846,1,1,,170464879,3440,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3466,1224847,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3467,1224847,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3468,1224847,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3469,1224848,3,1,,144209411,3440,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3470,1224848,3,1,,144213288,3440,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3471,1224848,3,1,,170464879,3440,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3472,1224849,3,1,,144209411,3440,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3473,1224849,3,1,,144213288,3440,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3474,1224849,3,1,,170464879,3440,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3475,1224857,2,1,,162108257,3440,Inconclusive,,,11.7704,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3476,1224857,2,1,,170464879,3440,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3477,1224859,2,1,,162108257,3440,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3478,1224859,2,1,,170464879,3440,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3479,1224863,1,1,,176484373,3440,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3480,1224863,1,1,,176484741,3440,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3481,1224863,1,1,,316919536,3440,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3482,1224865,1,2,,50085981,3440,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3483,1224867,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3484,1224867,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3485,1224867,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3486,1224868,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3487,1224868,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3488,1224868,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3489,1224869,1,1,,144209411,3440,Inconclusive,,,49.163999999999994,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3490,1224869,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3491,1224869,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3492,1224870,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3493,1224870,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3494,1224870,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3495,1224871,1,1,,144209411,3440,Inconclusive,,,39.0523,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3496,1224871,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3497,1224871,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3498,1224872,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3499,1224872,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3500,1224872,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3501,1224873,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3502,1224873,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3503,1224873,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3504,1224874,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3505,1224874,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3506,1224874,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3507,1224875,1,1,,144209411,3440,Inconclusive,,,39.0523,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3508,1224875,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3509,1224875,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3510,1224876,1,1,,144209411,3440,Active,,,21.9607,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3511,1224876,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3512,1224876,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3513,1224877,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3514,1224877,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3515,1224877,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3516,1224878,1,1,,144209411,3440,Active,,,17.444000000000003,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3517,1224878,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3518,1224878,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3519,1224879,1,1,,144209411,3440,Active,,,19.5725,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3520,1224879,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3521,1224879,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3522,1224880,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3523,1224880,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3524,1224880,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3525,1224881,1,1,,144209411,3440,Inconclusive,,,43.8174,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3526,1224881,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3527,1224881,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3528,1224882,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3529,1224882,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3530,1224882,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3531,1224883,1,1,,144209411,3440,Active,,,19.5725,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3532,1224883,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3533,1224883,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3534,1224884,1,1,,144209411,3440,Inconclusive,,,39.0523,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3535,1224884,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3536,1224884,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3537,1224885,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3538,1224885,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3539,1224885,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3540,1224886,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3541,1224886,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3542,1224886,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3543,1224887,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3544,1224887,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3545,1224887,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3546,1224888,1,1,,144209411,3440,Inconclusive,,,43.8174,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3547,1224888,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3548,1224888,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3549,1224889,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3550,1224889,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3551,1224889,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3552,1224890,1,1,,144209411,3440,Inconclusive,,,19.5725,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3553,1224890,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3554,1224890,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3555,1224892,1,1,,144209411,3440,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3556,1224892,1,1,,144213288,3440,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3557,1224892,1,1,,170464879,3440,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3558,1224893,1,1,,144209411,3440,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3559,1224893,1,1,,144213288,3440,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3560,1224893,1,1,,170464879,3440,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3561,1224894,1,1,,144209411,3440,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3562,1224894,1,1,,144213288,3440,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3563,1224894,1,1,,170464879,3440,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3564,1224895,1,1,,144209411,3440,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3565,1224895,1,1,,144213288,3440,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3566,1224895,1,1,,170464879,3440,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3567,1224896,1,1,,144209411,3440,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3568,1224896,1,1,,144213288,3440,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3569,1224896,1,1,,170464879,3440,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3570,1224905,2,1,,92309202,3440,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3571,1224905,2,1,,92309202,3440,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3572,1244082,1,1,,103165562,3440,Unspecified,,,,,Half life in human,Other,26191360.0,
3573,1259241,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3574,1259241,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3575,1259241,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3576,1259242,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3577,1259242,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3578,1259242,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3579,1259243,1,1,,144209411,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3580,1259243,1,1,,144213288,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3581,1259243,1,1,,170464879,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3582,1259244,1,1,,144209411,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3583,1259244,1,1,,144213288,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3584,1259244,1,1,,170464879,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3585,1259247,1,1,,144209411,3440,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3586,1259247,1,1,,144213288,3440,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3587,1259247,1,1,,170464879,3440,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3588,1259248,1,1,,144209411,3440,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3589,1259248,1,1,,144213288,3440,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3590,1259248,1,1,,170464879,3440,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3591,1259252,1,1,,162108257,3440,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
3592,1259253,1,1,,162108257,3440,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
3593,1259255,1,1,,162108257,3440,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
3594,1259256,1,1,,162108257,3440,Inactive,169655958.0,,0.0026,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
3595,1259309,1,1,,178126081,3440,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3596,1259310,1,1,,104169951,3440,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3597,1259310,1,1,,333473004,3440,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3598,1259310,1,1,,333473461,3440,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3599,1259311,1,1,,178126081,3440,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3600,1259313,1,1,,47193739,3440,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3601,1259318,1,1,,50085981,3440,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3602,1259325,1,2,,336954386,3440,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
3603,1259344,1,1,,144203873,3440,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3604,1259355,1,1,,26752835,3440,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3605,1259356,1,1,,144203873,3440,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3606,1259364,1,1,,144209411,3440,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3607,1259364,1,1,,144213288,3440,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3608,1259364,1,1,,170464879,3440,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3609,1259365,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3610,1259365,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3611,1259365,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3612,1259366,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3613,1259366,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3614,1259366,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3615,1259367,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3616,1259367,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3617,1259367,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3618,1259368,1,1,,144209411,3440,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3619,1259368,1,1,,144213288,3440,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3620,1259368,1,1,,170464879,3440,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3621,1259369,1,1,,144209411,3440,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3622,1259369,1,1,,144213288,3440,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3623,1259369,1,1,,170464879,3440,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3624,1259377,1,1,,144209411,3440,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3625,1259377,1,1,,144213288,3440,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3626,1259377,1,1,,170464879,3440,Inconclusive,54288833.0,2100.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3627,1259378,1,1,,144209411,3440,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3628,1259378,1,1,,144213288,3440,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3629,1259378,1,1,,170464879,3440,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3630,1259379,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3631,1259379,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3632,1259379,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3633,1259380,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3634,1259380,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3635,1259380,1,1,,170464879,3440,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3636,1259381,1,1,,144209411,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3637,1259381,1,1,,144213288,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3638,1259381,1,1,,170464879,3440,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3639,1259382,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3640,1259382,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3641,1259382,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3642,1259383,1,1,,144209411,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3643,1259383,1,1,,144213288,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3644,1259383,1,1,,170464879,3440,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3645,1259384,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3646,1259384,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3647,1259384,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3648,1259385,1,1,,144209411,3440,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3649,1259385,1,1,,144213288,3440,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3650,1259385,1,1,,170464879,3440,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3651,1259386,1,1,,144209411,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3652,1259386,1,1,,144213288,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3653,1259386,1,1,,170464879,3440,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3654,1259387,1,1,,144209411,3440,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3655,1259387,1,1,,144213288,3440,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3656,1259387,1,1,,170464879,3440,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3657,1259388,1,1,,144209411,3440,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3658,1259388,1,1,,144213288,3440,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3659,1259388,1,1,,170464879,3440,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3660,1259389,1,1,,124638040,3440,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3661,1259390,1,1,,144209411,3440,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3662,1259390,1,1,,144213288,3440,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3663,1259390,1,1,,170464879,3440,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3664,1259391,1,1,,144209411,3440,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3665,1259391,1,1,,144213288,3440,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3666,1259391,1,1,,170464879,3440,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3667,1259392,1,1,,144209411,3440,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3668,1259392,1,1,,144213288,3440,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3669,1259392,1,1,,170464879,3440,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3670,1259393,1,1,,144209411,3440,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3671,1259393,1,1,,144213288,3440,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3672,1259393,1,1,,170464879,3440,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3673,1259394,1,1,,144209411,3440,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3674,1259394,1,1,,144213288,3440,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3675,1259394,1,1,,170464879,3440,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3676,1259395,1,1,,144209411,3440,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3677,1259395,1,1,,144213288,3440,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3678,1259395,1,1,,170464879,3440,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3679,1259396,1,1,,144209411,3440,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3680,1259396,1,1,,144213288,3440,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3681,1259396,1,1,,170464879,3440,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3682,1259400,1,1,,170464879,3440,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3683,1259401,1,1,,144209411,3440,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3684,1259401,1,1,,144213288,3440,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3685,1259401,1,1,,170464879,3440,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3686,1259402,1,1,,144209411,3440,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3687,1259402,1,1,,144213288,3440,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3688,1259402,1,1,,170464879,3440,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3689,1259403,1,1,,144209411,3440,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3690,1259403,1,1,,144213288,3440,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3691,1259403,1,1,,170464879,3440,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3692,1259404,1,1,,144209411,3440,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3693,1259404,1,1,,144213288,3440,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3694,1259404,1,1,,170464879,3440,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3695,1259406,1,1,,363920424,3440,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
3696,1259406,1,1,1.0,363920424,3440,Inactive,26638650.0,3778.0,-0.017928299999999998,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
3697,1259406,1,1,2.0,363920424,3440,Inactive,4758626.0,3779.0,-0.00489813,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3698,1259406,1,1,3.0,363920424,3440,Inactive,5031823.0,10242.0,-0.0210917,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3699,1259406,1,1,4.0,363920424,3440,Inactive,26051275.0,27345.0,0.026904900000000002,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3700,1259406,1,1,5.0,363920424,3440,Inactive,160410009.0,389816.0,-0.028043099999999998,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3701,1259406,1,1,6.0,363920424,3440,Inactive,26638650.0,3778.0,-0.046818900000000004,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
3702,1259406,1,1,7.0,363920424,3440,Inactive,4758626.0,3779.0,-0.015353,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3703,1259406,1,1,8.0,363920424,3440,Inactive,5031823.0,10242.0,-0.0184437,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3704,1259406,1,1,9.0,363920424,3440,Inactive,26051275.0,27345.0,0.00031691900000000003,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3705,1259406,1,1,10.0,363920424,3440,Inactive,5031823.0,10242.0,0.0743117,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
3706,1259407,1,1,,363899901,3440,Active,,,,,CCRIS mutagenicity studies,Other,,
3707,1259408,1,1,,363894815,3440,Unspecified,,,,,GENE-TOX mutagenicity studies,Other,,
3708,1259411,1,1,,363899901,3440,Unspecified,,,,,CCRIS carcinogenicity studies,Other,,
3709,1259413,1,2,,104169951,3440,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
3710,1259415,1,1,,50085981,3440,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3711,1259416,1,2,,340083330,3440,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3712,1259416,1,2,,375178051,3440,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3713,1259421,1,1,,340083330,3440,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3714,1259421,1,1,,375178051,3440,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3715,1259423,1,2,,354913655,3440,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3716,1259423,1,2,,354952316,3440,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3717,1259423,1,2,,354998029,3440,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
